var title_f28_32_29184="Uropathogenic E coli adhesion";
var content_f28_32_29184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adhesion of uropathogenic Escherichia coli to epithelial cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-powered microscopy demonstrating adherence of uropathogenic Escherichia coli onto uroepithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Agn&egrave;s Labigne, MD, Institut Pasteur, Paris.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29184=[""].join("\n");
var outline_f28_32_29184=null;
var title_f28_32_29185="Drainage procedures used with vagotomy";
var content_f28_32_29185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drainage procedures used with vagotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A number of drainage procedures are possible with truncal vagotomy. A gastrojejunostomy is best suited for patients in whom access to the pyloroduodenal area is not technically feasible. The Heineke-Mikulicz pyloroplasty (transverse closure of a longitudinal gastroduodenotomy) is frequently used after oversewing a bleeding duodenal ulcer. The Finney and Jaboulay gastroduodenostomies are used when the duodenal bulb is deformed from scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Matthews JB, Silen W. Operations for peptic ulcer disease and early postoperative complications. In: Gastrointestinal Disease, Sleisenger MH, Fordtran JS (Eds), WB Saunders, Philadelphia 1993. p.713. Copyright &copy; 1993 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29185=[""].join("\n");
var outline_f28_32_29185=null;
var title_f28_32_29186="Reverse breech extraction";
var content_f28_32_29186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Reverse breech extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29186=[""].join("\n");
var outline_f28_32_29186=null;
var title_f28_32_29187="Pathology of relapsing polychondritis";
var content_f28_32_29187=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology of relapsing polychondritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Clement J Michet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29187/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/32/29187/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing polychondritis (RPC) is characterized by widespread, potentially destructive, inflammatory and degenerative lesions. Ear cartilage is classically affected, but RPC may involve cartilage and biochemically and immunologically related connective tissue structures throughout the body (",
"    <a class=\"graphic graphic_table graphicRef76071 \" href=\"UTD.htm?19/45/20188\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathologic changes associated with RPC. The pathogenesis of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=see_link\">",
"     \"Etiology and pathogenesis of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOLOGY OF A TYPICAL ACTIVE EAR LESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of an active ear lesion is representative of pathologic changes occurring at connective tissue sites elsewhere. There is a characteristic spectrum of changes that depends upon the time the biopsy is performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pleomorphic perichondral infiltrate of lymphocytes with a variable proportion of polymorphonuclear cells,",
"      <span class=\"nowrap\">",
"       monocyte/macrophages,",
"      </span>",
"      and plasma cells is initially observed at the chondro-dermal junction (",
"      <a class=\"graphic graphic_picture graphicRef68917 \" href=\"UTD.htm?15/13/15573\">",
"       picture 1",
"      </a>",
"      ). Lymphocytes dominate with CD4 helper T cells exceeding CD8 cytotoxic T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/1\">",
"       1",
"      </a>",
"      ]. Contiguous regions of cartilage show evidence of proteoglycan depletion. Coarse granular deposits consisting primarily of immunoglobulin G (IgG) and C3 can be localized by direct immunofluorescence at the junctional site.",
"     </li>",
"     <li>",
"      As the disease progresses, the integrity of cartilage is disrupted by invading granulation tissue, which tends to sequester islands of degenerating chondrocytes and depleted matrix (",
"      <a class=\"graphic graphic_picture graphicRef55022 \" href=\"UTD.htm?43/29/44498\">",
"       picture 2",
"      </a>",
"      ). IgG and C3 may be seen throughout the matrix.",
"     </li>",
"     <li>",
"      The late stage of the disease is characterized by complete disruption of tissue architecture and fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef80944 \" href=\"UTD.htm?39/40/40577\">",
"       picture 3",
"      </a>",
"      ). Gelatinous cysts may be observed with focal regions of calcification and bone formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electron microscopy shows prominent chondrocyte cytoplasmic processes extending into regions of damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/2\">",
"     2",
"    </a>",
"    ]. These contain as yet to be identified small electron dense granules and vesicles of varying size, shape, and density.",
"   </p>",
"   <p>",
"    The chondrocytes appear to be actively phagocytosing degraded material and are rich in lysosomes, lipid, and glycogen. Collagen and elastic fibers are eventually destroyed. Finely granular electron-dense material may be seen coating such fibers and may be on the surface of cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY AT OTHER SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other anatomic areas and organs that may be involved include the eyes, nose, airways, vascular system, skin, joints, kidney, and nervous system (",
"    <a class=\"graphic graphic_table graphicRef76071 \" href=\"UTD.htm?19/45/20188\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;At sites of aortic involvement, the media appears vascularized, and there is lymphocyte cuffing of the vasa vasorum. Mononuclear cell infiltration occurs with depletion of glycosaminoglycan content and with subsequent fragmentation and destruction of collagen and elastic fibers. Inflammation may extend throughout the aortic wall [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/3\">",
"     3",
"    </a>",
"    ]. Smooth muscle destruction may lead to aneurysm formation. The aortic ring may be dilated, and valve leaflets may be thickened or ruptured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tracheobronchial tree",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tracheal and bronchial mucosa may be edematous, and their cartilaginous rings exhibit changes varying from mild inflammation to total resorption by granulation tissue. The large- and medium-sized bronchi may show patchy widening or extensive narrowing and may collapse. Lesions may be localized or may involve the entire upper airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Synovia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial tissue biopsies have shown a chronic synovitis with edema and mononuclear cell infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal pathology is variable in RPC because of its association with diverse autoimmune and connective tissue diseases and with IgA nephropathy (",
"    <a class=\"graphic graphic_table graphicRef81401 \" href=\"UTD.htm?20/36/21067\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As a result, renal involvement may reflect both RPC and the related diseases. Three major changes have been attributed to RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild mesangial matrix expansion and cell proliferation",
"     </li>",
"     <li>",
"      Segmental crescentic necrotizing glomerulonephritis",
"     </li>",
"     <li>",
"      Tubulointerstitial disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mesangial deposition of IgG, IgM,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C3 may be seen by immunofluorescent microscopy, correlating with electron microscopic evidence of electron-dense mesangial deposits. Variable degrees of vascular and glomerular sclerosis and of tubular loss have been observed at necropsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the eye, episcleral vessels may be surrounded by plasma cells, lymphocytes, and mast cells; there may also be a vasculitis with immunoglobulin deposition in scleral and conjunctival vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/6\">",
"     6",
"    </a>",
"    ]. These changes may be associated with loss of basophilia and fragmentation of elastic tissue at the scleroconjunctival angle. A case of RPC manifesting chronic bilateral follicular conjunctivitis has been described, with conjunctival biopsy demonstrating a granulomatous obliterative microangiopathy with numerous eosinophils, plasma cells, lymphocytes, and epithelioid cells in the substantia propria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/7\">",
"     7",
"    </a>",
"    ]. The chronic conjunctivitis resolved following use of systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , indicating that such a presentation may be indicative of smoldering RPC and may be a harbinger of potential visceral disease.",
"   </p>",
"   <p>",
"    Inflammatory cells may infiltrate the peripheral region of the cornea, which can show edema and necrotic changes. The iris may also be infiltrated with chronic inflammatory cells and may contain granulation tissue.",
"   </p>",
"   <p>",
"    Optic neuropathy, an uncommon feature of RPC, has been attributed to ischemia, intrinsic inflammation of the optic nerve, or spread of inflammation to the nerve from adjacent intraconal orbital tissues. There is a description of optic neuropathy associated with periosteal thickening and enhancement in the apical orbit and in the adjacent intracranial space consistent with periostitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29187/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing polychondritis (RPC) is characterized by widespread, potentially destructive, inflammatory and degenerative lesions. Ear cartilage is classically affected, but RPC may involve cartilage and biochemically and immunologically related connective tissue structures throughout the body. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a characteristic spectrum of pathologic changes that depends upon the duration of involvement at a given site. A pleomorphic perichondral infiltrate of lymphocytes with a variable proportion of polymorphonuclear cells,",
"      <span class=\"nowrap\">",
"       monocyte/macrophages,",
"      </span>",
"      and plasma cells is initially observed at the chondro-dermal junction, along with coarse granular deposits consisting primarily of immunoglobulin and complement. Contiguous regions of cartilage show evidence of proteoglycan depletion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Histology of a typical active ear lesion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the disease progresses, the integrity of cartilage is disrupted by invading granulation tissue, which tends to sequester islands of degenerating chondrocytes and depleted matrix. The late stage of the disease is characterized by complete disruption of tissue architecture and fibrosis. Gelatinous cysts may be observed with focal regions of calcification and bone formation. Collagen and elastic fibers are eventually destroyed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Histology of a typical active ear lesion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At sites of aortic involvement, the media appears vascularized, and there is lymphocyte cuffing of the vasa vasorum. Mononuclear cell infiltration occurs with depletion of glycosaminoglycan content and with subsequent fragmentation and destruction of collagen and elastic fibers. Inflammation may extend throughout the aortic wall. Smooth muscle destruction may lead to aneurysm formation. The aortic ring may be dilated, and valve leaflets may be thickened or ruptured. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aorta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tracheal and bronchial mucosa may be edematous, and their cartilaginous rings may exhibit changes varying from mild inflammation to total resorption by granulation tissue. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tracheobronchial tree'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synovial tissue biopsies have shown a chronic synovitis with edema and mononuclear cell infiltration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Synovia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal pathology is variable in RPC because of its association with diverse autoimmune and connective tissue diseases and with IgA nephropathy. As a result, renal involvement may reflect both RPC and the related diseases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Kidney'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the eye, episcleral vessels may be surrounded by plasma cells, lymphocytes, and mast cells; there may also be a vasculitis with immunoglobulin deposition in scleral and conjunctival vessels. These changes may be associated with loss of basophilia and with fragmentation of elastic tissue at the scleroconjunctival angle. Involvement of the conjunctiva, cornea, and iris may occur. Optic neuropathy is uncommon. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Eye'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/1\">",
"      Riccieri V, Spadaro A, Taccari E, Zoppini A. A case of relapsing polychondritis: pathogenetic considerations. Clin Exp Rheumatol 1988; 6:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/2\">",
"      Hashimoto K, Arkin CR, Kang AH. Relapsing polychondritis: an ultrastructural study. Arthritis Rheum 1977; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/3\">",
"      Selim AG, Fulford LG, Mohiaddin RH, Sheppard MN. Active aortitis in relapsing polychondritis. J Clin Pathol 2001; 54:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/4\">",
"      Chang-Miller A, Okamura M, Torres VE, et al. Renal involvement in relapsing polychondritis. Medicine (Baltimore) 1987; 66:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/5\">",
"      Dalal BI, Wallace AC, Slinger RP. IgA nephropathy in relapsing polychondritis. Pathology 1988; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/6\">",
"      Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990; 97:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/7\">",
"      Yu EN, Jurkunas U, Rubin PA, et al. Obliterative microangiopathy presenting as chronic conjunctivitis in a patient with relapsing polychondritis. Cornea 2006; 25:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29187/abstract/8\">",
"      Hirunwiwatkul P, Trobe JD. Optic neuropathy associated with periostitis in relapsing polychondritis. J Neuroophthalmol 2007; 27:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5621 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29187=[""].join("\n");
var outline_f28_32_29187=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOLOGY OF A TYPICAL ACTIVE EAR LESION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY AT OTHER SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tracheobronchial tree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Synovia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5621|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/13/15573\" title=\"picture 1\">",
"      Auricular biopsy in RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44498\" title=\"picture 2\">",
"      Cartilage inflammation in RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/40/40577\" title=\"picture 3\">",
"      Biopsy in advanced RPC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/45/20188\" title=\"table 1\">",
"      Clinical features of RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21067\" title=\"table 2\">",
"      Autoimmune diseases in RPC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=related_link\">",
"      Etiology and pathogenesis of relapsing polychondritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29188="Cefoxitin: Pediatric drug information";
var content_f28_32_29188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefoxitin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"    see \"Cefoxitin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/35/564?source=see_link\">",
"    see \"Cefoxitin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10327785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mefoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14965749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefoxitin For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Second Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.: 90-100 mg/kg/day divided every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"      see \"Cefoxitin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-moderate infection: 80-100 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe infection: 100-160 mg/kg/day divided every 4-6 hours; maximum dose: 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perioperative prophylaxis: 30-40 mg/kg 30-60 minutes prior to surgery, followed by 30-40 mg/kg/dose every 6 hours for no more than 24 hours after surgery, depending on the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: 1-2 g every 6-8 hours (I.M. injection is painful); maximum dose: 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pelvic inflammatory disease: I.V.: 2 g every 6 hours continued for 24-48 hours after significant clinical improvement is demonstrated",
"     <b>",
"      plus",
"     </b>",
"     doxycycline 100 mg I.V. or orally every 12 hours for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perioperative prophylaxis: 1-2 g 30-60 minutes prior to surgery, followed by 1-2 g every 6-8 hours for no more than 24 hours after surgery, depending on the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mefoxin&reg;: 1 g (50 mL); 2 g (50 mL) [contains sodium 53.8 mg (2.3 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IVP: Administer over 3-5 minutes at a maximum concentration of 200 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. intermittent infusion: Administer over 10-60 minutes at a final concentration not to exceed 40 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Deep I.M. injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus. May dilute vial using SWI or 0.5% or 1% lidocaine to a final concentration of 400 mg/mL (see package insert)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS, mannitol 10%, sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bivalirudin, cyclosporine, cyclophosphamide, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, etoposide phosphate, famotidine, fluconazole, foscarnet, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, magnesium sulfate, meperidine, morphine, multivitamins, ondansetron, oxytocin, propofol, ranitidine, remifentanil, teniposide, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Anakinra, fenoldopam, filgrastim, hetastarch in NS, pantoprazole, pemetrexed, pentamidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted solution is stable for 24 hours at room temperature and for 1 week under refrigeration; thawed solutions of the commercially available frozen cefoxitin injections are stable for 24 hours at room temperature or 5 days when refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible lower respiratory tract, skin and skin structure, bone and joint, genitourinary tract, sepsis, gynecologic, and intra-abdominal infections; active against anaerobes including",
"     <i>",
"      Bacteroides",
"     </i>",
"     species of the GI tract, gram-negative enteric bacilli including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"     ; active against many strains of",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ; inactive against",
"     <i>",
"      Enterobacter",
"     </i>",
"     sp.; perioperative prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mefoxin&reg; may be confused with Lanoxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, bone marrow suppression, BUN increased, creatinine increased, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (with aminoglycosides), phlebitis, prolonged PT, pruritus, pseudomembranous colitis, rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, transaminases increased, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, erythema multiforme, hemolytic anemia, hemorrhage, pancytopenia, renal dysfunction, seizure, serum-sickness reactions, Stevens-Johnson syndrome, superinfection, toxic nephropathy, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefoxitin, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal impairment; use with caution in patients with history of colitis or penicillin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection; high doses in children have been associated with an increased incidence of eosinophilia and elevation of serum AST; safety and efficacy in infants &lt;3 months have not been established; do not use in patients with immediate-type hypersensitivity reactions to penicillin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5953484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function periodically when used in combination with other nephrotoxic drugs; liver function and hematologic function tests; number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into tissues and fluids including ascitic, pleural, bile, and synovial fluids; poor penetration into CSF even with inflamed meninges; crosses the placenta; small amounts appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65% to 79%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants (10-53 days of age): 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 45-60 minutes, increases significantly with renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Rapidly excreted as unchanged drug (85%) in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 53 mg (2.3 mEq)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Feldman WE, Moffitt S, and Sprow N, &ldquo;Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1980, 17(4):669-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/32/29188/abstract-text/7396456/pubmed\" id=\"7396456\" target=\"_blank\">",
"        7396456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regazzi MB, Chirico G, Cristiani D, et al, &ldquo;Cefoxitin in Newborn Infants. A Clinical and Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1983, 25(4):507-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/32/29188/abstract-text/6653646 /pubmed\" id=\"6653646 \" target=\"_blank\">",
"        6653646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13131 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29188=[""].join("\n");
var outline_f28_32_29188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327785\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965749\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046026\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442225\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046019\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147652\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147636\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046029\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147724\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046023\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046028\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147726\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147723\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046032\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046018\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046017\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298992\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147645\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147648\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5953484\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046025\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046016\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046031\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046033\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13131|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=related_link\">",
"      Cefoxitin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/35/564?source=related_link\">",
"      Cefoxitin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29189="Suture site transvaginal suspension";
var content_f28_32_29189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Site of suture placement for transvaginal apical suspension procedures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 464px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHQAlIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopDQAtFAooAKKKKACiiigAoozRmgAoozRQAUUUZoAKKKDQAGkNFGQBmgBpYE8jkc01SS2Qcg05skApgHvmgAID6UAJESVy3rSoMjPrSOQsfp2pyDCgegoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQaACigUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA0nBHvTqr3Em2WAf3nx+hqxQAjEAc0fWobtxHGrscKHXJ+pxUpIwQelAC8Um4A47+lU5rpREfKQtIONp65IqvJeEGNJJFDMAF2Nnn1NAGpu6e9AOapIZg7tKhCpwMnqaW5uiZ1trfmYjc3oi+poAuBgWxnmnUyKMIuAST6mn0AFISKQsCuc8dc1BFIJiWH+rB+X/a96ALFHekLAdcY96jEqEP0AHfPWgCWlqIP8nAycZA70u8D7wI/UUASZpKTIGASBnpQTxQA6g01TnPtTgc0AGKQ8DiloNADQwPHf0pGODjGc0jx7+hwRzTDMqMFmG09j2oAWU5ljT3yamHSoE+eVnHOBgGpx0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKAEozzilprAEc0AOopik52k8/wA6fQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZerzG3Ni46G5VD+ORWpnmub8b3K22kw3DZ8uG7gdsckjeMgDufap11q4B8yTSL5bU9JMKzfUoDuA/CgDYu4lntpInHyupU496q6Tcm4tAX/1sbGGT/eU4P8AjTYNZ0+5i3w3tuw75cKV+oPIqp4bn+0QXtwozDLduYj/AHlXCZH4qaAK19frcXOoWsdvIt5DGZIiDkkjuMd+ap6YReRSWyzLAgdU4jIZzjpk8joa0bySAahPBZKI76fG+UHAJAyEJ6gkAnio7u4Oi2k2o6q6eRa24G8nJkk56D1ycD60ASXl/PYeRpsLrcanOSY1IyET+83sP51pabYizgILtLM/Mkrclz/h6Vj+ENPuBbvquqKf7Sv8O6sOYk/hj9sDGfeumHSgA6Cq93dQW1vJLcyLFEoyzMcAVFqmpW+mWUt1ePsij64GST2AHcnsKx7Cwn1W4W+1tSqghoLE8rD6F/7z/oKALdu82rESFHgsDyA4w8/1HZf1rTkUpERGueMKoOPwqUjBLY5/nVCCS4ivblJEZrYBSj9SWJ5AHoOKAEjIsIlE65Esm0KvIUnoADzSNdWr3UcKy4YHhQPlJ9M9zUZaK8vbiF4ws8IwkgbIG4dR6NxVC6ilW6QpE0CQhIIpHI2oWOGcD17c+tAFqa7mhvQQiBiQrYOcZ71ZW4immG6OSONj8j5wHNZly62eoThBjyLdCgY9Gd8FjUd1qlvG0MrSmWygIVPKXdvcDlvovHPvQBveYs0xRHG5SNy45/CnJMJJXibgrzlemM1UkZzc2n2eMNATuEykYCEc5+vGKdZyyveSovnNCoPzyDA3Z7eooAuyKWG5CA3Y9qbDcq8hR/klHVDVW482Dy1thIZC+T8uQw75qzcW6XC4k6joR1U+uaALIINFZhupbAL9rLSwdPPVeV/3h/Wr8UySxiSJleMjIZTkGgCSop22xnpnoMjvT93XPA96rSOJrkQjpHhn9vSgCxEoSMKABjsKfQKKACiiigAooooAKKKKACiiigAooooAKKKDQAUUCigAoxRRQBHKDjcOo/lTwQQD2NKeaggJG9G/hbj6UAT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3dJ9t8Y2lo3/HvY2/2sr2MjMVUn6YY/jV/WF86EQJdpbysfMG5sb1XkjjnH0rP0vdJ4118sMrHb2yD2JDkj+VSa3LaG4/4mluTawAOkmDuaRsjaoHJGOv4UAVtZutMiFtLNpqalJKTl44Fdgqj5mJ9AOgrI8T3rXS2f2S5lawuYs21valYXMnOGbdghBx+NQ+JZLqCCOKYeRbuxNpLG4g+zgD7sjHuRwB3rT8OadZ3MGn+ZYXMZit43Z5UGyRgOM55OMk9qANPQ9LwIb25mM1yyByoOY1kIG5hjqeOtYjlvF3iRQu7+w9IuMv3F1OOgx3Vcip/GGp3Vzdw+GvD8mzUrkA3E69LODu2ezHoBXS6FpNroulwWFghSCEYBPJY9yT3JoAuxj5fT1xSswUEsQAOcnoKXpwK5PxRPLrF//wAI3ZOUEqh7+ZDzDCf4R/tP0HoMmgBmmAeJtXGpyKG0iykIsFYHEsoODNj0ByF/E0kl/rcXiO+tYDbTxgLLb20v7oyR4wxWQZyytkEEdMetdE72mlWCA7La0gURqMfKi9B+FVtd0ganBHJby+RfwHzLa5XnY3v6qeAR3FADLfX4RPBbalFLp93KSESYfKxHZXHyn861xyx6cccVz+l3sWu211p2rWqx3sPy3Vm/KnsGT1Q4yD2+tQol/wCHGG1pr/R1GBGcvPbD2P8AGv6getAGzAt4dRuBMsYtNo8tl4Zmzzn2xWV4uSKxiXVEyssWEkABImjzzGR+oPYit2xuYby3S4tpUmgcZR0OQRUjLuYBlDKfUUAchNazaXLcXtwJNSiuEVDEw5SLO5mf1I/wqLUNSFj5ygQxieP5Ltj8kVuem1QMg45wepro9XshNbXANxNFFIuJQnJK9MD0z0zXO3ZmOq2dksF5pSXCmFZo2SRJAo4DAjrjP50AXr+0huLGGzt1gW0hiB85n5jTb1CjnP14quurx2zy3hu5lsPKW3iZlwhf/Zz1479KyruGzfUoNO0wqtysIG+SUgTqo5BKnKkD1FdFoVtH/Zf2V7iC5kt3OxUG824/hUZ547E0AWtEujcS3BgaaSzBHlySg5Y98Z5I/wAikFyuoXSS219D9ltjuby3JY8HIYdqb4bF3HHcRXskz5lJgNywMpT3A96ltdJ+xvczR3LSXc+A0jIPu54AUDH40AW7K7S887ywditgN2f6VWvLGa1Y3Gk4Rxy9ufuSfQdj70+bUkhmFuim4u9uTFFglfdj0UfWq0+n32oZW9v2tomOfJtPl49C55P4YoAP7bSeGFbNd95KCBCf4COCX9AK1LO38i3CElnPLsepNQaVpNjpkbLYW6Rbjlm5LN9SeTWgOlAAOlFFFABRRRQAUUCg0AFFJRQAtJn5sUopO9AC0UUUAFBoooABRQaBQAUUUUAFV4uLif6j+VWKhgG4u5/iPH4cUATUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVXvbhLW1mnlICRIzsfQAZoA5vR7l1k8RamIjM0l55CRx8ErGqoPpyTmorjVI7vxJcWsziI6eikKMM0hYfdwfU7cY9Kt+FwbDwlavOyR3FyrTnec5kkJYA/n+lcJOLix8RTJrFqssssPlq9uXYq5OdwYclsYJA7CgDZ0G3FxrOoC1MQhSLbJNc/P9qkDgmQqeBg5A+tbXiHWG8O2Ed5LMbyeRFgtrVBzczH0H5c+lQ2Nnp2h6XLf6ha+VBFE7yOxJQKMD7p5y2M455pPCOnz6vfnxLrMbK7Dbp1swwLaH+9jszd/agDS8F6E+lWM0+oMs2rXz+fdy4/iPRB7L0FdEABSLgegqhreqWukWMt7fS7IIxzgZLE9FA7kngAetAFPxXrR0eyBto/tGoXB8q0tx1kkPT/gI6k+lZNus/hmzjSG3k1PWr5zNdOqnDtj5jn+FR0Aqtpcnla0mreJlaHUb/5LGAgsLSLHClhwGY9frit/xJvWyGSmwtiVS5XeNpwoxycnHA60AMF3aavocsWoeUW8vNzbQyhzHzypIq8lvDcS292GYFB8i7ztxjHQda5TQ4Wjne+jFoLkK8HlJbmFYkX5juXOSenPvWxrlomuWFuYcrcIPMiBcoFYrjqO60AVtUW31XWxFYTzWOu2SGWGZoyFkQnBVv7yHA+mMir+g62uotLaXUZtNUt/9faueR/tr/eQ9iKI0sdLvIJL11bUbxUt3nZTmUgYHsoJ7cZpdd0WLVhFMkz2eo2x3wXUeN8Rx0P95T3B60ARXOkyWF1NqGggJPId01mWxFcH1/2H/wBrp61paPqkOpWxliDxsrbJIpBh429GHY1j2fiCWym+x+JY1s7jOI7sf8e9x6EN/C3+yam1yylic6tpEKy3qptkhDYW7i/un/aHVT+HQ0Ab0YYqN5y30rldbksLPX01G+lv2jtmVcKwaGF2GAxXqMg9elX/AA7qxv1kR28wgkpJjBx3Rx/C69CO/Udat3mjWF5dpd3NnFLcqBh2yM45GR3GfWgBP7OtXupn+wwJ58ZVp0wrtu69O/vVbR9CFhey3kl7Ldu0YiVpAAQg6Akfe+prQsGukgkfUnhVyxICHhF7Ak9TWHca1dakXtvC6IyglXv5VzDH67R/y0b2HFAEupyWWk6ouo6hf4cgiK2SMb3yMYGOWNNRNY1mTddytpVgfu28XM7j/bfov0HPvUui6HbaZKZ3Ml5qD8yXdyd0h+n91fRRW4Hz1oAr6bp9pp0HkWUCwpncQvJJ9SepPuauKAM4HXrTRjFO9KAHjgUUDpRQAUUUUAFFFFACUUUUAFFFFABRRRQAUUUUAApaSigAPWlpo+97UMQFJOcUAOpCwA5OBVaN5piSFWNPU8mnrCCd0rM5Hr0/KgBjuZSUiPy9GYf0qwgCqFAwAKFUBQMAAelOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopCwFABkVyXii5TUbuPQIJPlkImv3BwIbcHlSexY4GPTNWfEOrXAu10nRCjarMvmNIwylrF08xx3J6Kvc+1Yev2NtoXhTULW3lkuZZyq3MjndLLI5+9IR2wMAds0ATeLb9Dqum25Vm0wOoklhk2sGYEAKOhAXOfY02w0dtU1Gw1bTtQZ9OhdzFvGGHzZJH97uvPasy30Wa70bTG0ki6n2tHcP52EjfGMFT6D5Tj0q5fpPaW+n+DdFuH+33QaW7ulGPs8GfmfHQbj8qigB115njfxLJZowHhvSpVNwVP/H7PjITP9xeM+9d8ny8EBRwBiqWiaZa6LpsFjYxiK2hXCj1Pcn1J65rN8ceK7DwnpK3d75s1xM/k2lnbjdPdSnoka9z79AOTQBZ8U6/pnhzSX1LV7oQW0fA7tIx6Iq9WYnoBXK2wnuZofEvjOMWkMZD6bpQ+c22R9+THDSkfggOOvNQaDoD+enjD4iPB/bQJa1tmfdBpSHpHGOjSc/M+Mk9OBXTahq+h3MNp9rnV4p2by22nAzkHccfKD05xQAviW40+P7HcXpeZ45FkhgQg7m5CsB3xk4qLWLi4nv47O0hZL1CQkkxwu0jDSqR1K5+6e9V/E87QyW72soha0aMRRBVJnyRkKTyFC55pytHJNLqMV6L37NI0SJbDd5MbNknb1LYGM/lQBDBGtk0tnc2qW/kwtNFK8xcuS20tKOMkkA/pSyRSTC6S1uvOuo0XddWpCOVLfOAuSu8AE5A/WpbO4lkiu540iS7unDytcn5LeLogf8A2sDp6nmsVQ9xcyXEUNvcXtrLGsd1aI3lsf8AZ7AY4ZefXNAF1Lm4bU4bCUnUS2WivPJeNo3XlBMMYIyOvtVnw4jxa5LOkvnxSKY7i5M+9ZpgRtAHYjngDGMdaWGJ9P1u2K301xJdGZ7oO+VEXO0gfw4OAPXmrfh6wspbWC8sHc2zyvcbHXBLfdHHbGDQBpXSvcTzW17bWz6ewG0yANub0weKyZPDU9gC/hnUJbPb0tJiZbZvbaeVH0NaWqabFq7WryTMsEbbimPvEHj6HNajypGjO7hUXksTjFAHF2K6r/wk9rctpEllNMGj1Eo4e3kQAlZFbOd+eOR0Nb2ua/Y6MircuZLpx+7tYhukk+g/qawNS8V3mqSNa+FYlMY+WTUJwRGnrsH8ZH5Viym28PI1wZJb7VZvl85z+9lPfB/hX6UAak/2vWAtz4lkS0sUO5NOjk4PvM3Gf90cetLJ4vt0CxafYzXEK8AxqscY+ma5GYT30pmv2EsnZAT5cf8Aujufc1dhtmbGWPsP/rdKAOgj8ZBW/wBM026t4/767ZQB64HIrqtPvobyBJbZ1eJuVIORj29Poa82ltZYyDG2Ce461s+FXayv1QBkguwxC9lkU8/mOaAO+U+tS+lV4zkCpx0FAEg6UUgPFLQAUUjMFBLEAAZJPYUoIIBHQ0AFFFFAAaTFLRQAlFKaSgAooooAKTvjtS0m0ZoAXNFJRQACoLvc7Rwqcbzlj/sjrU/pzim4XcSOvQ0AOQYH8vpS0UooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADVTUbqKxs7i7nJEUEZlf6KM8VbNcx40zdvpOkAnF/dDzQDg+Ug3v+HAH40AV/D1vLZaG99epO2o6k63Fw0a5cF/uoPZBge3JrL1S6jhudQSKRoLy4YRrZjPn3G7pyfuKSc5GcAHvW/4u1KCw0uZ5pSNrKGjRSzPn+HA9QD+VGiJbT3DXzzJLK0COjuMSRwkcZz93PNAFCJrbwH4PkklxLclt3lr/wAtZ26Iv44GfSrfgvSJtOt573VHWXWL9vOu5P7p7Rr6KorH0NT4x8SnXp1J0XT3MOmRsOJZP458dx2X866fxPrtl4c8P3+r6jIEtbSJpWOeWOOFHqWOAB3JFAFbxp4otPDOki5uI5Li6lkENpZxDMt1MfuxoPU9z0AyTXNeGNAez1dPEHipxqfjC6UrHFEQ0Wnx94oQeFA6M55Y/lSeANAv9Sv4/GHi9R/bVxEfsVmP9VpcDD7ij/nowwWbr2rubiJYI55oo4lmkXbuYcE9txHJFAGakH9pS7byZ/PhJdHiG0R5GMLkc49cda5O3j/tC/stJstPuV0je0s0kkh3zKCSGf0Bbpnr+FdT4VmmkivDcxxBkk2faYwVSVR/dycjHSo4mvIpbv7ZHbxid12wxqA8ygfvMYOW7YPXrQBStNVu73UIba+hs47iQs1s0WW8sqPmjlU8jj8KrXunXdtbT3McYnhEhnnk+6ZCBjiPp5ajgDIJ603StJCLfR/vY55Zx/H+/EYHCeaf4j1x1xxU+laPNHHeC6gnFs8ubWC5uS2wf3mXPIzzjk0AIbC5u7e2fUDAYEQTW9lbwMQSehcZ5PsTipPCy30Wrz+Z9ojszG37qaRCxfuQi8KO1LJp19NMIob5bGfdvbF67uV/iIj6AHsO1bcUUx1P7RDKj2pBEm0J83HGSOSfrQBStLfSYtOlSeMxW90/lF5WJL88Dd29h2q9olrdWiXa3XlrAZMQQx/dijAxj8etVtfFrFjUtWvo7bSLNPMlWUhU3A5DMfb09cVw974i1rxqGGitc6F4ZI41J12Xl8PWBDzGnX52GTxgUAdN4l8a2unXp0jR7SXWdeVQWs7Ujbbg95pD8sY9jyR0FYrWV/qZEvii8hueQRY2YKWqemc8y/jx7UaNp1joWniy0q3FvDu3sdxLyMeruerMe5Jq0GyeTz9KALEk4jiG4qsSjJUcAACuQeV727a7cne3EYP8Cjpj6962dZzKlvbIeZ5An1xyf0FJBYqLgCTaHIJRfUDpQBWsrVmbO0ha1Y7UgjpVkIsKgcChZwDQA82gaEj+LHWtG2tolKfL93DD2OMVTWYngCrsMoaWBUGcoSSPb/8AWKANqFvbmrAPAqrEflyKkViTzQBbU8UoNRg9qeDxQBR1lHms3t42CvORGCfQnn9M1eQBUUL0AwKa6BnVifu8in0ALRVea8iinghckSTkhAATnAyfpVigAooooADSUppKACiiigAo75oooAQjp9aMUMcFR60tADc4qrCNuoXI7FUP/oVWyD2qsFxfO39+IZ/A/wD16ALQpRSClFABRRRQAUUUUABooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooNAEcr7PpjNcvoUx13xBd6yvOn2qvZWhHIlII8yVfYkBQe+2pvGk09zHa6JYyGO51JijyKcNFCOZGHvjge5pur3Fnommw2UFvMbaKHylt7QYKL0XJ7dwPegDJu7yPxKJbazE8OoxDbJG48pXUnHU9eB1FUNftZ5Liz8J2E5a+1BRNqV0vWO1X5due2R8o/GtnR7fSItHt9ZheW1s4N08rXB3ONgIwzHoBzwO9RfDa1uLpNQ8S6lGUvNacSojdYrZRiJfxHJ+tAHYWVnBYWcNraRrFbwoEjRRgKB2rzPVdMn+IPj6Pz3B8I+HZ/mh3cXuoLg4Yd0jyB7tkdq7jxjri+HvC2q6tJyLW3Z0UdWfoij6sVA+tQ+BdFPh/wlpunSZ+0pH5lwSQS8znfIxPu7NQBy3hqLXLjSLubStckOvQTSQ3lrqpaWAShzgYGGiBUqQV+XaR8prf8ADniyPUdQl0bV7aTTPEMSb3sZsESqP+WsDdJI/ccjoQDSeIdCu01I694aNvHrIRY7mOb5Y7+JeiSEDKsuTtftkg8Gsi5uNF8fxPo+oR3eleIbBhOkLkRXllIOk0LdHX/aXKnoetAHeFFkiZCoC4xjGARXJ32m6rLqkF/NFbxRWT7ogMyNsxzgD9aqaV4ru9B1C10PxuVjuZ38q01ZU2Wt6f4VPaKU/wBw8E/dJziu8QZByMHNAHGsdU1S3a9sozFcxSbYXWPaJxxh2DYIXqCOvHBq5rGrxWF8hNlHcTRYDncA/JH+rQ8tz3/Wt6/SdkJt3AbB+U9z9adFBkQvOsbXKrgyBeR64PagDNbw9aPdvcnd5rHcCOGzju3U/Q8Vl+JvFWkeDoUt5PMudUutz2+n2qh7i5b2UdF9WOAKwfE/xAuLy5m0fwMsd3eRSGG61SQbrWyI6gf89ZB/cHTuaw9E0eDSbi4uzLPeard4N1qFywaeX0Geip6IOlADhp1/4hv4dV8amOSaFt9ppETbraz7qX7SyjuTwOwFdFJO8rkkhmPJbFYd3rEMDhFDzTjOUQ5xn3qnJq96WUxxwxgjnJzigDpScdeppwYA1y39q3zZCNE2e5XAFWbPVX2x29xG0czHG5yMfhQBt3UQuYhtk8p4m3pJj7rD/HpUMN1dm4D3NvGWjZAssbgjGDn+lTzTJaWBuGUleF688nFJbWaxJIiEtli3PUZoAht76VrxoJ+SszLn/ZxuH9KsMT5mQOKzLlvs+uxcgrOF/Mcf1rTKkHvQBcgJwDWjpIC3cq5Y70yg7A9TWdDwADU77o4xMrENGQ4x14NAHSRcZH/68VLH96s+xcq0iE7kJDxsTnKtz+nSr0Thhke9AFgHmpB0qJOWp5OKAHjGaUGod/zdaerCgB20bgcnI/WnMwUEsQAO5pM8HHJrP1YfaIUtN23z2wWHZRyT+mKANEHNLTIzkAgYyOnpT6AA0lKaSgAopKWgApcUlFAAeSOaKBS4oASoZDtuY+PvArn8qnNUtTykUcoz+7kVjj0zj+tAFz+dGaRc9DS0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIxxS01wCRkZoA5izY3fjrUpi42afaR2w7/M53t+gSsbX4X8RrFNpU4uBFKyTrbSbXCZ+XPfOAcehOa0/Bk6Pot5qj73W+vppfu5O3fsXj0AUVV8LQ+Xf63rEkgtbU3L+ZEyDKrGPXsO9AFXxRFFqmoaX4KsIwtmVW71JB/BbK3yofd2GPwJr0BUVVAAAA6AdK4X4Vwy3mm33ia9Vhea7OZxu42W6krCB6DZ83413g+6O1AHnvjo/wBt+M/C/hZAxgEh1q+VT/yyhI8pW9Q0pXj/AGK2/EGotLcrp9sm4q6mWQnMSjnhsEHjryR0rlvBd9Bda54w8Z3kkjRS3f8AZNlsUsRb2+QSg/2pDIT/ALtacR0w6pdGJZp4dSibFzhWiOzkgJ/FjOCx78UAbr+faaZDLFdW80cKYMshwOoy3BIwB2rL12Dw74qvk0y+il+1QDzbW9iJjeNgASYZV5BAIJHT1BrLZ/7J0/UJbTcYrl0Q20C+ULc4OWKtnG70HBqzpUlmJNKvNNhstOlnJiK3BzLKgOMoPfHtQBn6tPqmjadNpPjjTW8UeG5lMb6hb2++VV/6eIF5OMD95GO2cA1D8PfElvba3b6Dp+ux67od3HI+mXJm8y4tzGAXt5s/McA5VmAOOD2rqbm/1TU4bd9Ije1njul82N3VlMRHU49s8Dmq3izVfDHg2c6rc2Vr/bV9+4hjtbdWvLwk8IoHLD1J4Hc0AdLqupWek2E99qd3Da2UCb5Z53Cqg9ST+VeS61q2p/EIfK13pHg4jIAzDc6ivfd3ji/8ebPpUV7aaj4q1K11XxtHDHbWzGSz0NW8yKFjwJJm6SSD0xtHareqaoUYADzJ2xgFvugdCfagCSJLXTrKG1tIYbKzhULHDGoREA7D/PNZ1zdtcghdyWx6k8NJ9PQe/eqLu882bl/Obuv8A/CpGDt1oAN/RIwqoOiqOPr9af5fy7m6d6lgt2C9OtWIodzqknRjtP0PFAF+10vEAmj++mHHHJ9vxFX4dJjWd/tNtvVHEkUpzxn6d6veHwZIngkGJbd/JcfQcN+IrfEIWLp04zQBjIsTO0V3F+6cggMuFz296jvJoIb0o8gXK5x3rSmAW4iABcnPy5qlqkLJdWkh8tF3lSEGTgj1+tAHPeIf3UlhcRnGyYDPTg9a3DGGGQOKzfGMROmu4+8hBGefStm2xJbqfVRQBWJ2gU5bsxAhl3DBAqC9zHVZ23KKANvw3ei7smHKSW7mIr/s5yv4cmtuCQBWA9a4jw3MYNbkhZvlnhIA/wBpa6lZsHbnkE5/GgDYgfJp00uO4qvbMNmTVW6l+fAoAvK+7NPD4YDNVLZvlqWP5pRQBdDfKc1XnhEkoO4iRhs+i5yf5CpuFHr7VSsn+1TG4UnZykZ9QOC34n9KANP0pwqNeZGYHIPAqQUABpKWg0ANNKKQ0ooAKKKKAAUtIKWgANU9UXdYyD6Y/MVcNUb+UNNBbDku25/ZRz/hQBcwATilpEwRSmgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuT8UeNodA1SWxOj6tqDwWX9oXElmISsMO5lLEPIrMflJwoY0AdZRWZa6/pF3aR3Vvqdm8EkqQK/nKP3rhSkZyeHIZcKefmHHNZFz430keMdM8OWN3Y3t/cyTR3EcN2jSWhjjL/PGMnkjHOKAOqorEh8W+G54LuaDxBpEkNmwS5dL2NlgYttAchvlJPHPfilj8V+HZdGk1ePXtJfSo38t71byMwK3HymTO0HkcZ70AbVFcXonxI8PXulfb9S1bSdLglvrq0tHuL+MLdLBKY/MjY4DBhtbjONw5PU7Wka8NR8Q63piwBV00QETCTcJRKhbpjjGPU5oA2qKyY/E2gyax/ZMet6Y2qbmX7Gt3GZsr1GzO7IxzxTF8VeHmuL+Bde0kz2CNJeRi8j3Wyr95pBnKAdycYoA2aKy7PxDot7Pdw2er6dcTWgJuY4rlHaEA4JcA/Lgg9ajXxRoD39rYrrmlNe3aLLb24u4zJMjDKsi5ywI5BHWgDYooooAKzvEd6NN0LUL0sF8iB3BPqBx+taNcx8QiZdDi09AGbULmK12nupYFv8Ax0GgCjH9p0PwNpcEUcpmEMYkaJeVyMsB7nJA9DWd4+h/s/wJa+H9KQwXWs3CWKRs5Zh5hzKSx5JC7smuqGoXMniJbG2gU2EcRMk2PuuP4RXNaWT4l+JV/qP3tN8PIbG2J5V7puZWH+6Nq/nQB3VlbxWtnBb26BIYUWNFHZQMAVz3xH19/DfgzU7+1G+9KCC0jxndcSEJGMd/mYfhmunB49PavOPE8v8AwkfxR0Tw/E+bHRF/tnUsYx5nK20Z987n/wCAigCTTNO0fRPC9h4WuL+e3fTrZWlvI32kuf8AWfN6sWYkY/irL1zT5YPscWmyeTBDEsMckcmSQ75RR0+8G5H+zk10PijTLO8a+ljt4vMjtTdF0X/WMcjJ9cKOKzbMrGbX7RLPIrxmGC7RMwxOw5Y5++7YwcdOgoAtaXeGe21O1tHK30Aj33E6rGGhXKhhnIGAD16/jV+DS7XVdVTUVuori2jKyqkceGZwMLk/3RgkKAOSetZegW1xq32+ApAYWYO13guJXHARlOMqF/h6DA5rL8S64dKP/CH+BnVvEEq5uLx/nj05D1ml/wBsjO1PXB6CgDV8Y+NY9Gvl0Hwrp8WpeJJh5jW4OyG1U9Zbhx90d8dTXL6PoiaXd3GqapeHVvEd0P3+pSpjaO0cK/wRjpgYzyTU+jabY+HdPNppiu3mt5s9zOxkmuZD1eRjyT/LtSPMXY/zJ5oAkmmJYkHBPUr3rKCRG4uFudymRhskAz8vpV7p7nr9KtRQZI3cn17UAUrfSkA3pKrL+RqwtosfzMDWgluDGyg4+nUVBZieWGW3uVVr2Jc5PAcdmH8jQA8xrt44xxVJm23kXQjeOtJY3r3XmRMpSZGw6H+E9/6U64hKNvJ+YYP9aAOmtittqVtdIf3c5FrN/vD7jH8Mg/hXTjmPjoVzz3965GJlNpJHnKP0J6g+v8q6TS7gXNoGJG77r+zDrQBXvh+6Rs7dr/e7gVBra+ZYq6HGxlf8BU1625ri3cHAw31yKjmAn0gqOyYNAGP4jTfo8uOm0N/KrWlybrZPTFQaoS2jzYHPlmotAkLWqA+lAE2pjEbVnQfPECfUitXUOY2JrC0lnNtNvYkiZgufTNAEAlNr4g0+UdPOCt9Dkf1rqPOInI9GrjNYJF1EQcFXVs+nzCumLkXje54oA6mF/wB0MVSlcGXmiGU+WF/Gm3H+twO3FAF+1Pykip7RsynNVISVjJqWzkyWPegCfU5MxCAcNOTESP4VPU0+ORYLc4UhIl4APp/jVWQ7pmdjkN8i/wC6KjlmZru1tkOVb95OfRB0/M8UAbNt/q1yAGIz+fNTVDCwK+g7VKKAHCg0CigA7U2nU0igBaKSloAKKKQ9OKAIb64W1t2lcZA42jqxPQD3qLTrZolZ5zvuZPmc+h9B7CoZwbnVYIuscCec49WPC/1P4VooKAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXE+IPAlv4h8aPqWrl5dLbTVsjbxXk0JkYSsxEioVV0IYDDEjrxXbUUAeW3ngjX11eaCwGjjQ5fENtrfmvNIkyLGIg0IiEZX/llw2/2wOoq2Pw98QbdJ0u6k0mDSdNS/jF7bzyNcz/aI5EWQxmMKrjeC3ztk85HQ+g+MtdXw5oE+of6K0qsiRx3ErxrIzMBtBjjkctycBUYk8e443S/iVqOrjTrbTvDsf8Aal1eXNnJDdXcttHE0KK5bLwCTBVxwY1PtQBg23ws1d9FeyurfS1nW1tbRbh9XvbzzUiuYZWHlzArChWI4RQ3JA3AZre1fwNrH/CW3Wv6X/Zczrq8OowWdzK8ccqrZG2beyo21wTuUgN90dO1HWPiLqWteE71fD+krFenQZdSupJr8wmzBMsYEbJGxkcNFIR9wfKORmuvvvEMugfD6x1uaB72OG3tpLsmXDrEdollyQdxVSXIOMhTyKAODuPh74xl0iW0e808x3Uuozz2lvql1ZwpLcztIj74498qqrEGNtoPqa7X4feFr7w7PePfTW0nnWljAvksxO6CDy3JyBwT09uuKxdY+KbW18bXTNFkvmlvLm2tJFM8izrbiMTyEQQSuoEknljCkEqSSvGS5+J15BPoyXHhyTT0voIpXOq3D2hV3kKNEhaIqzrjJDtGSGTH3qALQ8DXolMgax8w+J/7a3ZbPk4Ixnb9/BIx0561yFt8I9Xh8NXWjt9hmlj028sLXUZ9YvZi3nIVB+zsDHDnjdt35xwBW/L8WjaS6ydT0UWyafHK62/2ljeOVlWNAYGjXh96sGjaQAFc/eGa9x411fV7vw+k+lajo7x67BE+1bmOK7je3uG2KZoYWbBQZBTGdvJoA2fH/gS612LSF0S4ttPMcTaZf/eTzNPkC+bGm0feyi7c4AyeRWS/w1vIvF9zdRwWV1pU+qW+ooZdVvIDbCMR/KLWP9zIR5fysxGOMggYroPh745n8V3d1b3emQabNDEsptzds1xFkkFJonjRkYY5I3rnIDHFdxQBm+IL2/0+xFxpultqjq4823jmWOTy8HJTd8rMOPlJXPPPYweHPE2l+IUlGn3BFzAdtxaTIYp7dvSSNsMv1xg9ia2axPEfhfS9faGa8ieK/gB+z31s5huYP9yReQPVeVPcGgDabpxXJ6qz3XjexSIeYumWkt08fq7/ACoPrw1Vmv8AxL4ZUrrML+IdKH/L/ZRBbuIessA4kH+1Fz/sd6b4XuRq9vr2saXdQXBvpfJgaKUFURFCrn+6wyxIIBHQigDS8Ua9/wAI/wCCr3WZIx50VvvSJcfNM3CJ7ksQKd8P9Cfw94Q03T7hhJeCPzbuUjmWdzukY/Via57xBbpqHirwp4ZtzutbFv7UvFY5JSL5Yd3rukOf+A16CrYGO9AGX4l1qy8OaHfavqkhjs7RDI56lj2UepJOAK4PwJbyaXoeoXXiWNodb18vqGpTuDsh3jbDAD1O1NowM9G9ar65dReMviEFl/eeF/C0484LyLzUSMrH6FYhyc/xEDmvQNUubX7PDLLNHDNOo+zmZN+1uxC/jQBy9ze211pEQ01pIpIo/InwjFdnULg87SchT271PYNY3LItrZXUWoiISWq3AKRk4+ZolJ2gjJPIqzZWtzBfvIkragbjAu7gqNswwRsXBwgUZPqSawPEur23hvTpNYtY7m81dylho9lM2VMz9FXABwOrE9AOtAEfirxTrNgI/C+jzQXXie7DSG5c7k0226edKQBls52rjk+1ZeiadaeH9LNlZPJKzt5txcynM11K3LSue5J5A7DioNI04aJaTedOb3WbxhPqN+64aabH/oA+6q9Bii5mlBGxOvO70oAtSyE/eb5ifzqtI4jfbnL4zgdhUtpbq6n5i0h6t3/CrsenBUIiUBj/ABHvx3oAjs18x8dWJwatWNxHc3DwR8Og43d8daTSLaaOKF5kxMRn2Na0Gk2wYywoVuW6SZ6fhQBTeIW9wZow75IEo7ezj+VSa4rWNvb6jGN5gcbz6xt94fhXQ29uu7aw+8ADkfn+FJb26TW9zYzpgKCuOxQ96AOW162KapZ6jZkPHdLtOOOf/rjn8KdqEIa18xOm0EH+VTW1tJHoFxpzbmnsJSsZPXAIZD+I4qzcpG9iTGv7twJF+hGcfrigCHTW82IqTyAMH045rV0mQxSlSPklAyPRx/jXO6LMEnXJ45U1sWg/0ya1kOMkMp9PQ0Aa2pNhracc7jsY+x/wNQxOX8+I8fKTj/P1p7ZuLCRDgE7hj0I7fng1mmV4r2wlZMLOTA59CemfxoAdKmbCVAf4SKztBJCup/hJrY25EgA71j2PyajKg4BOaANK7/1LE1zuiuWt58nP75se3NdBd5Nu3NYelKVinH/TVj9Rng0AZXiBiGfHXbkV0ML+Y8L/AN5A36VzHiNz5zj/AGDW7Zt8lt/1yU/pQB0cEgyB68VKW3Pn1NZlvJ+8X2q8rcigDQVgI+lPgBCMBxVbedg4qzCwCc0AOc4PTKrj8aqaIpcT30n37pxsXP3Y14UD9T+NGoB5IGiiJWSc+UnsSOT+AzV2FUQRxRjCRqEX6Dp+lAGpD9wVMO3vUCN8n4U+N90rAdFwM+tAE9FJQPegBaQmmvIAOo5OPxoHNAC4pc0UhGKAFoPQ0maWgCpZRsLi7lcHMj8Z/ugYH9auCkXPc0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdr2i2GvWItNUheSFZFmQxyvE8bqcq6OhDKwPQgg1naN4L0HRp4JtPs5FmhnmuUkkuZZW8yVQsjEuxLFgoznPr1roqKAORvPhz4Xu7WG2k0+ZIYoHtgIb2eEvEzFmjco4LruYna2QMnFdG2nWj6UdMeFWsTB9mMTEkGPbt2nv04q3RQBy58B+HBo+laZDYyW9rpeRZNbXU0EsG4YbbKjiT5s8/Nz3zUbfDzwyzwsbG4CxLGvlrfXAjlCNuTzUD7ZcNzlw1dZRQBycXw78MRidW05545oJLbyrm6mnjjjkILrGjuVjBIB+QL0FPt/APh2BVBtLm4KzJcB7q+uLh96o8a/NI7EgLI425xz0rqaKAMHw74R0bw7O8+lwXCzNEsG+4u5rgpEpJEaGV22ICT8q4HtW9RRQAUUUUAQ3bbIJHP8ILemMDNefaD4Vh1Xw/pmtW13c6Zrs1urvqVuwDy9SFmQ5WZR0+cEgdCp5rvdUjeXTrqOLBkeJ1XPqVOK80uddFh8DhqtsZBd2mnm2ijU9Z2HlAe+GNAEXhTxFFp1ze+Itdt3mtNT2x/29ZxubXZCSg3xEb7cEgnPzpzneM4roviL4rfRPAl1qmiFb28uAltpxhIdZZpSFjIxwwBOePQ1ueFNIXQvC+k6UgAFpaxwH0LBRk8e+TXnep6RazfEl9H8JwQ6dcWVqmrzl0Etl55kIjDW+Plc4dvMjKP67ulAHb+CfDVv4T8KWejRN5zxoZLiduTPM3Mkh7kljn8qs6HbXlrazvrVwt2wkaRGwG8tQOgwP0ryfxy+op4jtNU1uHUNNvo41txbw6g0VpcENxLa3GRGs3by5wu8cc9a6Lwr8QHt7iDSteD3LSSrBb30cAidnIyIrmA4aGY9BgbX6qe1AG1ZaldaprAbS57v7Os21lESpbrEDlsk8lj1rjV1OPXvEuoeL7h8adbB9N0VD/zzDYmuR2/eONqnrtT3rpPiZM1vpw8P+H28nVfEMx8xw+GggAHnT+2Fwo929q46+MCJBb2SbLCzjW3tUxxtX5c4+goAJ9RknfMKLEueC/U/h2q5bxvLGN7Kx9his+1tzIcnk+tdBY2+xeKAKFhMsGorFKdoxu59M12NvFGrdiknAY9Bnt+Nctr+mtLGl1CuZYuqjqy45rR8I6pFeWRtLhvmQBdx647MPx/lQB1a2S+VtC7QowF9B6VLa24KFWHzA4o0+b941rPxOgyD2dfUH/PrUlyWt5kmA+XPzCgCZUGOmGFJKUhmWThQ4CuatyYdBMg+U1VuohLC6dQw4oAxtbh+x63Bdk4hul+zS+gPVT+HSoRbmGzEGdwi+Ue69v0rRuoP7R0WW2EgaYIShI5yOQfrkVkWN2bmCF34+UKR6EcMD9DkUAc9g2d6QO7ZH0rfvm2R2d8BkK2yQ/7J/wDr1j67EY5A3of0rY0ki80uWFs4KgY+poA2tm9S42kSYYsP73r+PFZOtxMNJuHgH72NhOvsVI/pV7QpDJpxRxl4SUI+hp+0NFMrcrQBBEwkw4+667hWJ9zVmzxmtm2XYkarzgHn+77Vh6gfL1eI9j1oA0rs/wCjGsfSC5tZC4AzKwH0zxWneNi2b0xWbpzf6ACfUk0Ac34gO64lwecYresSf3Z4wsKD8cVz2oES3xGMgtXQWnyiQem0D/vmgDTtWzJV4SYxzWZZnLk59quE4IoAvJKSQM1fifcAgHHVm9KxoCS/HWty3TEQ496AEQbrouxykKbVHuep/wA+tT2x3SE9qgmbYhXjkk/nT7ZgFyaAL4c5AFWYl2jjvVSAbuTV9McCgBI3JkIJp043IV/yabjD5pkzHp60AJIqyOoxlU6fWrCjAFMhTCj1qWgAoPNISAaAaACjNLSd6AHCigUUAFFFFABRWNrvibTNCvdMtNSkuUn1KbyLURWk0weTGdpZEIU4yfmI4DHoDjZoAKKzL/Wrex1vStLlSU3Go+b5TKBtXy1DNuOcjg8YBq358n2/7P8AZJ/K8rzPtOU8vdnGzG7fuxz93GO+eKALFFZer63baVf6PaXCTNJql01pCUAIVxFJLlskYG2Nhxnkj61qUAFFFV7CeS5tI5prSezkbOYJyhdecclGZeevBPX8KALFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADXOMfWvnpFvbvWYPhtLBcW9w2ttq0txOQIvsUcolUQ/3yxwMDpzmvoZgG4NcX8T9Ce+0mHV9KiT/AISHRGN7p745YqMvF/uuoKke4oA7HIzz615R8OHg1KPxv4n1GcWy63qslpbTk4Y28A8mMDHuH/OtHxl48t2+D7eI9Admn1SBYdNX+P7RN8irj1Vic/7pra0HSdN8MeCdK0l445l0mKOMKRuLTY5x6kkk/jQAmhRoyXGhXjfare2DLMbpA8c6seVw3ZeBzXJan4AhlhjvLGwgS2sZfNTSdYctAgQ7g0E65eAHGcfNH/sDrWzqlzquqXznTXnXzcJHCYQ0e3oxdz0yQeKf4iu7u7t49EuIFhF2SzqOqWse3fkZ/iOFHsT6UAc5FfQ3+ualdXgmtvEOoRqsNldKFZbZFyFtnBZZlJJYtGSeRuA7VPs32yzthCV86FNjxnrweSe34da2NbEN+j2t9bxXVqxDNDMu5cjoR/dYdmGCPWqNxpd/p0RuLN31O0UjfBdTBLqP08u4PyyD2m5/6aUALaWskSfOmPc1pRAhMjtVXQ57fVrmSKK6bzYBma3njaO4t89PMiPzKp7MMqexI5rWktjaSqJhtQ/xDlT+PSgCNGDp8v3h2Ncxqdq2n3yXdodpJ6dgT2P1rt/KWEByimI4+Ze3sapappSXMTeUBvYEqOzex9KAH6JqY1OBYi6w3KcRs3/LNh1RvY9K61lM0AWRRkgFsHp6/rXA6RpHkRyT3IlVdgwVUeZFg8MR3A/lW5pl9JebHjlVruHKrydsy+hoA3dOlMMptpTwejGrUy7MqR05BrOmbz4FuIQwcfeQ/eB/umtC0mF1bo24M2PmHp7GgDPGIbsKhAZvnQ9g3pXPXkQtNTuYhw0o88KOgbOJAPxwfxrob1dicOFZiWjGO/tVHVo1vbGHU7cfvYPmkUd1PDD9B+VAGBrSiWyDryag8K3RWVo2PAq3KuwTW56YyD68cGuc0ufyNUxjgtQB2unubfXZVx+7nUt/wIVoAYnlQ9ayr1gHtZhnhs5rT3g3Mb9mXtQBTgbbI6YwFkJ/A1j60ALuFgc881qTtsvJl9VBH51ia+xEgIPQigC5fv8A6EfpVBG2WCjvt7e9T6o4+wY/vLisy5nCWWxTg4wMUAQaFD595dSlRtjhOCf7zEAf1rQVvmmIGB5h/kKf4ZhEejXE5AxPcYX/AHVH+JNRuDlx2L5oAuWg5DDpmrLNz1pkS+XaxAcs2Sfpnimk9B70AaNgMyZrdjYLFzWJpg5BNaU0m2MigCKZ98gqzEegFZyElvc1ftWBcyEfIozj9KANWD5SATyBzVtG9etZUUpPJ5NSC5ETbnOI+5oA1G5Oc1DMCBuHNPDCSMFTwRxTeChGelAEsTHaKWR8cd+tULm5+zAJGrSzuf3cfQn1J9APU061WZov38qvIT1QcD2HtQBYjYu2R0qxTI0CDAFPoAKKD0qNnCozMQFUZJJwAPWgCSmu2CK5Ofx3p00z2/h2C78RXSHaU0xA8SN6POxES9OQWz7GojaeL9a+bUNQttBtG/5YaYBPcMPeeRQq/RYz3w3egDoNb13TNBthc61qFrYwE7VaeQJvb0UHkn2GTVPQ/Ej63e4stH1OPTdhYX93F9nVzxgJG5Eh+pUD0JpNB8IaJo90b22s/O1JhhtQu5GuLlh6GVyWA9gQPaugCgE44z1oA4n4hWWp3fiDwXLpulXN9BYaobu6likhURR+TJHyHdSTmUHCg8K3fAPnMPgPxILnXjp2htZSXdtcb7q6mgWeZnnSTyVuIX3yK6h13TIpQbQD97PvtGaAPIbXwLaanruil/AVvo+gwT3ElxY3D27xuTAiq5hjdkGWGMDOdu5gCazI/Bviq08PJBBpMFxPHoY07ybpoZ1I+2bjGFdtrEQ8ruO3IUE9a9xooA8R8EeCdd0zV9PY6Xc2mlW/iI38UVw9mjRQHT3iLbLbES5lbG1F7555Y63xm8Laj4g1C0m07Qn1V4bSSOISm3kthIzA/PHK6PGflX97E28AsAM4I9YooA8H0jw9Pqvi7WZLPQAuqW3iiKZ9eDxbbeGOOBpYVJbzTuXcu3ZtIkyTxgWbT4aXd7pyxa7odvctDoF1awLM8b+XdNPIybfm4bawIftnqDXt9FAHhGoeAdfvPEcd7q9nq17J5VgbS4tJ7AfY2jjjEqtLMjTJ+8VnzCSG3EHvn3eiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAprdRmnVm+JdWg0HQNR1a8IFvZW73D84yFUnH44xQB88eA7S4m8XXemtDNLovgzUry/eNwFRruWRhCin+6qlnz2yfavVL68n1eWxZ2eAxs88BjXMkilTtcL6Db17ZrF+HsR0rwFZS6vD5ut+KLz+0b+IL8x89shT6AIFAz6GtvWvD99qWsSxWur28SR5ENsMxtFGQM4A7ds96AJPC+n3V/Z3cM2pSG1TyULwn5SVXcyqfTkAn2NULGb+0JdT15ycX8vl2ob+G2iyqEem5tzfjW54sN3o3hHVJ9NcGQ2q2tpDGAFEjHaG+u5s/hWbexLaWUFnDykEKQjIxwoA/PIzQBnREefuZjkdMda6bSIUdShCupG0qenP8AWuYtYf3nmFgWAwpPIHua6HQttkqxSKYmduJWOVmPXr/Q0AYniXw5bWIhkvYWl0mFiYLuJylxprnuki4YL9Dj1BHFLDdaxpUQ+1RP4i0vGRcW0ai9iB6F4hhZv96Pa2P4Cea9CR1eJ45ACuPnUjIwfbvXK3enS+HpfOskkn0Yku9vGNz2+eu3/Y7n0oAg0S/s723NzpN1FfaeGKsUY7o2HVWB5Vh3VgCOmO53hbRS2/7ohlPbuDWFeaLpmuyJqdncSWWrFAiapYOEkkUdFkB+WVf9lwe+MGqS61qXhucjxHbq9qo/5CmnRs0WPWeDl4vdlLr3JXpQBsTxj5oZiQTwGBrk7gXWhaiBIPlJyjkcOPQ+9d7i01rTobm3limt5lDRzQuJI3X/AGGXrWZdW6Xdu9nqABx8qn09DmgC/pd5HewC4hOXb7y/3qmEZtpfOi4BGWT2749x3rhree48O6j5FwxaBjgN2IrvLa4jvLdXjYFW6HPI9qAH3kKXtsw4OeUYHDKfasjSkNreXFtM5e3lUBQR0Pc/jV9XNq+z+Aniq2sJ9y4i7c8UAZviKy+ziOWMcINv4Vwmrg22oJIvCnmvTw6X9hzycdPevP8AxHakW8kb53xng+1AG7azC70YYOSozWnbSiS3hc9VOK47wffZDwM3UcCuj01ziaI9jmgC1fHNyhB4Oawdfb5wD3AxWzcv/qmz0asfxCqqA5yXXH0xQBDq8m6xj+grGvZMQ89uau6m+63gA71SETXN/a269XdQfpmgDrYovsmj6fbngLApYe7Zb+tZzBnlKD72efr/AJxWnqMm65f0VtgHsvSqmlL5+o7wNyrmVsdgBQBduQFlKL91MKPw/wAmqsZ3SNnkZwBSXLNgRqfmOFPt/eNTWSAyKB0HSgDZsU2Lmm3cmWAqQNtjwfSqMjZk5oAnjORj1q652RInf77fj0qrZhWlXzOEXlj6DtTmcyFnPc//AKqAL9s/y8023vEvYZUXBIdgB64pli2/jOMVlaW6QalBEWAzIykHjk80Ab+lX4QCCbcSzAAj3NaErmIkqNzDoB3/APrVzqH/AIm1ntOA0o/Ef5FbsYlQOZiuS5KAdl7UAJBaGMvNKQ1zLgu46AdlHtWhEpA5qnfXtvYWrXV/cQ2ttGMvNPII0UepY8VzKeMW1HI8JaTe6yDwLpv9Fsx7+dIMuOesav8A4AHaOxC/IMv2BOKwtb8U6RoLxw6pqEa3kozHZwq0txL/ALkSAu34LWZ/YHiDV1z4i197eButjogNuv0ackyt9VMf0rc0Lw7pOgxuuj6db2ZkO6V40/eSn1dz8zn3Yk0AYg1bxVrXy6No8OjWx/5e9ZO6XHqttGcn/gbofalTwNaXriXxTe3niGZSG8q9IW1U/wCzbpiPtwWDH3612AHsKUUARwQxwQpFBGsUSAKqIAqqPQAcVJilNAoAAMUUUUAFJRRQAtIKazbVJ9BmlXkD160AOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzP47yfa9B0Tw4Dga/q9tYyDOMxbt8g/FUx+NemGuJ8V6UmtePPCIkbC6YbjUQv95gFjX9ZM0Abs+nRvPDeWcECXcYCB5AflQdgB6DpWXIbdry61NLJD9kPlfaC5z5RA34B7jnjp1rltZ0nxrH4h1C4Gr60NNeQtZppK2pWKLAwjxzDJfOfmDHPFZj3Xj8Xqf2GfEF5OrqJINcsrSG0kjzgnfG25Tj0Bz6UAdl44kigt/C2n2qhYLrVIECjoEjDSY/8cFUNSJyWJ68mpfEbC88d6DZyou/T7KbUHCnhHbES/oZKh1E5JyRz/OgCogbdGUOHzuXH8Xsfet6xuY8i2uUARx8uRlX9fo1Y1hBFITHcDMbDoelasUL2sZiut1xZsfll6sP971I7HqKANYBreOMWpMkefuu2SP8AdPf6GnR6hyTEfun5kIwR+FZjvNZjIbzoevmZGVHbPr9RUZuIblg6YDkcODz/APXoAz9W0+W0kl1Hw2drsxknsScqx7so7GptN8S2WoIsN1I1vJnC5OHVvY9uadcGRQJEZ96c+bGOVPqR3rF1HT7TVVcXgjtLknK3KL+5kPYN6GgBb7SJNFvnvdEum0qe4bdJJBEJLa4Y9TNb5CsT3dSj+rHpVyPxVAyxw+KIY9KmdgkV/FL5tjMT0AlIBjY/3JAvsW61kG81PQCbfVYmuLNxhSDnH0bp+FJHciEGbTZBPZSgiSJxnCnqpQ9QfQgigDpdWtftUTWt8MED93J3H0PcVz2i6nc6HfmxvCxjPMbditJp1mEgx4UuY7SMcnSLss1m3tER89uf9zK/7FQzzw6lPHpmoRS6bqz/AOpt7ogmQjvFICUlHspDDuq0AehRzpe2m6PlsdKhs5FkDwSdeetcHpWr3Gh36214rBuh3dx612M7rPGl7akEdwtAEULnTb4wsSYmPU9qqeJbISr5g6MOfrWlqKDUrAyIcSAZ4qlp9yl5A9nO37zGKAPO7KY2Wr4zjJx0ruLCZfti46Oua5LxTaG3uVmUEENg1csr3Mdu4bkHaaAOqmZDIEPZs1heLZNnkgHhjtNXXkzchhznmsjxvLlLYj++D+GaAMzU7ri3XdkgCr/hKI3Opy3Un3IFOPqeBXLX8+++jRemK9B0O2+w6LGCMSTHzG+nQf1oAS9lJkcnq2T9K0NDj8rTr65JILKLdMep6n8BWTdHL/StjUALXT7Kwj/1hTzZMep/+tQBSjO+KWcjljsQ+nqfxq5YKNwNVZD8sUYGAuc+/pWnZx4QEgDjtQBNcMQnFUlYs36065l7Utsu4qfXr7UAWl+W3C95Dz9KkYbYj9KYDuk57fKBUWuX9lpFms2q3ttYwv8AKjXEgTefRQeWPsATQBd0wjeMngnj3rO1TTftupiGIMkiyb1YD7rAZFULLU9TuWI0HRZDnj7bqxNnFjsRFgzP+KID/eqTVPD91cwhvEOr3Gp7jzaW4NnZ+uDGjb3Hs8jD2oAT/hIbC11wwzvJf6rCSzWGmJ9pmRzx8wTiMe7lRWnLP4s1f5lisvDdqe8m29vCP90Hyoz07yd6t+HGtdO0uO1sbaCyt4/uQW8SxKv4KMfpWg8okZADyx4oAzNM8GaQt3HfX6XGs6gh3JearJ9odD6xqQEi/wCAItdWpxyeT71WSUJGMDA7ChJSzGgC6p9qWoo2pfMy+1fTJJoAkopufegGgB1KKAaKACiiigBKKWmFwCc0AV52Zpo4U/i+Ziew9KtAVVtU3XE1wHDxy7dnsAP8at0AFFIOppaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAR/wBe1cxcnb8RLZl7aTMT3PE0XauoPIrj52aT4mSQJkONEJznABaYD/2WgC+Jnhu4HtYpGt7pvMkedyNnbC56Hjp3qaDU4WuYBLcAmXhI41JU5JAJz0PHSuT1C3hENnpt1cS3uo2KlyS5JAZgQ+e+2uws5I7q6V7CW2kto5HWcxqOXzwPqDkk+9AHIRyfaviD4qucDbaw2tiG6/wtKw/OQUy8AaQFgGwd3PrVbwi4ntfEOoYP+ma1dPk90jIjH/oNTXBKyYPUHB9qAL1hHG7DzDtTHJrWkaXTVZpQZbQ8FoxnGf71ZOmCKU7JvuNlSp7j+ta+nWs+mJ5dvM93YfwxucvED2DH7y+x5oAiYQmNWtWRYsZ2fwkf7P8AWsu58va3y7WB4PQg+n0q3qGlgs9zpEnlTE5kgb/Vt7Adj9KzL6O4t1Vpk/dsMl15wfegB9veBZAsm5G7kHGadKsTs5QIhbrheG9iKowzB+HwwqJvMjl/dMSp/hJoAnJltIWVI0a1bhrWZsxn/dft9DWVd6FBcSF9Gke0vQMtaTHaR/unvWtDeAN+8UIenIyKlktYrhVMTIr9QX+bB9j1X60AcPNcXljd7Z42huV6qwwSPUVrf2jb65YNZ38cMyyffhnQPG+OmQeMjs3UdiK257adrUw6nCL237HP71PcN3/GsS80GCWTOlz7ZgoJimGGJ9qAKU1rdNCbeGQ3scX3bO+nxNGP+mF02dw/2Js+nmKKu+GNXe1uZrWN5X8sAzWk8ZiuYB6tGeq+jqWQ9mNVJkv7IBbuIh1HG4Zx75rPvZvtMcS3dsJhbnzEwzRvAT/FFKpDof8AaU/XPSgD0SK7S3cTRkG2k6fX0NZWr4guU1CyfMbdT/npWDpGs3Ea7WV9WtX+8qBI76PPfaNsc/1UJJ/ssav2Vyl7GRpk0F3byOY3ch8xPj7skeN6P/ssBQBY19Y9S00XKBiQuXUdcVx8rvp8wiZw0bqJI2HQj/Ed61VvJLR7iEhcqHZ+TsVUzlt3XHBx61zguoNctT9kk3khpbVgMBj1ZCD90ng/hQB2EeoI6xENyQB+NZ/jW5ZoYVTG4EVz+m6l5kMZBwVIGD2NWPEFwbh7dAc5OPx7UAJ4fsm1PXUUgmNSDn26mvSbtxnapwEGAPQVieEbIWdpJPja7nYuevv/AIVfuG3MV/M0AS6RFHPqCGfIRSXb6Dmpmme9vHuX4eVsDPZewpQggslTCiaf73+yo/xpIl4clSSo2KBwQfT8KAHIDPclsAAnA9MDpWmx8u3yKyLnU9O0aWKDUbpI7uQfu7SNWluZB/sQIC7fUDFQzX+sXoLWenQ6VbHpPqx82Ug91tom+v35F7ZX0ALgSSZ2ZUYqvJOOAPUnoPxxVKDxDZzOYtFiuNbnQlW/s1Q8KHuHnYiIdDxuLDHApsegWl8Q2ty3WtMCCFv2XyEI6bbZAIuOxZWbjqa32+6i9FQbVUAbVHoBjge1AGUkOu32Dd39vottjPkaUPtE+PQ3Mq7R7hI8+jd6WDStK0e48yytduoyD57yWRp7px6tM5L7fbOPQCtCe4FtEJQgklYhIkH8TEfyHeqscDQqxmYSXMp3SuPX0HsOwoAv6e20kkAZ5ODnn6nmrc0glAQngHNZyNsXAOKVJGdhtPFAFmCPbuxyDVtAICgOTIByfSoICRgnoDzShizkk5J60AXxIzEAdKv26YHJrPtFCrljxVoyliFSgC0ZOcL1qaJfl579ait48HJ5NWlxjFADeh4paDwaYXxQBLSiolfNSA0ALRQKKACsnXXf7KlvDkSXMqwA+gOSx/75DVpSSrGrs5VVUZJPQfWsmyBv7171mcRRyGOFT0IUEFvxJP5UAa6qEUKoAUDAA7CiSQJGzHoKeelU7lvMmit1Iyx3sP8AZH/16ALMWdgJ6nmn0ijFLQAUUUUAFFFFABRRRQAVyfiDWNYk8VWnh7w6bC3uDaNfXN5fRPMkcYbYirGroWZmzyWAAXvkCusrnvEPheHWNTs9Tg1DUNK1W1R4Y7uxZA5jYgtGyyI6MuVBwVOCMjFAGPd+NLrw+v2HXdOm1TV7e1a+vTosQ8qG3DsqylZZA3IVvkUu3ytjOMmdPiFp09xO1nYandaTbMFuNWhiQ20J8sSfNlhIQFIyyoVGcE9agvPhzb3S7m8Q+IUupLVrK7uhcRmW8hLs+yQmMhcF3wYwhUMQCBU0fw906C5uBZ6hqlrpNywa40mGVBazHyxGc5QyAFQMqHCnGSOtABbfEC3dbGS80PXNPtb6eCG3ubqKIRv524RsSshKgsFXawDgumVAJIib4j2MhRdM0nV9Slc3LKlskIzDBJ5bzbnkVdhfhedzdQuOaraz4Aun8FatotlrmoX8l1ax2dr/AGpMvl2aq3yunlRqS6/eDNliUUFsc1B4r8CXy2OkQeC3FjNZWD6WZjfCD/RyEwpU282/lc5Gxgejc8AEV78a/ClmuntM8yrdWlveuHlt43t451DIGjaUO52kEiJXx+VdM/jXTURmaG8wurf2McIp/ff3vvfc9+vtWRpPw2i02xsYrHXtY0+WOwtbG7+wSRot2IECKzb0ZkOBjKFTjAJ4qxd/DqyudVe7/tfWYbdr/wDtP7FFLGsIuNoBcHy/M5xnG/APIxQBb8DeN7LxlG82m2N9DaiNZY7ibymSVW6YMcjFW7lHCsMjIrN1r4mWWl6pqFmdC126SxvYdPlubaKFozPKiNGigyhiW8xF4XAJ5wMGtLwp4Hs/Dur3Wprf3+oX9xCtu012IQ2xWLcmONN5yeWfcx9afdeCdNuZr6R5rwNeatbaxJh1wJoBFsUfL9w+QmR15OCOMAEOkePLDUb2ysmsdRtL65vp9Pa3uFj3QTRRGVg5R2XBTBBUtncOnOM2T4p6TmxS103Vbqe7EzJDEIRIFinaFiFeRd53KcKm5sY45q/eeALGa5ku7XUtTsb9tSk1RLq3aIvFI8IhdVDxspQoOjKTnvWVd/CXSrnRLXSJdY1s6dCkiPC8kMgm3yvKzEvESr5dhvj2NjHPANADPGPxBmXwl4muvD2n6qos7S9FvrHkxNbCeBX3DBYtw6EZZNpK4yamuPi14ds/E0OgTyu94biGykkWaABZ5Nu1fLMglIyygssZUZ68HFu7+G9lcWWqaeus61Bo1+tyH02KWIQRtcBvMZcxl+rswUsVBOQtXIvBMNtrU1/p+tazZQXFzHd3FjBLGIJ5UCjLZQuAwRdwV1DY5HJoA3da1nS9CtFutb1Ky061ZxGJrydYULEEhdzEDOAePY1if8LH8D/9Dl4b/wDBpB/8VXVUUAcr/wALH8D/APQ5eG//AAaQf/FVzF9408KHxwNQh8V+GntJNJltnkOr24AkEqsi4355BfkDt2r1GuR8T3U9r448IIlxNHbXUl1DJEJSqSN5Jddwzg/cOKAOG1nXfCcbRyaV4v8AD0spiMeX1m3HkqeqjL5bOT19BzV7w/4q8LWU1qV8YeF7OGONFmCavATMVJwSA2AcYz1zXS6vqmoXE8cHhqRZIraX/SbiSX5VI/gJPOORyM1b0mxvbHV0l1HU5JftQYCASuU8zO47AeihRQB514H8TeHtN8GWtnfeJvDUN4s1y8kf9s2zffmdgciTHIIPX64qqfEehXV6ZbrxL4dEanEajWrUBR6nEnJrZsNW1M6L4tiN7ePdafrF1Ajee5ZY8q6AZPQK3FWIZdUMqPHqV9JAQCP9Jc9vrQBHD4r8KrsY+LvDYK/w/wBrW3/xda9v498JxrhvF3ho/wDcWt//AIutrSZ3kgCyXNwZPVpW5/WtXzHVMSmTHYq5/wAaAOTl8deDZlAPi7w2jDoRqtv/APF1ny+JfDOrSiwg8TaDdz3DCONLbU4GeRieAFD5Yk9gK624Sckvb3kpxzsMjD+tZNze30B2zSzqMY+ZiVI9KAOXltrm0cmIG4gHYffA9vWom1BcgIx4PTHI+tbsjmV94AU+q96zb6xhuiWZcP8A304oASK6RhiReD/EoyB9fSrKLtXzIJQUPRkOR9KxWtbm2z5LeaO4PWmRXEYmz+9tpf7y8c+470AdLDqMsPDqHFWDJZXxPmoC3TJ4I+hrFSaWUfOqTpjO9Plc/hTJZUU4BKnj5ZBtINAG/Jay7VFs6T2/TyZxkD6Gse/tLSWFopoZdOkzhGA3I3tnsPaoY9Rki6FsD15H51oRa3G2Vl2kH8aAOLu/DmoWrGa3C3UHXdC28D69xVZdSji1hZtVkmtLyCDdDewv5NycHAjDYxIOnySBl46Z5r0CJNP3mWBmtZW/ijOOfp3rP19naDFyLK9jVeDPGM7iQBz+NADLWyRNHupZpFaW5LSvIxxhmJIX8j0z25ry64lt4piml26xWcbsfMDk72P8Sg/cH049K6/U9Fgmg+ylJhG7AZguCAp9NvcGp30G0lKR/ZtSIACqI49w2jqPegDztriSGeRuoY7jx+f616F4d0XZpces6lu84nZawgZYk9WAPf3rQ0PwLaTaijfZ9WWNRuQXFuFUkdAT6V0Go61pMN+LOO4k1PUoBtNnp0P2mSM+jbfli+rsooAQgJCigKqqowq/196qgxwwyXl7LHb2cXLzTusaL/vMxAX8TTbj+2bzG6Oz0WA8bW2312fw4giP/f0UW+h2EVxHdzwy31/H9y71KT7RKnvHu+WP/tmq0ARDV/t4aTRtPudSVvu3Ln7HaAdj50g3OPeJHHvViPTL27O3VNVdIT96z0YG1QdRh5yTMT/umPr0q3K8kr5cs7njcSc/nV1MKoJ+hz60AV7CxsNFtZItKsra0SQ5lEChTIfVm+8592JqPBlkBx1Oce9SSsZXPp0q1bQYGTQBJAiomccjrSFgS3QY657Dr/Q06RgDgdqq3KtORagZRhvlI4woPT6mgBtkftJa/bJUqy26sMEJnk49W6/hTnILNjp2qW4cEbV4/wAKjCs3AFADPvEAVaiQKAaI4duO1ScDvQBIG+XHrU0YG0ueMcfWq245AUZJ4qxtLFUx9zgn1PegCxGzPgDpWjbIqct1qnHtjAOeamjl3uo9e9AGgJAB71JG+aoo+X7YqdWA7igCw7jGO9RqpLc9KQMXcbcBR196l4FAAoA6U4GojIBQWkAJVdwoAnBoJNMjYksCpGD370rqWDLkigDM1RVv2jtY5VwJVaZevyjJwfqRWhBAsMaJGNqr2H+feq+m6fFYQeXGMsXLsx5JJq9QAhIwc9KytDc3T3V6ekkhSP8A3F4/U803xNdvaaRMYjiaUrDEP9pjj/E1fsLdbS0ht4+FiULigCzRSMcECloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhviqyWsXhnUpMhbPXLUsw/hWQmIn8nrua4b41bf+Fd37NgbZrZsntiePmgDoptFtzbSW1sBbwysWmVFz5gPXnsfcU20Om2Lw2q3UXnFj5cc04aQN0IGTknnmuL+Iuh67qHiKK5+yTatoCW+3+zodT+xJ5u4kvMf41IKgDPGDxVPw/wDCrTzrFhrmsQ6TFNZyCe3s9ItxFBG/ZmkPzyke+AT/AA0AS2MX2fxt44sHX5JprfUV9GSSHY36oajs7eSxZYlMjwZ2rgcqPcVoam/l/FueA8+doEbn/gE7j/2arREiXbCSEG325SVW5Df3WHrQBPaQuh3xEj/ZPStCLUgkpt7jMc2M7JOCfoehFSaavHyqD25qxeW0FwhhnXHHAYZ/KgClOYpMsH8t/rxWdcSTJ8jhZkbsadc6Rc2x/wBGmLxjqkg3ED2NU71mtdplcbD3Unj6+lAEbxQN/qme3f8Au4ytQ3CzWqb5o/Mj/vw8/pQ80Tncr5BHHOf1qSG6IAKsPSgDP82KYjypVL/3c4YfgaWezWSPEiKxx0rRk+zXAxNCrEd8cj8e1RTWsijNlKroP+WcnX8DQBy+qsmi2/2tpJfKDpGI0ieVmd3CIqqgLMSzKAAD1pyeIZSoSbQvEbr3H9g3uP8A0VUniNpf+JSJImT/AInWmZ/8DoK5T48+N/EQ8f3EfhPUNTgtvCVrFe3cVnHM8VxM8iMY5zGCoQRAtmT5eGHc0AdbHrNhd3cdjJb6lZXMkbSol5p89puVCoYqZUUNgumcZ+8KtNYRud0UuV9wP50vjfU7TXdf8EapaNvtL3R764iYf3WeyIz+dUhGqNmOYqaAEudPu1y0IDAdNp5rkPE+qX2lSq15HJJYrbvNIqjJDKy8n8Dn8K7u3nZeHkDfU1S8U+Tc6PLbyqDb3B+z3BwSVSQFdw9wSKAOdvrm7jSKaUr5MOZBIxUY49D14re+GOvw3V6dQlgU6dDi3iuUjZXLt95jzyg4GfU1yfjC1RLLRzaKLlrG6hLAAOZIwCjZHfglq6TwFqUraktu8UcWlpIY0hkz5jcFixPQZyOO27FAHpGv+G4tVuJp9V1HUr6zYjytO8/ybZBgcER4aXPPDsw56VDBYRWNvHaWcMVpEARFbW6iKID0CrgCtS1uI7XEYO/TzwrNz5Z/un69qjuIXW7j8wu1rKcRyAf6s+je3vQBl29nKcyThNzYwi8gD60ksR3YC10ctvsjXHznHWqRtDkkjrQBlRwBRkgmmTZLEDpWjOm3jFVTFk5xQBXhhJ5Iq0W2rikICr0qE5duaAE3Y+Zvw96kA2RkPwzcn60sa+o4pLsERFVIEj4SPPQknqfpz+VADUTzG64z6c1aSMKM0RxeUihBlR39acFOQPegBjNSeWzHjvUwVfMRCfnbJxVpU29OvagCOzg2MZXXdtHyj/a7VISFHJ+Y8kj1NLLOqoI1OMc/jVJpi7YAzigCcyDnJ4FOWVo4x3d+QPRfWo4ITLIqudo6k+g9asEoZCQPp7CgCaEOepwPSrscQH3+fpWf5+WHtU8M4IyT8nf2NAGku0KKVjkYFU0uQTx0qZJ8n60ATBO5qQYqAS7+PSpUHBoAlpe1MFOFAC0UVUv7uGwtJ7q5fZDCpdifQelAGJf7NS8W2VmrF49PQ3c6dRvbiPPv1IroowQoJ69TWF4QtpFsJdQu0xe6jIbmUd1U/cT8FwPzrU1GcxwrHHzLK2xB/M/lmgCeCQTMXH3QcL71NUUEYijWNfuqMA1LQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXE/GlXb4W+IzCMyRWvnKMZyUYN/Su2rP8Qaeur6JqGmu21by3kgLem5Suf1oArX18409rwQiaza0MpjAySxwQPpg/pWRc6pcQaRHc2jW1tHHA8b25IISZcFVX1zyPpg1R8A65Nd/Dnw3MyiW+ZEsZQ3H72MmN93oco340r6ebS/jsrVhc3TTm6WUgKIhztQdeSqt83rj1oAh1xFPxJ0C+I2vdaRcxOvsrxNj8Nxq3dmNAPNlEe47NxP8VQeOFeLx34GucsA8l5aMo6HfDuGfxjFWNWtI7m1khlXKv3x0PrQBJp32uAKVKzHktGOGAHQp6/Q1rWupW16pQMplXho24Zfw6/jWVpUBjhjSOUyFVwd3XjuPatG4itNQiC3UWXXgOAQ6/8AAhzQBJJGw2/ZZ1x/Er8Z+hqreHZxcxKynuo/nUEmm3UMga3vHmhB5WX5mA9mGM/jUV9ez2B5Ek0ZGTiMsB9RQBWudLsbhi0QVSeRjis240hlwY5CAPU8Vej1WxkIZkVGP9xsEfhQ0pMmRLG0fUBlwcfWgDGMF/CSFZJF7ANzSCe5gJ86JseoGa1nkYA7ojj/AGGDf/Xqq1zEpzuZD33AgigDE8SSXNzp0P2OOJ7mC9tLxI53MaP5NxHKVLBWIyEIztPXpViHxPqELagY/A3heJtRyb3GpuDckgj95iz+fgkc561pGaBx8xX8xzURjsZOWCj9KAMEteX+saRK+iaPoum6ZZXNtDbafdNKpMskDcL5MaoB5J6ZyWrRlVMZA/KrUkFoEOyVVHs1Z048lSVu02+5oAy7248tyNrfgKzr3VJPJkEI/ebTjcM8+lW9QuSTgXEOSO9YOpO1sqhbhnupeIoIBukY9seg9zQBQW/utPsRJFYzTmabZbrnG53P3cdRg5zXa6FpOo2gsoLS3tDdKztdXE7Z8uUtkhB/EegA9qboWiSacsV1rEpn1HYdhYZ8oH7yIOmfU9+1dHbLDZTR6herzFl4I0GRGcY3Ed2xigDW07Uns7zyNViWBZVRcMc72PUEfwgetb9v5unu3l/6RZN0HUx/7PuPeueuYre4t2ur9CZXTCRA/MB3UepPeqOk6heaCrLcyNcW4OTEQWeBP7u7+ICgD0YbJYgYwSvTHcVWnChDtHI96bBOsyCSA4ZlDBR0ZSOCKsRlJuCQHHagDHkhZ39qf9mAXnFbH2YfSq80JGQDQBhXKYBxUMcPOM1qyW+c7hTBGFzjoKAKscZ3c8Dvx+tQ2e27uXuOqQkxREjhj0Zv5AfQ1YvywhEUa7pp/kXj7vq34DNTRWoht44YgREgCIPQUAMxSMyICXOABnPpU7Qlh6c4rOu4luZvshJ2ACSUg9uy/jQAllK8he5Yf6w4QHqqds+/U/jVkM/LDOR0FG2MMF7kA4HbinedtOCvHrQA1bcsST35NPEax9OM9agnuVbAJIAPT1qHzHkfLcEfMBQBblnEXyfxHDH1x6VGJv3e7+KQ4UAcBajhtzNL8+Tn5if8+1WGCF8gYX+H6UAJHG785IA71cVNwXPAHQf41AZ1RQF5A6+9Itz6UAaMaKvORxTy64wDyay/tRFPinLGgDWg2oOKto4I4rLilPFXrc7lwOtAE+c1IOlNRcCnUAAIrk/EKprmt22hKxa3iIvL7HTbn5Ez2yecegrT8SavBoWk3N9cbnwQkcan5pZGOFQe5OAKr+DtIm03TXl1ErJqt85uLxx/fb+AeyjCj6UAb5UBcAYHTisi1f7dr88inMNkvlDHQu3LfkMCruq3qWWnTzs2NiMRn1xVTwvaSWej2yTY89x5sp6kuxyaANgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmv1HGadQaAOD8JKNI8deJdBOFhuWXWrRCOAJPlmA+kq7v+B1DpMi6fq1xdy28mw3UkUSnhYk5LNjuB69Oan+JjDR7jw/4oQFf7MvVhumUZzazkRyA+wYxv8A8ArbvtHt7nybLZKghVpIZQxwpJ5U+o6cUAcr4vnkutX+H13doYWOqyIy9OTDKq/niumukTeU3ruBA25556ce9YXxKeePwXDrNzCBeaHdw3zDsfLcByPYoWrc1nTo7iZL+3G8iMxyhD/rYSd2AezA4KkUAZ0NtNFdMYJCQefLJxgj0Pb6VoCYSKI7tWVx0Y9R/jWUTNE6whgysN8M54WZf9r0k9T1NXIL9BiC9QAnoJOp+hoAslZolLW7CYDoq8N+VV11aEyCO6GyT+64KkGp2tYpsfZbkqT2Y/yPWq9wl+NyXVol1COj4Dfz5oAW5GmXIAnjR892GT+dUZNA06Qo8E0sOD/yylIB+oyf5VVeHTp/u/arVs4wpOPyNQNYTghtP1GNgeCG65oAll0aaJmMN27DP8aD+mKhkt7uMYdlYH6imC51y0bElusi+qkGl/4SSaLIuLM7vpQBXJUFhcGFcd+c1HJFprcyzoT7cVZfxPYSD/SLMMe42g1E2teHWGWtYwcc5jFAFKZNFCfM54/u1hX50lCRG8reu41d1PVtLlmEOn2CtM/Coi/Mfwq1pngya/Im1mT7DbjkWkfLY/2j6mgDkGh+3XIs9ItGlmb78j/ciHqex+ldbomhafoKg2sfmXrD95cP8zMe+D2X2rR1nSNButa8FaI2l2Vxp7arIZbeeFZUkxY3ZBcMCGOQDz3FeYajrulWev63H/wg3gf7BpviAaUUfw2VXyC2PNe8z5MbDj5SMnsKAPRbi+iguAAjXFwB+7XHC+4H+NSwxSTzfabuRmmHKID8qZ6j3pt1oelaF8TNWttD0yx023bSLGRo7O3SFSxmvAWwoAyQoGfYVeUJASOQGOR7UAMgjkmnEzTyBlyuFPP4e9bkaw/YhbFSUI+4STu+tY8kLl2aNgm7v2zUdrdi1Z1tkkuZZPvEnIJoA3bKX+z4GWXi0UkqADmP6H09q24Z1kWJ5CHgPMcqdPxIrEiiea2Q3GNx6hTVa1L6RLLLBMkMTD57aU/uj9PQ0Ad2rkc9V7NnNKCsiZX5u2awdK1OO9gEmnSBZAMtbMwOP92tCCWGVyYcxT5w0ZOMn3FAE0yckHr6VTkj5+YYA5q+jnb+/AVvXtSSQs3TJXrx3FAGfBEWk85sjJ+X2HepGzvx6CrMuUXOOOlVZCcZH4igCC6kMcLMeSB8o9W9KqWls1tbu07BpHPmzN6nPT6DoKl3GaXeyHbHyg9T3NRT+ZNIoDlURgzgdz2/CgBwhAy7cOx7+lQzskagjLs3CoOrf4CnysVUggufQnk1H5ZDvI3MrgBm/uj0HpQBCkDKQ9yweYccD5U/2V9qeGVN2ec8mnFH4wMClity+5n+4vU/yoAfLIYIAOjy88dQuKpmVmFWXiLuZHPznqPT2pAiLjjmgCJELetWUhApUIHQVOoz0FADUhXGTU8QjBHApgiJ4yanhjCnmgCZNnYVctyAaqqR6CpUbk+1AF4ngUm7nHPNQGXoAetcx4uvJbvboFhM0N5fxOZp0GWtbfo7+zHO1fc+1AFXT54/Fvi46lEd+iaKzxW7kfLPdcrI6+oQZUH+8T6V3AYAAdgKzdI06z0bRrSwsIBBZWcKwQx5zhFGAD6k+vc0mos8s0VjFJh5julYHlIwefpnoKAMzxQftj6ZYIx3Xt0pwB/yyj+dj+i11AAB/GuX0qQ6l4z1G4TAtdMjFjEB0MjYeT8htFdVigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwPHuknXfBut6WoJe7s5Ykx137Tt/XFY3h3xvpw+HOheINault1u7WLcDlnebbtZFUZLNuB4Fds3UeteP6fpUHh/xOfCWtROmkXt5LqHh3UImMb20rZaS1DjlG5Yr/eUsO2KAOstPFmneIL86HeaPrVs95BJ+7vrB40ePo2TyB1xziofhtdzzeGLjSdRYyX2i3D6ZcdiyIf3bj3MZQ5qXQY9P8P3OqRtBcwSuPPa6up2mknRTgEs2doGeFGMZ6c1W0mUad8Xtbsxn7PrGmwajEV6M8Z8p/wAdvlmgDoltY5o2tbk+asnKvnHmY6NnswFYWprPpAK30H27TW4WYJlox6MOpHuK7LyVCMAdqt2HY+oqKRUZTHNhuMEMM8fSgDhLU6ZeAPpl9LCRnciPvAPuDyKcZdbtvns5re7TP9/a2Px6Vc8S+G43mN4LSO/hOfMQsUuEGP8AllIuCf8AdasS00eO5hkutF1nUisTYeC4jW42kfw/wsp+tAGl/berRlvtunsdvcjdkfUdarnXNOPFzp+z324rFl1m+tZnWSOeLbyN6OOPcUtt4kvbpykds8/biMN/MUAbR1zSFP7uSeM9MAcVmahqlq+VhLS59VqUWGtXv3LJLeNud06KD+QqzF4VD/NqlyZD2SBNo/OgDlxf25kKG0UydgOWP4CtK28O6jqSqVtotNtm/wCWswBf8F/xrsLTT4LCIJpunxxH+8Vyx/E082dzKN1xKEB9Tk0AZ2mWGkeG482qeZdPw9xL80jH29BSXM15duSiBUyBljjitBbWygcux8yT1PP5elEjPKMJCSvqaAOW1qSPR9f8KajPDeS2tpqUj3DW1rLcsimzuUBKRqzY3OozjvXP32jeBL6TWo7nVPHD6ZrOof2lfaaNEuRDNJuDAEi08wLkDgOOlehNEQfn685pNgKjjPGM0Ac8dRt9d8e6pqOnQ3yWP9mWNssl1YzWu51lu2ZVEqKTgOnIGPmFX5UWTKHkg9B2q/8AZJnGSfK5zlec/jTxbLGcjj3xQBmiDz90LlkwOFx+tWbWFYohthVWI+bBqSaNAVlbJYH71RXMUrAvG+doLCMfxD6UAMuL4Wy5LfgOtV55p9RkVGjSO2A5ZlyxPoParrW8KRiVueA2ZODzVCa5laTy7GIvt6ysMJ/jQBd0qzstA0d2uHghVCXaRMoB6e5P0rRsNR/tGzt7m6+QMMpdKpUgdsg9ax7O2Blja9b7TKpym7on0H9a3hOuxtzKoxjcfWgCzFevbKi3pDxsTtm6q3p9K1IGBP7tyF68NkflXPuZDGRbA8gZZ+Vc+nvVAu8F5HFZyCC4Kl3gLEoceh7ZoA7YOWUiRQyf3l9fcVBLHubKcjHUf4Vz9n4gjMiQXRNvNIdqqxwGPsfWtm2nZyoDpIMcbzz+BoAWZhGgOzLdBgVHHHGiKuBuAJJ+vWrYljeUCX5Wxwr0Nbxtxzz3FAFBkjVi+ASaYWTPTPr9autZKsGwAkDoSaotasijaMepoAY0g5wBTXkZk2rkKeo9aR96yiNYy798fwg96GZuu3A6CgCPDfMTnk9KekWcE9DTTLJuARST6npTAbnBBfk4zgcUAW1RFp/mKOlVijsT1xViKA4G7v8An+VAD1fPQVKqs/XIFLHEOABU8ZQggNnH3vagCNF3Hg/KO9TAdcAn19cVl+I/EOk+GtPN3rV/BZwYwoY5aQ9gqjlm9gK4q4ufGfjR3W2J8HeGD/y9TKDqVwnqinIhB9Tk80AHxP8Ai3ongu4GlxyQXmuvhfIMm2K3z0aZ+wHXA+Y9utaHgPRpy7a3qN3dTtdhJw1ynlvM/QSGP/lnGAcJHzjqeTVnTvhj4JttKFonh3T7pGHzz3C+dLKT1ZpDySevWuX8VeHdX8GTWN7o2s3s/hGOdReWF5N5psVb5RJE7fMUXP3GJx2oA9Oa8gmupFEjC3sR5kzjlQQMhc+o61Qe7XSNG1PxBdowublRIqEfNjpFHj15H4moBDDaatZeGdPDNFsa8vXkO4+XnAUk9d7foppt5cL4l8Ww6dbDfp2jTC4vJP4WuAP3cQ9SvLN+FAGx4Q019K0K1gnJa7cedcORy0rnc5P4nH0FblIKWgAooooAKKKKACiiigAooooAKKKKACiiigAoqtqd9Bpmn3F7dmUW9uhkkMUTysFHXCoCx+gBrndP8c6dqxtxolpqOofabAajb7IRAZYTJ5YIExQj+8M4BXkE5GQDq6KKKACiiigAooooAKKKKACiiigAooooACAetc7448Ow+KNAudMmlaCV9slrcL963nQ7o5F9wwB/P1roqQqCckc+tAHnOkareeMfBtxHeeXY61YO9jq9u+dscqgbmGOSp+V1I6hsVV8cXcdjYeGvGtmkktvok5iu8DB+xyDy5W299pCOPYGp/GKN4Q8Y2/i2D5dHvdljrqdFAPENz9VJ2Mf7p9q6a9/sSytDY3s9jBpt1EYltZHULKrZDbR/FkHHHrQBrLcLIkToytDIoZZAeGB6H6EGo74Ep8gJ/wBpetee+CL2fwnrE3gTXJHaKNWm0K7k5FzaAg+QSeskWcY6lcHtXeJPugR4jvidcqcYyO9AEMd3JbRgTK8kWf8AWR9v94f1qpqGl2uoSHUNOunsr9RgXUBBB9nX+L8atSOyDfF8yj7y1SWGKaUzadObS59AMo59GWgChdeIb3RiIvEVj8mdq31oC0bZ9V/hqxB4j0SXOx4XbGX2x9PrgZNXjdOgMN/D9nLLgvjdDIfxH6GsK/8ADdq032rRLiTSrwcgxDMZ/AdPwzQBuW+ox3mBZW78DgtEVB+nFMuhqO0mFYs5wQQRWBJrniXSomXUrSG5jJAF3ENyKPVgOa39GurfVbcyRXlvekdRGSu322nmgDOl+1j/AI+r5IiOqLyajF5ZR/K07zP6ZGK1NQ0O2uX33Kjj+EEimRWFlbDEUEan6A0AZqakzEra2rfitTxLqN2MsvlD0PpWluKL8sahaRXd/uqxNAEMdguAZpMn0FWljiUAInA9RTkhkPJ+Ue9SHy0HzPn2FAEDd+g9gKhZVx2qwz7uI1wKryRtuJdlAoAq3gQwSKFJyO3aseYyo8ZiULLAqrnd1GOla12ytE8cRPmNwCRkD/PNUrWVpVc+WVGSq7h1UdDQBBNJFHMnnIXjPyMS2fLf0OOPxqeWWNOpHsB1xVa6tBHNJcSvIYmG2RFXcGHqRTGvo4280JutwMOy/fiPqQeqe4oAH85wWiUKp4yetLaqyupmO/HIJ7Grow+GTDKRkMOhHqKURjnJH40AalpIJE+YgnuTT5lBXb0U9QDjP1rGN3DA33zx2qRtQurjCW2IVxzM4yR9FoAzvE+mWNxaoupv5VqrZjiiJEjN22t1znsKx7WXxNYJJdRxoLEZKwzN8zKO79k+v511cNnCshmXdPOessjZbPt6CqWs3MMKtFMpvZzylsOI+O7f/XoAXw74z0/VoYYp8xl1JWOUYbA4JVv4h6EZHvXRwyzx4ksLj7Tbg5aKb7yj2I/rXini6J9TYSSn+0dTj5toYv3VtZnHUMOWIpfBHj250u6j03xIzT7hsW8iUgA+hB9PXpQB73ZajbXyboWyqnBHergRHwOw9a4G6ga5Zr7Rb94ZXQDMJ3xuB/sH7p+lVrfXPEWnNILhIrnJBLtkhf60AejvAhHr9ahNov8AcFcdYeNJJb1Y7loI4wcuy54A7YP5U9PGcBLyBjuZyBvUHaPTg9qAOnlt1VlCxFif9rAH1pBAAOgJByfastfEUH2GO8uZ/wByzFBGkXzOR6c0kmvWaaWL0zyyGQ7EQlRJ78UAaLA5OFwKoTverqCFfL+w+WSy4+dpM8KPbFUrfxPbSXEMTxtGJCRveQMAMegyaxtX8Z2L35W2cyxwfKgXox/vH0oA6qeeUAxxt+8/iPHyeufSuW8TeMG0u+j8P+GbQ614qf7tohxHbZ/5aXD9ETnOOp9q5GfUte8U+JVt/DcwN6i4naUD7JpqN/G4/wCWsp/hU9O9d74e8JWOiabJY6dJPEryGXUNQY/6ReSdWLP2B6nHQcCgDJ8JeFBDrLaxqd7HrnisMUn1CVT5FlnrFbx9Bg8cc+uOld75MQZzGizXCjOXOT9Mnp+FCQK0KxwAQQZyBGMZHoAOg/nV2CIIAFUKueB7UANhVto3qq552r0FVfElrDdeHtUt7uMSW8tpLG6kbsqVOeK0AVDhMjdjOB1x61jeONVg0TwnrGo3cvlRW9rIxbGTuIIUAdyTgAepoA8w+HWtanB8LfDbJdfa/GHiKFYrZ5hkRxplRIwH8KRjcfVj716v4Z0S30DRrfTrV3kEYy8r8vNIeWkY/wB5iSa4P4IeEdQ0Xw3p9/4nVU1prKK0jgHSztl5WIf7RJLOfU47CvUxgqPT3oAWiiigAooooAKKKKACiiigAooooAKKKKACiiigDN8SrO/h7UktLaW6uHt5EjgiZFZ2KkAAuyqOvcivIF8GeJLjwlpls2jywXUHhi00t4pJ4SfPhnjLDKuRgqhYHPQjODwPcaKAPHI/B2sjxcbhNG8nU/7bnvj4l86I5smDbIMbvNOFKx+WV2Dbuzms2DwRqI8M29mfBRXVIEthq90b2Ef26ElRpUyHy+/DNmbb12dCa91rzy1+KVveS2SWfhjxJO1+JjZbY7cC48ogSYJmG3Gf49ue2TxQBzEfg3UkEU1x4U+0eGv7VnuF8KiW3PkxNAiI2xnEBxIsj+Xvwvm5GSKlsPBsg1zdrHgNb+1max+wu97FIujwoiLJCWZw+FYO+Iwwk3bTxXY2vxG0a602e+t4r14IdFGut+7UEwHf8gBb/WAxsMdOnNQ2fxM0i71e4s47PUBDbKTc3ZEXlwYhExLoJPNChWA37NuSAGOaAPNrTQr298E+I7y5vbeWy0cDQ9OnkuRCs9hBdBp90r4CmREEJYsFJjznBzVaw0Q+LNM8QTeDNHWx0FtatJJLCwNkVuoUt9siJ9+1c72RyCSpKkEg9PR9Q8cXt4NBax0vVtKhvNStE829gi23NvLv+6VZ9pO0HDbXAI4Gan8JfFbw34q8QR6TpUrPLMkklvL50DrMqYydiSNJHwcgSImQDQBy2heGNa8NXOj32m+H9UureGDUbX7FNdWSzQee8Do2IykKR5ib5I923IwD0GNpngLxBbS+EXk8OGa+sLPTLeSW6ktpoIPJ2mQq4dZoWXL/AOq3q5Vc8ZB+gKKAKGtWNxqFosNpqt7pcgcN59mkLORg/LiWN1xznpngc9c4n/CL6v8A9D34k/78ad/8i11VFAHK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLXVUUAcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItdVRQBxt34Q1C6tpre68Z+IbiCVSkkUlrprK6kYIINrggjtXGahC/h/wAV2Wn61r+vafYGNbfTNWS20xoVOMGBj9jHkEYGByrDuOley4qlqdhbajYT2d7bQ3NrMpSSGVdysPcUAec+M9Eu7Dw/qGta34l1i6i0hWu7UzQabJ8yrkMD9iJjPbIBxVXTptSeC0a68UeIbUXscc9thdNZZGdA2wn7GNknOAGwG7HtWD8Q/hrrWj6THc+EtQ1PVNIs282Xw5d3BmhdAc7Y1PLKODsYngYGelcw3iq90rSE1jQ40vNDuQIr+ym/eJAw5aMMfniwc4jk6fwtQB7ImjX7QiWPxl4m29wbbTlZfqPsnBzxSxeH7qY7h408Q7/e203P/pLVrwbfaZ4g0O31PQL37XaOoAVjl4SBzGxPzDH91ua0prbzCXhbY46qTQBgXGkarD8reMPErKeuINOx/wCklQLpUqsR/wAJj4iU/wDXppo5/wDASujjuSp8u5Qg+tJcWcUq7hhlPTnkUAc3JaanbuBL4t8UCJv444NOYfj/AKJRbeGY5JhOvivXI5m6SGx0wE/RvslaElrdWxJgPmRn7yMaLe/iKmNwYG7JJkrn2oAq3+g+IImJtvE2vXMY9tNVvyNnj9aowRsJRFf+MfFOnTdNtzZacq59m+yYP51vwyamil7dEni/uo1SRa7bTDyr+3KggrtlThvwoArwaDd3EQe28e6/KhGcxw6af/bWnnw7fr18c+IwfT7Pp3/yLTf+Ee0S6bzdPMllKf4rSUx/p0NI9l4h08j7Df2upRLz5d3Hsk+mRxQA19CvhkDxv4ldh2Ftpx/9ta0ojJFBGjmSZ0UKZZVUO5H8RCgKCepwAPQAcVkyeM5tNPl63oN5bHrvgAkT/GpT488OeX5ktzLCcZMckDZFAF92c9SRmo2idhyMis228daJfuRYTxMRxulcRf8AoXahPEdtvlN3rGjRR/wiGbLD6mgBdatLxraP7EMEk5bftH3Tj9anjjhggjjeQu6IFOPXv+tcz4v1zSZrW3S11ZLmQzB38ks3ArUTXfDRP7vUXP8A2wc/0oA0/M3Z2DAqhdIgMbpGhdAVClc/Keq5pT4j0ROBOxH94wsP6U1/E2jRj5JDKx/hWJif5UAYt/qerW92Le005XAJKlTtBXGcAnoRj8av6bb3Wp28dzmWON/+WZX5h6c9x3B/LIp7eKElRkh0zUHDDAP2bIOeO/asbS11RLGWFNJuRG7MsReXy8Rk8AjqCpzj0GKAOpj0iKE+YcB+m9zlhVa8ltbVss5kkPYf41z0Fv4mSJo7+9tY7NFIFxI++QDsDx+vWrVnoWn3DsLq/a+lTl1WTaF/CgB1xroceTE26VuEgt/nkP1boKrx6JqV3l9QJt4m/wCWKHLv9T2+prdgk0/TYitrHDCvTMYyfxrI1TxNBG5S2YGTpxyT7UAPPh23AXzXFvGDnYpDZ/3jXO+K9O06aFobGNQrKUZ2+Zm9sdvr0qa4u7y9DNh4we56VSCWy58x5JJB1AGPyoA5nQ9a1LwvdLDaR3F7b7sPAmSAPUMf4v0r1vRPE9t4gshLZzIHJ2lXGGQj+EjsRXGywtPCQiJboeBI55HvjvXG6kk2h6jHPoxupr8sPMfG5JR3D44Ht6UAeu6haWcjSPNLI8pPzZPOa564hjV8RqQnXIBLH2+la/g7xTp+twrHeRtaXcXEkL4LRN0wT3HvXTXVlP5ypHBDJu5VwODnofb8aAPOrW01LUr1bdZDDGesjdEUdW/Afmaq+JLS8a5h+wX9ra6fEpiMz/ede2FPRie9dfqrpaRyW8bGSWQ5nlQfKT/dHt6muWlhiEvnyr5jZwhk6A+gHfHrQAGIaXpclmfMl1G4fMk7DJSLHCJ/d9SeuOK56W01G+vLPRdIKRahfuI4twJEaYPmSt7KOgPXiti8v4rVJJ7qYRqMl32lu1ejfD3QX0nSGv7tP+JzqWJHZ+sSdkHphcH3JPpQBoeFvDdh4e0iPSdG3fZ1Je5uicyXEmOSW7sT37DitphJNJ5ar5Vsh2knru9Mdx70/wArLoEwI15GOMmrcOfNK7PlAGD70APgiEYxgAe5yaoeJtXh0TSXu5opJ2yI4beMZeeVjhI1HqT+XWrSyyiSczhYrdACsjEfNx8xb0ArC0lZ9d1f+1508vTbfK6YhPzSZBDXB9NwJVQf4cn+KgDQ8NaddWVm8uqzC41O5kM07IMImTkRp/sKMAdzjJ61wV6ZfiV4ytYraRv+EO0C4825l24XUrxD8saf3o0IyT0Lcds1dvNVvPH2rXOjeHy8fhi1cw6nq0TlWuXHW3t2Hbs8g6DIHPNd/o+n2ul6ZbWFhbx21pbII4oUGFRR0AoAtIAVG4cnrT6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5nSPBmnaU+htbzXbHSEuEg3sp3CYgtvwozjHGMfjXTUUAeeXHwp0t9Kg0+11fWrKBdMOkzNbyQ7rm33MwVy0ZwQWbldv3iDkVYf4Y6TcapbXWo32pX8NvuEVrctEUUNG0ZXeIxLt2u/wAm/bz0ru6KAOMsvAMEC2CXWva5fxWE0EtrHdSxFYvJ3bVwsa5+9gs2WOB83FWvC/g2Lw5Jbx2Osau+mWwdbbTZZIzBArHoMIHYDsHZsdq6migAooooAKKKO9ABRRRQAUUUUAFGKKKAEI4OK858YfDp7rVpvEPhG7h0jxBKAtyHj32uoJ/cuI+jf7w5Fej01hwaAPnrQrKTS/FEz+G1Xwt40wWvPDV45+waqB/Fbv0PGcFeVPBA5r0fS/GWl6/qDaaJJNE8URqC2n6gvlyFvRc8SL1+Zc57V0Hi/wAKaV4t0v7DrdsJVU74ZkO2a3fs8bjlWHqPocivJPFun3WlWi6b8TY11bQd22y8VQxEXNjnoJ9vKHOP3i8eooA9WtJjdebb6jbG2u4+oxlHH95G7g+nUd6jlgntWJjfI9K850/xxd+DZbWx8d3X9raDKA2n+I4Rv+U8DzSvB4/iX3zXqDXUEVlHdCaObTXUOs6EFVU9GyO3T1oAoC6c8MNr+/SqkkxJC3tuNo6OOlbNxao/3gpHZs8H0/P/AOvVfyjb8MCUPYjIoAzooVR/Nsbkx/7OcrVtrx2Gy8tUnH99RVlY7WVc7Ah/vJ0/Kon01nz9nutuOnFAFF4NOmcGNpbaT0zgU5YrlCPI1AOno1PmtbuNSHeGQDuw61TMDbwSkaDuQcCgDQjOqdnhkHbcCafLHfEfvLW2kz156/mKzHlW3Bxcrt/3siqz6miNxqCg+5zQBoXNnau2bnw/FLx1EMbUyGLSI5M/2CkJxwWs1H6jNUf7e29b9D9FpD4jlI/dTlsdwtAC+Lr62OkNDYWK+dK6oSLQ5VSOvbHarsGuW0cEQitZ9wUKQkB6457Vg33iy9jUpG0u4g7MoPvY4qlD4rv3tUMy3STFcsgXAB9qAOw/tdnQlLG/I9DHj+tRS314xxFYYB7ySKuP0rjH8S30rYQTPz3NRtqWqXJwsWD05JJ/SgDqbjU7pTiSa2Rh2UFiP6Vitq5j1+VpLhmga2XGeBnce1URpOp3PN0zgZ+8zbQKq/YYYdWNrJJ5w8kP8oySxJyM0Aas/iKIKQqmRPQ8isi+vrjUSpEEa4+7IvDD6Nxj9a1YNLeYgwW6xjHDPyRWnBosaEPdScD1OBQByotLi4QxyXMzv6IxB/Op7HS59OKmW3jSGQ4M6glh/vZ7e4rq5dS0zT0IQJkcdKzzq9/qEm3Trd/LwVL7eMfU9KABtKhdFxKJh3JfalULoadaPse9iiwcbYoj/wChGrY0q7yDc3EMSn+EDd+lSSWtiFxOHuF9H+7+QoAypLrSoufJluH65dv6VSvtX86B47exjiQ8ZCH+QroT9gGAYYlakaW1WMrHsQkfjQB5Nd/botRF1aQalJeKMRstuFjcf3GyeR79RXp/w58dRXqNaXWYLmLCTwO2WiPof7y+n5VT1fRtJ1CA/bWkm2/Nt804P4CuB1TRRaSrd6JC1ldxnMUsa8N/sv6qfegD6I/s+K6Rz5cZcAsQMAL/APWridcja0uHSKxa5deQUIVAPqTxVT4d+OU1Wweyu0e01K0AFxaODuhH95M/eQ9cVSutcutS8SW/hPw+7/2pcHzXmZNxsIRy0hyMEHgAH1xzwaANDwppz+JvENvFNa+XpmklZrxSwZZLjny4c9DtBDN9Vr1GNJJbyW4kf92QFiH06k0mjaPBoumQadpilIYzlmY5dyTlnY93J5J96s/b7M3z2KTqLuOPzWix9xem49gKAHFFWJi7BFAyxzjaB1qtpmp2mp6c13auPsI3bZidqsqnlgT/AA8de/Wq94lrrdhNDcrnST8kpkyomwRge6Z/Pp0pbrT472Mf2gFj0y3GVt8gI4UdZBwNoxwOnHNAGVplyvjJRdeTcRaEshEMcyFDelTxIynnys8gH73U8Vg6nd3PxE1y70LRLiW28KWMhh1XULZ9j3cuObaFh0UfxsP90dzUeoaxqHxJmfSfBs0tn4WDmO/15Pl+0Kpw0Nr3OeQZOg5xmvRdB0qz0PSbXTNLto7WwtoxHDCg4Uf1PueTmgCTR9OtNI0y30/TbaK1srdRHFDEuFRR2FXRQKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAAiop4UmjaORVeNgVZHUFWB7EdxUtFAHjuvfDO48PpdTeCIobzSLhvMu/DF6/+jzHnLW7nmGTnj+GuH+HnjI+GdQvdN05buHTrZz53hvWWVLuLOd32VjxJycBDjOeK+mGXPeuP+Ifw90LxzZxpq8BjvYTutr+DCzwN1BVseoHB4oAwtE8UaZaWsF5Z3ovPCd7KIo5266bKePJmB+ZFzwNw+UnB4IrtXJQlHGU4yPTPSvAPGuneJvDWum+1a6ttNa5/dS69ZWwFnfjst9D0Rj03/d5wa0dE8Z+IPAdpZWPifTGnsHk22riUEeWRnEMn3JBg8KTu9KAPY5YtuZIMgY5BrOl1QxEALgg44Gcn0FV7bxLpl74Yutb0udvIhhZpreVdskeB0ZOoP8AOuK0TxZdW1rayawimS6AkjnjIZZEzjBA+6R+frQB6OfMubISNKInwTz2FYn2CTUGLeaxhHHmOev0FReKNesIrENFK8zkjCRrnd7E9hXPN4zu9u1bYKNoHX8higDqW0zSbSQLcs80n93kn8h0qzb2to65t9LBwP4xXA2Pia8tFdiA8jnJdjya6PS/EUt7ETPMkLAjODzQBuPaySD93osQBHDNgCqv9iXsxJXT7SE+pccD8AanXVYiPkv5Ef1U5/nV+2upJMeZcXMi9ixAz+VAHP3nh+WB4ftBt4UnmWCPZudi7d+1Tr4OgjJ8+8nlYjOEUL/jW88MUs0cstuWaH545ZDwGPHr+tVJNZWS8ltbMGSdDtYDrQBDFoumWKg+SGOMAucsapXWqIsnlWEAaTp8i8/nVi6tJrg776QJGf4Fb5h9fSpIWjjhBtQqQjgv6/jQBlJpt3duZdRn8pe0UY5/GrKWun2DLIYkjkA2h361BPqcssjjTIWuGHBmLbUB+v8AhmqNxYPKDJqV3vb7xjT5UH4d/rQBJd6+hlFvp8UlzN/sjIH41ANO1S/lzqE4toz/AApycVDc6zZaXafuPKVEX5pB8qAepNc8niu51hf+JPbXd9bk4aW3TbCv1kbC0AdlDYaPpy7nAd+paVtxJ/pUV/4ht4IXZV2xKMlydij8TxXm03iCzmkMV34i0qwmAyUtg19OfYYXap/A1n28nhUXbX1xpXiTXJ1wRNfwMQue6oxVR+VAG1qfxMspLhoNNS51CXOB9ihMgz/vAYqiNS8X6o/+haBNAhPD3syxZ/4CMmtvRvFuixCO1t9I1uKFOdtvaJgn6K1dNovjPwlbzs+rNqOl5YBX1C0ZE/GQZUfiRQByFvofit323cunwZ6qitJj+laE/hnVE8wf2scquSRbjv0717VZ21nNbrcQtG8MmJRJGwZSvUEEcEY71Wit7dwkckLB7pjISV+6gPAJ/lQB4RN4E1y+gkVtfCvL8zBrJWGfrnisXU/Afiqxt2htLPQ9SXGSUaSB+O55wf517H41+KPgrwbftZ39w01whAlS1QOIiRwrHOA2BnbnNYifHH4eXWlzXPnXYnTAWyNqxmlJ6bV6HPrnigDxpTeeHNOl1DX9L1Cy1DSgXt5oJhIrKQdqs2SShYjg8V9F/Bjww2leF49Z1EeZ4i1xVvb+5cZY7hlIx6KqkADp1r578aWWueKb3Ute1CM6Lp48i4GkyHM7wCRVDzgDCjBJw2PbivsZGVVCqMAcAAY49vagB2B+OKyrrSYrieN7yWSSFDuFuvyoxHQsBy30PHtWjIXIOxlX0J5rL8Sa/pXhrSJ9V1y6itbOIfNI55Y9NqqOWYngAcmgBdVudP0yyk1bV7qO2s7OMu8sr4jRfU9iew/IVwMVlq3xUHm6ulxpHglmDxafylzqS9mm/uRHGQg5PeptG0W+8f6taeIfFltJa6JbES6Voc3du1xcr0L9NqdF+tenhMNnNAEFhaQ2NpDa2kMcFtCgjjiiUKqKOAAB0AqwBilooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApCM0tFAEFxbRXMDwzxpJC67WjdQysPQg9R7GvLvEPwx+yW8kfhA2v8AZrvvm0HUcyWch9Yc5MD+hX5favWKbtGaAPmvV/Dmj2FvI6te6brflky2OqOkW5QDjbIBtmC4OMMa1/AkNtqOj/Zrcxqvl7p7SUZZH6iVD3BHUdq9x1TS7LVLKS01K2iubZ/vRyLkH/69eTWlnF4O8anRjaNJpd4RJYyMcvGx++qsfvD2NAFKbRQshVUIK8YwRmmQ6ZC5AJKMP4X616JcaajzmMMDLt3FSctj6dvwrMu9MttjJdeUUbgq/P6npQByr6KoX7h+vaqdzo7beHZc/wAY7YrYuIbWyVzp99PEUHEXnbh9cMCP1rnZPE2oQyOsl1ZTA87J4MdOnKGgCz4Uv3826s5YALq0kCSO/T5uVOfcV29lduWUtJuHYKP6V4hrmsXN5qsV/C0FlcxKY3+zsSJ17BlPBx+dX4fFmu3kYsraRolf/WSQR/vCO+CRx34HpQB7YJ5tVkeOK4W3tIyFZxhpGPce30qQTWunh7bTIFMr/eIGWf3J/wD1V5zYailtZpZJcDT7eMYKyZEjerEnufWtS213S4bTbb6ja7MfO/mgs31NAHTTSjIMv7ybrtU/KPqe9UrkJLEGv3zGpyI14X8RXL6l4y0+yt3aO6g2L95y4Fefan42v9caddDjjkSME/aLqQRRrj0HVqAPTNW8U2tnGfLMUdvGMFidiD+lcRceJNZ8Qz+T4etWliL7ftkqlIF+n978Ki8P+FLO7FpqHi3X7O4lIDeRNdIkCE8gbcjcR3JxUnxh8fW3h/TIdE8G3Nvd6rdps8+1YFbZDxlCOA55wB0HNAGZ4mv/AA94RkjttdvB4l8TuATbXMuy0tz6uo4x7csfasW5uvFHjFIxdOTpwPyRSKbazA7bLdCGce7nmqfgzR9E0ONbu8uYrjVZRukuAryYJ5wgwefVupNd3Z6vZzQh7e01W6yCwEdhJtbHuwA/E0AYWm+DxFD5V1qt+6MOYbNltIvptQA4+prQt/BOgIQX0mO4bu1xI8pP1ya2Ir+9khE0PhnW2iA3EyCKNVA65LPgf/WrPg8V6nLMI7LwnNKpLBZZbsBGI42jYDnnn0xQBbi8HaHOqj+xNPwPu7YduR+GKdD4UsLN/wDiW202nyj+OzlZc+zKSVYf7JBBpL/VfHdsp8rR9JsA4Cxq8MlxIpI4J5AB78jFcZ4o1DxfZ3NvB4g8S3NnNKDtW18qJHA68Acn6ZoA9f8AhXeyeF31zQtfvrK30dVS+sZZWWBY0clZUwThcMAdo4+Y1mfEz41aEPDWow+FdTuZ7yRPs8dxawOFgXozq7YBbsMdM15FY+F/EcWsw31t4P1HxLa7c289+JZYgzDl8MBvxwfugZHSuxs/hz4w8f8AiiCfxJAuiaTA8bsIIzCyqqkBow3G4t14HOMUAeXweDLqwe0vPF1/Y6Faypv8u4cfaUU8/JHgsGPB3Ec5q5pHiLQtE8Q2MngLw7farJavIBctG6yyl1xnK5YEdulfU2jfBbwPp0xuJdHGp3rEO91qcrXDu3qdxxn8K9A0/T7TTrcQWFrb2sI/5ZwRiNfyFAHzZpGn/E3xI1zD/wAI5LZaVOrLHHqVysEMauuCPJUfNkHqwY+9eheFrD4m+DNBtbCQaV4rgijCJuujbTw46IXZSJABxk4NetBQO1LtXtx9KAPNJbj4p6oiLbaf4X0KN+GmmuJLuWMeoVQqk/U1b0L4Z6fBrEOteJr678S67CcxXOoMPLgPH+qhHyJ064J969A2gYxTsD8qAGhcGnUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAhrlPiNoNxr3hp4NOKi+hkWeHnaSV5Khu2fWusprD5TigDyTSdVurtBb6jFLqj2vEmz9zqViR6pxvX/aXr71LqXiPdG1tHqOn6omfuzAW12B2Uq4CufyJruPEfhjTtdaOW7hkjvIjmK8tnMc0f0Yc49jkVxGseAPFMomW38T22pQsPlj1exSRvpvUcfUCgDl7m80WO9KXkt1pRbPHlMu0+6nIP4HFct4h1GGWaOz0q8XWzJxn7B5bqfYjk12GnfBjVrucf23q1tb2ucmGzVmP0G7hfrXpfgvwHovhJpJdNhke7kXY9zO26Qj0B7D2FAHiOmfC/xPfQW881oba2l6q8gEqL6bfU+/Irr9S+G19FBHL4UeXS5xEFmtbhBKkrr0dXz8rHuele1geo5ooA+ek8E+P0YRSJ50D/M+Lsoqn6glj9OBWJqXw++Is2QLS3kjLlV2shMa56gMTn8a+oMD0H5UYFAHyb/wqzxrauklp4a027uGVg8t1IrFfTq2AfoKsxeD/iXoel3FyPDmh3DOFQpLBFOUxwPLiRfzOfrX1TijFAHx5YWXxNtZ7m4g8GWsmoyna13NpKO6jsEBIVBnsF/E1ofDD4d+JhcX+ua1oV1PfTzOkPnPFb+X0DMVOSCcbRx0FfWZHrSFFbqM/WgDxaPwt4iaNlg0mCAv1xqZUse4JVM4+mPrToPB3ioEBbDQYok4jie/uHi9yVCgt+JNey+Umfuj8qdtUdqAPMm8F+JLqBlnvfD1vKYyiPFYSSiPP91Xfb+OM1Npnw91mCcT3fi+YzbQmbbT4YymBj5GYMy/hivSAB1AowMEY470AcFL8NdMvpkfXtU17WQj71jur5kTOMfdi25x75rodG8I+H9F2HStGsLaRDkSJAu/PrvI3H863aKAEwKMClooAQDFB60tFAAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Location of suture placement for sacrospinous ligament fixation.",
"    <br/>",
"    (B) Location of suture placement for iliococcygeous vaginal vault suspension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29189=[""].join("\n");
var outline_f28_32_29189=null;
var title_f28_32_29190="Contaminants in water used for hemodialysis";
var content_f28_32_29190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contaminants in water used for hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Richard A Ward, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29190/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/32/29190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis patients are particularly vulnerable to contaminants in the water used to prepare concentrate and dialysate, or in water used for reprocessing dialyzers. Compared to healthy individuals, hemodialysis patients are exposed to extremely large volumes of water, have inadequate barriers to such toxins, and cannot easily eliminate contaminants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated water intake of a healthy individual is 2 liters per day or 14 liters per week. By comparison, a hemodialysis patient may be exposed to 350 to 500 liters of water per week, depending upon their treatment time and dialysate flow rate [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With normal individuals, the gastrointestinal tract separates blood from contaminants in the water. By comparison, the barrier between blood and water in hemodialysis patients is a thin membrane through which transfer of contaminants is limited only by the size of the contaminant.",
"     </li>",
"     <li>",
"      When dialyzers are reused, water is introduced into the blood compartment of the dialyzer during reprocessing. Contaminants in this water may be trapped in the blood compartment and the patient directly exposed to them during the next dialysis treatment.",
"     </li>",
"     <li>",
"      Hemodialysis patients are unable to renally excrete any contaminants taken up from the dialysate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accumulated experience, combined with the observation that some of the most toxic contaminants arise from municipal water treatment practices, suggest that",
"    <strong>",
"     no",
"    </strong>",
"    municipal water can be considered safe for direct use in hemodialysis applications. All dialysis facilities therefore require a properly designed and maintained water treatment system to safeguard patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different water-borne contaminants to which hemodialysis patients are exposed and the maximum safe level of exposure will be reviewed here. The different water purification systems and the methods of monitoring the various water delivery systems are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=see_link\">",
"     \"Water purification systems in hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TOXICITY OF WATER-BORNE CONTAMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Municipal water supplies can contain a variety of contaminants that are toxic to hemodialysis patients (",
"    <a class=\"graphic graphic_table graphicRef64883 \" href=\"UTD.htm?39/3/39995\">",
"     table 1",
"    </a>",
"    ). These contaminants can arise from the source water used by a municipality, or they may be added during treatment of the source water to make it potable.",
"   </p>",
"   <p>",
"    Adverse events arising from contaminants in source water are relatively rare, possibly because most water for dialysis applications in developed countries comes from drinking water supplies that are regulated. In the United States, for example, the Safe Drinking Water Act ensures that drinking water is nontoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/4\">",
"     4",
"    </a>",
"    ]. However, dialysis patients in localities with less sophisticated municipal water treatment continue to be at risk of significant morbidity and mortality from contaminants in the source water [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/5\">",
"     5",
"    </a>",
"    ]. Paradoxically, the contaminants that have proven most toxic to hemodialysis patients are substances added to water for protection of public health. These include aluminum, monochloramine (usually referred to as chloramine), and fluoride [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aluminum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aluminum, in the form of alum, is added to water to remove suspended colloidal matter; this process is called flocculation. In hemodialysis patients, exposure to aluminum can result in a severe neurologic syndrome characterized by the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Speech abnormalities",
"     </li>",
"     <li>",
"      Myoclonic muscle spasms",
"     </li>",
"     <li>",
"      Personality changes",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Dementia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    .) Chronic exposure to aluminum is also associated with severe bone disease and erythropoietin-resistant anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of morbidity arising from aluminum contamination of water has decreased markedly with the widespread use of reverse osmosis to purify water [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/1\">",
"     1",
"    </a>",
"    ]. However, an outbreak reported in 1994 apparently followed very aggressive alum flocculation of water under conditions of extreme drought [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aluminum toxicity might also occur if acid concentrate, which is used for bicarbonate dialysis, is pumped through a delivery system that is incompatible with fluids with a low pH. As an example, an epidemic was attributed to the use of a pump that contained aluminum housing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chloramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chloramine is used as a bactericidal agent in municipal water treatment. Its use increased in the United States after 1979 when the Environmental Protection Agency placed limits on the amount of trihalomethanes in drinking water. Exposure to chloramine is associated with hemolysis, hemolytic anemia, and methemoglobinemia in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/1,13-15\">",
"     1,13-15",
"    </a>",
"    ], and might be manifest clinically as an apparent resistance to erythropoietin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. First described in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/13\">",
"     13",
"    </a>",
"    ], reports of chloramine toxicity continue to appear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluoride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoride is added to water to prevent dental caries. This agent could contribute to bone disease in hemodialysis patients, although the evidence for such a role is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. By comparison, acute exposure to high concentrations can be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients are also at risk from exposure to contaminants that might enter the water in a dialysis facility:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Copper and zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper and zinc can leach from metal pipes or plumbing components. These agents have been associated with hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], and some cases of copper toxicity have been fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead can also leach from metal plumbing components. Dialysate lead concentrations of 52 to 65",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    have been associated with abdominal pain and muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there is no direct evidence of lead toxicity when lead levels in water or dialysate are below 5",
"    <span class=\"nowrap\">",
"     &micro;g/L,",
"    </span>",
"    blood lead levels can be abnormal in many hemodialysis patients, and higher blood lead levels have been associated with the use of chloramine to disinfect municipal water and possibly inadequate removal of chloramine by carbon filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antimicrobial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis can result from residual",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    left in dialysis water storage and distribution systems after disinfection with hydrogen peroxide and inadequate rinsing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In addition, some hospitals have begun adding antimicrobial agents, such as silver-stabilized hydrogen peroxide and chlorine dioxide, to their water systems to suppress the growth of legionella. Dialysis water treatment systems might not adequately remove these agents, and one outbreak of acute hemolysis in a hospital-based dialysis facility [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/29\">",
"     29",
"    </a>",
"    ] and methemoglobinemia in patients receiving extended hemodialysis or hemodiafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/30\">",
"     30",
"    </a>",
"    ] were associated with the use of silver-stabilized hydrogen peroxide in the hospital water system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bacteria and endotoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to bacteria and endotoxin, which almost always enter the water in the dialysis facility, is associated with pyrogenic reactions, including shaking chills, hypotension, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/31\">",
"     31",
"    </a>",
"    ]. Such adverse reactions are particularly associated with dialyzer reuse and use of high-flux dialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low levels of microbiological contaminants could contribute to chronic inflammation in hemodialysis patients, and using water of high microbiological purity might help protect against long-term morbidity in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3383?source=see_link\">",
"     \"Ultrapure dialysate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WATER QUALITY REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many countries have established quality standards for water used in hemodialysis applications. A number of these standards are based upon those first developed in the United States in the late 1970s by the Association for the Advancement of Medical Instrumentation (AAMI).",
"   </p>",
"   <p>",
"    The AAMI standard was updated in 2001 to reflect increased concerns about microbiological contaminants and changes in the United States Safe Drinking Water Act. The revised standard was reaffirmed in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/35\">",
"     35",
"    </a>",
"    ] and further updated in 2011 by adoption of the International Organization for Standardization standard for the quality of water used in hemodialysis applications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/36\">",
"     36",
"    </a>",
"    ]. Both the 2006 and 2011 standards apply to water used in any hemodialysis application, including water used to prepare dialysate for conventional hemodialysis or for on-line hemodiafiltration, water used to prepare bicarbonate-containing concentrate from water and powder, and water used to reprocess dialyzers for multiple uses. Both revised standards also apply in any hemodialysis setting, including in-center hemodialysis, home hemodialysis, and hemodialysis in an acute care setting.",
"   </p>",
"   <p>",
"    Because the fluid a patient is finally exposed to is dialysate, it is important to ensure that fluid purity is maintained between water purification and dialysate preparation. In 2004, AAMI recommended that the final dialysate meet the same chemical and microbiological purity levels as the water [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/37\">",
"     37",
"    </a>",
"    ]. In 2011, AAMI tightened its recommendations for the microbiological quality of dialysate by adopting the International Organization for Standardization standard for dialysate quality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/38\">",
"     38",
"    </a>",
"    ]. That standard limits bacteria and endotoxin in dialysate to &lt;100",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and &lt;0.5",
"    <span class=\"nowrap\">",
"     EU/mL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chemical contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AAMI water quality standard includes the following three groups of chemical contaminants (",
"    <a class=\"graphic graphic_table graphicRef71221 \" href=\"UTD.htm?41/11/42172\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first of these groups includes substances normally found in dialysate. The maximum allowable level of these contaminants is based upon the clinically acceptable variation in their concentration in the final dialysate.",
"     </li>",
"     <li>",
"      The second group of contaminants includes substances included in the United States Safe Drinking Water Act [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/4\">",
"       4",
"      </a>",
"      ]. Although no specific toxicity of these substances has been documented in dialysis patients, they are known to be toxic to the general population. Generally, the maximum allowable level for these contaminants is set at 10 percent of the drinking water level.",
"     </li>",
"     <li>",
"      The final group of contaminants in the AAMI standard consists of substances with documented toxicity in hemodialysis patients. The maximum allowable level of these substances is based upon the lowest concentration reported to be toxic in the literature.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bacterial contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to chemical contaminants, the AAMI standard includes a maximum level for bacteria of &lt;100 colony forming units",
"    <span class=\"nowrap\">",
"     (CFU)/mL",
"    </span>",
"    and a maximum endotoxin concentration of &lt;0.25",
"    <span class=\"nowrap\">",
"     EU/mL.",
"    </span>",
"    Those levels are lower than what was specified in the 2006 AAMI standard (&lt;200",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and &lt;2",
"    <span class=\"nowrap\">",
"     EU/mL",
"    </span>",
"    for bacteria and endotoxin, respectively), and bring the AAMI standards into line with other national standards. As examples, Sweden limits levels of bacteria and endotoxin to &lt;100",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and &lt;0.25",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    respectively, while the Japanese Society for Dialysis Therapy recommends that the levels of bacteria and endotoxin in standard dialysate be &lt;100",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and &lt;0.05",
"    <span class=\"nowrap\">",
"     EU/mL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/39\">",
"     39",
"    </a>",
"    ]. The more stringent standards for microbiological contaminants have been adopted out of concern for their possible role in the chronic inflammatory state associated with hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3383?source=see_link\">",
"     \"Ultrapure dialysate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Because culture results do not become available for at least 48 hours, during which time bacteria continue to proliferate, the AAMI standard also recommends establishing action levels for bacteria and endotoxin, typically at 50 percent of the maximum allowable level, that is 50",
"      <span class=\"nowrap\">",
"       CFU/mL",
"      </span>",
"      and 0.125",
"      <span class=\"nowrap\">",
"       EU/mL",
"      </span>",
"      for bacteria and endotoxin, respectively. When the level of a contaminant is found to be at or above the action level, appropriate steps, such as disinfection, should be taken to interrupt the trend towards a higher, unacceptable level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although AAMI intends compliance with its documents to be voluntary, the United States Centers for Medicare and Medicaid Services (CMS) has adopted the 2004 AAMI recommended practices for dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/37\">",
"     37",
"    </a>",
"    ] and the 2003 recommended practice for dialyzer reuse, and has made compliance with them a requirement of its revised conditions for coverage for end-stage renal disease facilities issued in 2008. Since the AAMI water quality standard is included in the recommended practice for dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29190/abstract/37\">",
"     37",
"    </a>",
"    ], all dialysis facilities in the United States must use water that meets the maximum allowable contaminant levels given in the table (",
"    <a class=\"graphic graphic_table graphicRef71221 \" href=\"UTD.htm?41/11/42172\">",
"     table 2",
"    </a>",
"    ). The CMS has not yet adopted the more stringent standards for the microbiological quality of dialysate that were introduced by AAMI in 2011. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Water quality requirements'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No municipal water can be considered safe for direct use in hemodialysis applications. All dialysis facilities require a properly designed and maintained water treatment system to safeguard patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant number of municipal water supplies contain a variety of contaminants that are toxic to hemodialysis patients (",
"      <a class=\"graphic graphic_table graphicRef64883 \" href=\"UTD.htm?39/3/39995\">",
"       table 1",
"      </a>",
"      ). The contaminants that have proven most toxic to hemodialysis patients include aluminum, chloramine, and fluoride, which are substances added to water for protection of public health. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Toxicity of water-borne contaminants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Practices intended to suppress microbial proliferation in hospital water supplies can include the introduction of substances into the water supply that are toxic to hemodialysis patients, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      . These substances might be inadequately removed by some water treatment systems used in hospital-based out-patient dialysis facilities and for acute dialysis.",
"     </li>",
"     <li>",
"      The Association for the Advancement of Medical Instrumentation (AAMI) water quality standard includes three groups of chemical contaminants: substances normally found in dialysate, substances included in the United States Safe Drinking Water Act, and substances with documented toxicity in hemodialysis patients (",
"      <a class=\"graphic graphic_table graphicRef71221 \" href=\"UTD.htm?41/11/42172\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chemical contaminants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The AAMI standard for dialysis water includes a maximum level for bacteria of &lt;100 colony forming units",
"      <span class=\"nowrap\">",
"       (CFU)/mL",
"      </span>",
"      and a maximum endotoxin concentration of &lt;0.25",
"      <span class=\"nowrap\">",
"       EU/mL",
"      </span>",
"      out of concern for their possible role in the chronic inflammatory state associated with hemodialysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bacterial contaminants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/1\">",
"      Hoenich NA, Levin R. The implications of water quality in hemodialysis. Semin Dial 2003; 16:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/2\">",
"      Hoenich N, Thijssen S, Kitzler T, et al. Impact of water quality and dialysis fluid composition on dialysis practice. Blood Purif 2008; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/3\">",
"      Martin K, Laydet E, Canaud B. Design and technical adjustment of a water treatment system: 15 years of experience. Adv Ren Replace Ther 2003; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Safe Drinking Water Act, 1996 (Public law 104-182), Washington, DC 1996. www.epa.gov/safewater/sdwa/index.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/5\">",
"      Jochimsen EM, Carmichael WW, An JS, et al. Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. N Engl J Med 1998; 338:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/6\">",
"      Ward RA. Water processing for hemodialysis. Part I: a historical perspective. Semin Dial 1997; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/7\">",
"      Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/8\">",
"      Parkinson IS, Ward MK, Kerr DN. Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol 1981; 34:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/9\">",
"      Ward MK, Feest TG, Ellis HA, et al. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet 1978; 1:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/10\">",
"      Pierides AM, Edwards WG Jr, Cullum UX Jr, et al. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 18:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/11\">",
"      Simoes J, Barata JD, D'Haese PC, De Broe ME. Cela n'arrive qu'aux autres (aluminium intoxication only happens in the other nephrologist's dialysis centre). Nephrol Dial Transplant 1994; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/12\">",
"      Burwen DR, Olsen SM, Bland LA, et al. Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 1995; 48:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/13\">",
"      Eaton JW, Kolpin CF, Swofford HS, et al. Chlorinated urban water: a cause of dialysis-induced hemolytic anemia. Science 1973; 181:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/14\">",
"      Tipple MA, Shusterman N, Bland LA, et al. Illness in hemodialysis patients after exposure to chloramine contaminated dialysate. ASAIO Trans 1991; 37:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/15\">",
"      P&eacute;rez-Garc&iacute;a R, Rodr&iacute;guez-Ben&iacute;tez P. Chloramine, a sneaky contaminant of dialysate. Nephrol Dial Transplant 1999; 14:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/16\">",
"      Fluck S, McKane W, Cairns T, et al. Chloramine-induced haemolysis presenting as erythropoietin resistance. Nephrol Dial Transplant 1999; 14:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/17\">",
"      Richardson D, Bartlett C, Goutcher E, et al. Erythropoietin resistance due to dialysate chloramine: the two-way traffic of solutes in haemodialysis. Nephrol Dial Transplant 1999; 14:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/18\">",
"      Ward DM. Chloramine removal from water used in hemodialysis. Adv Ren Replace Ther 1996; 3:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/19\">",
"      de Torres JP, DeTorres JP, Strom JA, et al. Hemodialysis-associated methemoglobinemia in acute renal failure. Am J Kidney Dis 2002; 39:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/20\">",
"      Junglee NA, Rahman SU, Wild M, et al. When pure is not so pure: chloramine-related hemolytic anemia in home hemodialysis patients. Hemodial Int 2010; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/21\">",
"      Rao TK, Friedman EA. Editorial: Fluoride and bone disease in uremia. Kidney Int 1975; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/22\">",
"      Arnow PM, Bland LA, Garcia-Houchins S, et al. An outbreak of fatal fluoride intoxication in a long-term hemodialysis unit. Ann Intern Med 1994; 121:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/23\">",
"      Manzler AD, Schreiner AW. Copper-induced acute hemolytic anemia. A new complication of hemodialysis. Ann Intern Med 1970; 73:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/24\">",
"      Gallery ED, Blomfield J, Dixon SR. Acute zinc toxicity in haemodialysis. Br Med J 1972; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/25\">",
"      Kathuria, P, Nair, B, Schram, D, Medlock, R. Outbreak of lead poisoning in a hemodialysis unit. J Am Soc Nephrol 2004; 15:617A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/26\">",
"      Davenport A, Murcutt G, Whiting S. Cross-sectional audit of blood lead levels in regular outpatient haemodialysis patients dialysing in north London. Nephrology (Carlton) 2009; 14:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/27\">",
"      Gordon SM, Bland LA, Alexander SR, et al. Hemolysis associated with hydrogen peroxide at a pediatric dialysis center. Am J Nephrol 1990; 10:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/28\">",
"      Davidovits M, Barak A, Cleper R, et al. Methaemoglobinaemia and haemolysis associated with hydrogen peroxide in a paediatric haemodialysis centre: a warning note. Nephrol Dial Transplant 2003; 18:2354.",
"     </a>",
"    </li>",
"    <li>",
"     NHS National Patient Safety Agency. Risks to hemodialysis patients from water supply (hydrogen peroxide). NPSA/2008/RRR007. https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=50485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/30\">",
"      Bek MJ, Laule S, Reichert-J&uuml;nger C, et al. Methemoglobinemia in critically ill patients during extended hemodialysis and simultaneous disinfection of the hospital water supply. Crit Care 2009; 13:R162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/31\">",
"      Favero MS, Petersen NJ, Boyer KM, et al. Microbial contamination of renal dialysis systems and associated health risks. Trans Am Soc Artif Intern Organs 1974; 20A:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/32\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/33\">",
"      Baz M, Durand C, Ragon A, et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/34\">",
"      Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15:840.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Water Treatment Equipment for Hemodialysis Applications, ANSI/AAMI RD62:2006, Association for the Advancement of Medical Instrumentation, Arlington, VA 2006.",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Water for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 13959:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Dialysate for Hemodialysis, ANSI/AAMI RD52:2004, Association for the Advancement of Medical Instrumentation, Arlington, VA 2004.",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Quality of Dialysis Fluid for Hemodialysis and Related Therapies, ANSI/AAMI/ISO 11663:2009, Association for the Advancement of Medical Instrumentation, Arlington, VA 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29190/abstract/39\">",
"      Kawanishi H, Masakane I, Tomo T. The new standard of fluids for hemodialysis in Japan. Blood Purif 2009; 27 Suppl 1:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1891 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2143548A13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29190=[""].join("\n");
var outline_f28_32_29190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TOXICITY OF WATER-BORNE CONTAMINANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aluminum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chloramine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluoride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other contaminants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Copper and zinc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lead",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bacteria and endotoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WATER QUALITY REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chemical contaminants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bacterial contaminants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/3/39995\" title=\"table 1\">",
"      Water contaminants in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/11/42172\" title=\"table 2\">",
"      Chemical quality standards",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=related_link\">",
"      Maintaining water quality for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3383?source=related_link\">",
"      Ultrapure dialysate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=related_link\">",
"      Water purification systems in hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29191="Anterior neck muscles B";
var content_f28_32_29191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    The prevertebral region and root of the neck, anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29191=[""].join("\n");
var outline_f28_32_29191=null;
var title_f28_32_29192="Treatment of the obesity hypoventilation syndrome";
var content_f28_32_29192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the obesity hypoventilation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Thomas J Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29192/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/32/29192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity Hypoventilation Syndrome (OHS) exists when an obese individual (body mass index [BMI]",
"    <span class=\"nowrap\">",
"     &gt;30kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    has awake alveolar hypoventilation (arterial carbon dioxide tension [PaCO2] &gt;45 mmHg), which cannot be attributed to other conditions such as pulmonary disease, skeletal restriction, neuromuscular weakness, hypothyroidism, or pleural pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with OHS typically have a diminished respiratory drive, obesity-related respiratory impairment, and sleep-related breathing abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/4\">",
"     4",
"    </a>",
"    ]. Obstructive sleep apnea (OSA) is particularly common among patients with OHS, occurring in 85 to 92 percent of patients who have OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Conversely, OHS is less common among patients with OSA, occurring in 4 to 20 percent of patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history and treatment of OHS are reviewed here. The clinical manifestations, diagnosis, and pathogenesis of OHS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=see_link\">",
"     \"Pathogenesis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715328\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is important because untreated OHS can progress to acute, life-threatening cardiopulmonary compromise. In addition, untreated OHS is associated with a high mortality rate, a reduced quality of life, and numerous morbidities, including pulmonary hypertension, right heart failure, angina, and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/4,11-13\">",
"     4,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective cohort study compared consecutively admitted patients with obesity-associated hypoventilation and severely obese patients without hypoventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/12\">",
"     12",
"    </a>",
"    ]. It found that patients with obesity-associated hypoventilation had a higher mortality rate 18 months after discharge (23 versus 9 percent), as well as increased rates of invasive mechanical ventilation during the admission and long-term care after discharge. Specific therapy was recommended during the admission for only 13 percent of the patients with obesity-associated hypoventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715504\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic goals for patients with OHS include normalization of the arterial carbon dioxide tension (PaCO2) during wakefulness and sleep (ie, PaCO2 &lt;45 mmHg); prevention of oxyhemoglobin desaturation during sleep and wakefulness, erythrocytosis, pulmonary hypertension, and cor pulmonale; and relief of hypersomnia and altered mentation. To achieve these goals, all patients with OHS are managed with nocturnal positive airway pressure and lifestyle modifications directed at losing weight. Bariatric surgery may be considered for patients who fail to lose sufficient weight with lifestyle modifications and either hope to eventually discontinue nocturnal noninvasive positive airway pressure or do not tolerate nocturnal noninvasive positive airway pressure. Routine treatment of comorbid conditions and the prevention of complications are also necessary in all patients with OHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2738498\">",
"    <span class=\"h1\">",
"     POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal noninvasive positive airway pressure is first-line treatment for OHS, regardless of whether or not the patient has a coexisting sleep-related breathing disorder. It is indicated for all patients with OHS and should NOT be delayed while the patient tries to lose weight. Patients with OHS alone are generally managed with bilevel positive airway pressure (BPAP). In contrast, patients with OHS and coexisting obstructive sleep apnea (OSA) are usually managed initially with continuous positive airway pressure (CPAP) and then changed to BPAP if the CPAP is insufficient. Selection of the appropriate mode of noninvasive positive airway pressure (ie, BPAP versus CPAP), an approach to initiating noninvasive positive airway pressure therapy, and outcomes are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with OHS, nocturnal noninvasive positive airway pressure therapy decreases nocturnal arterial carbon dioxide tension (PaCO2) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/14\">",
"     14",
"    </a>",
"    ], daytime PaCO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/7,15,16\">",
"     7,15,16",
"    </a>",
"    ], and daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/14\">",
"     14",
"    </a>",
"    ]. It also improves quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Adherence with nocturnal noninvasive positive airway pressure therapy, as defined by the duration of daily use, has correlated with the improvement in PaCO2 in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. There are no randomized trials that assessed the effect of noninvasive positive airway pressure on long-term mortality. However, a prospective study of 130 patients who received nocturnal bilevel positive airway pressure for OHS (as well as supplemental oxygen for persistent nocturnal hypoxemia) found 1-, 2-, 3-, and 5-year survival rates of 98, 93, 88, and 77 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/15\">",
"     15",
"    </a>",
"    ]. These survival rates were better than the 18-month survival rate of 77 percent reported for a prospective cohort of patients with OHS, most of whom were untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Negative pressure ventilation is not a useful alternative because there are numerous practical problems and its efficacy has not been established in patients with OHS. The rationale for considering negative pressure ventilation is that it may mitigate or prevent chronic respiratory failure by decreasing the work of breathing and ventilatory muscle fatigue. However, its practical limitations include the following: (a) fitting the various negative pressure ventilation systems (eg, shells, poncho wraps, and tank ventilators) is difficult due to the obesity, (b) even if a negative pressure ventilation system is found that fits the patient, the level of ventilatory support is limited by reduced chest wall and abdominal compliance, and (c) patients with OHS are predisposed to obstructive sleep apnea and negative pressure ventilation during sleep may promote upper airway occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715738\">",
"    <span class=\"h1\">",
"     WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is widespread agreement that weight loss is desirable in patients with OHS. In addition to improving general health, weight loss can improve alveolar ventilation (sometimes normalizing the awake arterial carbon dioxide tension [PaCO2] and arterial oxygen tension [PaO2]), reduce the risk of cardiorespiratory compromise, improve nocturnal oxyhemoglobin saturation, decrease the frequency of respiratory events (ie, apneas, hypopneas) during sleep if the patient has coexisting OSA, correct pulmonary arterial hypertension, improve left ventricular dysfunction, and improve pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These benefits appear to occur regardless of whether the weight loss was due to lifestyle modification (ie, diet, exercise) or surgery.",
"   </p>",
"   <p>",
"    Weight loss should be supervised and controlled. Rapid, unsupervised weight loss is discouraged because it is generally not sustained and may have serious side effects (eg, cholelithiasis). There are no reliable predictors of the exact amount of weight that must be lost to ameliorate nocturnal upper airway dysfunction and cardiorespiratory failure. Individuals with OHS are usually morbidly obese (ie, more than 50 percent above ideal body weight) and clinical experience suggests that weight loss of more than 100 pounds is often needed before improvement is seen.",
"   </p>",
"   <p>",
"    All patients with OHS should make lifestyle modifications to lose weight. For patients in whom lifestyle modifications are insufficient and either hope to eventually discontinue nocturnal noninvasive positive airway pressure or do not tolerate nocturnal noninvasive positive airway pressure, referral to a bariatric surgeon for consideration of a surgical approach to weight loss is reasonable. Weight loss medications are potentially harmful and often insufficient, so we believe that they should only be used on a case-by-case basis after a careful evaluation of the potential benefits and risks to the individual patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lifestyle modification &ndash; Lifestyle modifications refer to various combinations of dietary change, exercise, and behavioral modification, which are described in detail separately. Individuals with OHS may have more difficulty maintaining long-term weight loss than persons with uncomplicated obesity because of exercise limitations related to their respiratory failure. Thus, while lifestyle modifications are necessary in patients with OHS, they are seldom sufficient to achieve and maintain a degree of weight loss that satisfactorily improves alveolar ventilation and sleep-related breathing disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"       \"Dietary therapy for obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"       \"Role of physical activity and exercise in obese adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"       \"Behavioral strategies in the treatment of obesity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication &ndash; Pharmacologic therapy for obesity is not universally accepted because of concerns about efficacy and safety, the observation that weight loss slows with ongoing treatment, and the observation that most patients regain their weight when the medications are discontinued. Regarding efficacy, many of the weight loss medications initially achieve weight loss of 5 to 10 kg over 3 to 12 months before the weight loss plateaus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/24,25\">",
"       24,25",
"      </a>",
"      ], but this is typically not enough to normalize the awake PaCO2. Regarding safety, pharmacologic therapy has the potential to cause drug-induced pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/26\">",
"       26",
"      </a>",
"      ]. This is a particular concern in patients with OHS whose respiratory abnormalities already place them at increased risk for this complication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"       \"Drug therapy of obesity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bariatric surgery &ndash; Considerable attention has been directed towards surgical methods of weight loss (ie, bariatric surgery), since lifestyle modifications alone are generally insufficient and pharmacological therapy is of uncertain efficacy and safety [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/27\">",
"       27",
"      </a>",
"      ]. Bariatric surgery leads to a restriction of caloric intake alone or in combination with malabsorption of nutrients, thereby causing weight loss. Bariatric techniques include Roux-en-Y gastric bypass, adjustable gastric banding, sleeve gastrectomy, biliopancreatic diversion, duodenal switch, intragastric balloon, vertical banded gastroplasty endoluminal vertical gastroplasty, jejunoileal bypass, and liposuction. Perioperative mortality related to bariatric surgery is dependent on comorbidities and the procedure performed, but is reported to be less than 2 percent of patients who undergo bariatric surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. The indications, contraindications, techniques, and complications of bariatric surgery are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"       \"Surgical management of severe obesity\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Prior to bariatric surgery, all patients should undergo attended nocturnal in-laboratory polysomnography as part of their preoperative evaluation. The reasons are to detect coexisting obstructive sleep apnea (OSA) in patients not already known to have OSA and to ensure that the positive airway pressure level is optimal in patients who are receiving positive airway pressure therapy for OHS with or without OSA. Several prospective studies included routine polysomnography of candidates for bariatric surgery and identified sleep-related breathing disorders in 75 to 83 percent of the operative candidates [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]; these detection rates were significantly higher than those based upon clinical impression alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/33\">",
"       33",
"      </a>",
"      ], suggesting that referral for polysomnography based upon clinical presentation alone may miss identifying a large number of patients preoperatively. Arterial blood gases were not part of the routine evaluation in most of the studies but, in the study that did perform arterial blood gases, OHS was detected in 8 percent of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition to accurately characterizing the nature of sleep-disordered breathing events (obstructive versus hypoventilation), attended nocturnal in-laboratory polysomnography facilitates optimal titration of nocturnal noninvasive positive airway pressure therapy as indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients should continue their positive airway pressure therapy pre- and postoperatively. Inability to tolerate noninvasive positive airway pressure therapy may necessitate tracheostomy, either prior to or at the time of bariatric surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/35\">",
"       35",
"      </a>",
"      ]. Even with optimal titration of nocturnal noninvasive positive airway pressure pre-operatively, patients with sleep-disordered breathing may be at risk for hypoventilation postoperatively due to the effects of surgery, general anesthesia, or medications. The propensity for postoperative hypoventilation is frequently underestimated, as evidenced by a prospective series of 15 patients who underwent Roux-en-Y bypass, all of who experienced severe, prolonged, and frequently repetitive periods of oxyhemoglobin desaturation postoperatively. The oxyhemoglobin desaturation occurred despite eight of the patients being administered noninvasive positive airway pressure, supporting the recommendation that all bariatric surgery patients should receive continuous pulse oximetry monitoring during the postoperative period [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Given the high incidence of sleep-disordered breathing in patients referred for bariatric surgery and the increased potential for respiratory compromise during the postoperative period that requires expert intervention, a sleep physician with expertise in the application of noninvasive positive pressure ventilation should be consulted on all patients with OHS prior to bariatric surgery. Preoperative, intraoperative, and postoperative management of patients with OSA are reviewed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37893?source=see_link\">",
"       \"Intraoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34965?source=see_link\">",
"       \"Postoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Reassessment of OHS following bariatric surgery is performed after significant weight loss has occurred, usually within one to two years after the surgery. It consists of an arterial blood gas to reassess the awake PaCO2 and PaO2 in all patients, as well as in-laboratory polysomnography in patients who had coexisting OSA to assess for resolution or improvement of the OSA. Early, rapid weight loss (typically 45 to 70 percent of excess body weight) during the first postoperative year is often associated with the amelioration or improvement of OHS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/37\">",
"       37",
"      </a>",
"      ]. However, this has not been universal as some patients have persistent OHS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/4,21,38,39\">",
"       4,21,38,39",
"      </a>",
"      ]. Discontinuation of nocturnal noninvasive positive pressure ventilation after bariatric surgery without polysomnographically documented resolution of obstructive sleep disordered breathing and hypoventilation is NOT recommended, since residual obstructive sleep apnea may persist or hypoventilation may worsen despite substantial and sustained initial weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/21,40-42\">",
"       21,40-42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1606890\">",
"    <span class=\"h1\">",
"     TREATMENT OF COMORBID CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid conditions that impair ventilation or reduce the ventilatory response to hypoxemia or hypercapnia are likely to contribute to the impairment caused by obesity. As a result, the clinician should make an effort to identify and treat such comorbid conditions. Examples include chronic obstructive pulmonary disease (COPD) and hypothyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COPD &ndash; COPD may exacerbate the symptoms and signs of OHS because both diseases impair alveolar ventilation and increase the work of breathing. It is reasonable to perform spirometry in patients with OHS, in order to detect coexisting COPD. Treatment of the COPD is indicated for all patients who are found to have coexisting COPD. This includes the cessation of smoking, bronchodilators, and, possibly, inhaled corticosteroids. The diagnosis and management of COPD are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Supplemental oxygen therapy is a widely accepted therapy for hypoxemic patients with COPD alone; it has been shown to improve survival and it is not associated with worsening hypercapnia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. In contrast, supplemental oxygen therapy may worsen hypercapnia in coexisting OHS and COPD. In situations in which a patient with OHS and COPD requires supplemental oxygen, it should be used along with noninvasive positive airway pressure therapy because there is evidence that hypercapnia may not worsen if the supplemental oxygen is used with noninvasive positive airway pressure. If the patient cannot tolerate noninvasive positive airway pressure therapy, the patient should be carefully monitored to ensure that worsening of nocturnal asphyxia does not have adverse effects on hemodynamics, symptoms, or alveolar ventilation.",
"     </li>",
"     <li>",
"      Hypothyroidism &ndash; Hypothyroidism may contribute to the chronic ventilatory failure of OHS by decreasing chemo-responsiveness, causing OSA (due to macroglossia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upper airway dilator muscle dysfunction), or causing either a myopathy or neuropathy that affects the respiratory muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/46-49\">",
"       46-49",
"      </a>",
"      ]. These consequences of hypothyroidism may be improved with thyroid hormone replacement. Screening for hypothyroidism by measuring the serum thyroid stimulating hormone (TSH) concentration is warranted in all individuals presenting with OHS, since the clinical presentation of the hypothyroidism may be quite similar to that of euthyroid patients with OHS.",
"      <br/>",
"      <br/>",
"      In cases of subclinical hypothyroidism, which are characterized by mild elevation of the serum TSH (&lt;10",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      and a normal free T4 level, there are no data to strongly support either treating OHS patients with supplemental thyroid hormone or observing them. Given the potential contribution of superimposed hypothyroidism to the respiratory failure present in OHS and also the potential for a substantial portion of individuals with subclinical hypothyroidism to eventually progress to overt hypothyroidism over a number of years, the decision to observe patients with OHS who have laboratory evidence of subclinical hypothyroidism mandates periodic laboratory and clinical monitoring for the development of overt hypothyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1606915\">",
"    <span class=\"h1\">",
"     PREVENTING COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OHS should be advised to abstain from alcohol. In addition, benzodiazepines, opiates, and barbiturates should be avoided if possible. While most of the dangers of these agents have been described as worsening sleep-related breathing abnormalities in patients with coexisting OHS and OSA, we believe that the evidence is relevant to all patients with OHS, since most patients with OHS also have OSA and there are theoretical risks of adversely affecting ventilatory chemoresponsiveness and upper airway function in OHS.",
"   </p>",
"   <p>",
"    Alcohol has been shown to increase the frequency of respiratory events (ie, apneas, hypopneas) during sleep and to worsen nocturnal oxyhemoglobin desaturation in patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/50\">",
"     50",
"    </a>",
"    ]. This may be mediated by alcohol-induced suppression of upper airway dilator muscle activity during sleep and decreased ventilatory drive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Benzodiazepines, opiates, and barbiturates similarly have the potential to worsen the frequency or duration of respiratory events during sleep via adverse effects on ventilatory responsiveness, upper airway patency, or arousal mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. If any of these agents is considered imperative in the treatment of an individual with OHS, clinical monitoring is warranted to evaluate the impact of the medication on symptoms and arterial gas exchange. Polysomnography may be a useful adjunct to help assess nocturnal ventilation and adequacy of therapy. Failure to abstain from alcohol or the effects of benzodiazepines, opiates, or barbiturates may mitigate the impact of primary OHS therapy (eg, positive pressure therapy).",
"   </p>",
"   <p>",
"    In addition to the sedatives described above, supplemental oxygen must be approached cautiously in patients with OHS because it may increase hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/57\">",
"     57",
"    </a>",
"    ]. In situations in which a patient with OHS requires supplemental oxygen, it should be used along with noninvasive positive airway pressure therapy because there is evidence that hypercapnia may not worsen if the supplemental oxygen is used with noninvasive positive airway pressure. If supplemental oxygen is necessary and the patient cannot tolerate noninvasive positive airway pressure therapy, the patient should be carefully monitored to ensure that worsening of nocturnal asphyxia does not have adverse effects on hemodynamics, symptoms, or alveolar ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory stimulants (ie, progestins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ) are a therapy of last resort for patients with who continue to have serious alveolar hypoventilation despite positive airway pressure therapy. Progestins have been shown to improve awake hypercapnia and hypoxemia in patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], while acetazolamide has been shown to improve alveolar ventilation in patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Despite these benefits, neither is considered an appropriate primary therapy for OHS because they do not affect all of the pathogenic contributors to OHS, in particular the recurrent upper airway collapse that occurs during sleep in patients who have coexisting obstructive sleep apnea (OSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/63-66\">",
"     63-66",
"    </a>",
"    ] or the altered respiratory mechanics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/67\">",
"     67",
"    </a>",
"    ]. Leaving these contributors untreated may have adverse long-term consequences. In addition, progestins and acetazolamide have potentially serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The respiratory stimulant,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , has not been studied in patients with OHS. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5573090\">",
"    <span class=\"h1\">",
"     TRACHEOSTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheostomy has no role in patients with OHS alone, but it may be effective in patients with coexisting OHS and obstructive sleep apnea (OSA) because it relieves upper airway obstruction during sleep with subsequent improvement in alveolar ventilation and the arterial carbon dioxide tension (PaCO2) during wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/60\">",
"     60",
"    </a>",
"    ]. Not all patients return to eucapnia following tracheostomy because upper airway obstruction is just one of several factors responsible for chronic hypoventilation in patients with coexisting OHS and OSA; other factors include decreased compliance of the respiratory system and decreased ventilatory muscle strength, which are unaltered by tracheostomy.",
"   </p>",
"   <p>",
"    Tracheostomy is rarely necessary since the same goals can be achieved without surgery using noninvasive positive airway pressure therapy. This is fortunate since tracheostomy is associated with many problems, including the following: The surgery is more difficult in obese individuals, debulking excess subcutaneous tissue may be required, obesity may limit the use of tracheostomy buttons during wakefulness to facilitate speech, recurrent episodes of purulent bronchitis may occur, and psychosocial problems after the procedure have been reported in a majority of patients, including disability, adjustment disorders, and marital discord [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29192/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715527\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity Hypoventilation Syndrome (OHS) exists when an obese individual (body mass index [BMI]",
"      <span class=\"nowrap\">",
"       &gt;30kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      has awake alveolar hypoventilation (arterial carbon dioxide tension [PaCO2] &gt;45 mmHg), which cannot be attributed to other conditions such as pulmonary disease, skeletal restriction, neuromuscular weakness, untreated hypothyroidism, or pleural pathology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is indicated because untreated OHS can progress to acute, life-threatening cardiopulmonary compromise. Untreated OHS is also associated with a high mortality rate, a reduced quality of life, and numerous morbidities. (See",
"      <a class=\"local\" href=\"#H715328\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with OHS, we recommend immediate initiation of noninvasive positive airway pressure therapy, rather than delaying the initiation of noninvasive positive airway pressure therapy until the outcome of the attempted weight loss is known (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2738498\">",
"       'Positive airway pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The process of initiating noninvasive positive pressure therapy, selection of the mode (ie, bilevel positive airway pressure versus continuous positive airway pressure), and clinical outcomes are described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=see_link\">",
"       \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with OHS should undergo lifestyle modifications (ie, dietary changes, exercise, behavioral modifications) in an effort to lose weight. For those patients in whom weight loss due to lifestyle modifications is insufficient to correct the OHS, we suggest NOT treating with weight loss medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For the same patients, referral to a bariatric surgeon is reasonable if they either hope to eventually discontinue or are not tolerating nocturnal noninvasive positive airway pressure. (See",
"      <a class=\"local\" href=\"#H715738\">",
"       'Weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comorbid conditions that impair ventilation or reduce the ventilatory response to hypoxemia or hypercapnia are likely to contribute to the impairment caused by obesity. As a result, the clinician should make an effort to identify and treat such comorbid conditions. Examples include chronic obstructive pulmonary disease (COPD) and hypothyroidism.(See",
"      <a class=\"local\" href=\"#H1606890\">",
"       'Treatment of comorbid conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with OHS should be advised to abstain from alcohol. In addition, benzodiazepines, opiates, and barbiturates should be avoided in patients with OHS if possible. Supplemental oxygen must be approached cautiously in patients with OHS because it may increase hypercapnia (See",
"      <a class=\"local\" href=\"#H1606915\">",
"       'Preventing complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacological therapy with respiratory stimulants does not treat all of the pathogenic components of OHS and has potential side effects; therefore, it is regarded as a therapy of last resort for patients with who continue to have serious hypoventilation despite positive airway pressure therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracheostomy has no role in patients with OHS alone. It may be effective in patients with coexisting OHS and obstructive sleep apnea (OSA) because it relieves upper airway obstruction during sleep; however, not all patients return to eucapnia following tracheostomy because upper airway obstruction is just one of several factors responsible for chronic hypoventilation. In addition, tracheostomy has attendant surgical risks. (See",
"      <a class=\"local\" href=\"#H5573090\">",
"       'Tracheostomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/1\">",
"      BICKELMANN AG, BURWELL CS, ROBIN ED, WHALEY RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 1956; 21:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/2\">",
"      Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/3\">",
"      Chouri-Pontarollo N, Borel JC, Tamisier R, et al. Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest 2007; 131:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/4\">",
"      Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/5\">",
"      Banerjee D, Yee BJ, Piper AJ, et al. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest 2007; 131:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/6\">",
"      Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/7\">",
"      P&eacute;rez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/8\">",
"      Mokhlesi B, Tulaimat A, Faibussowitsch I, et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath 2007; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/9\">",
"      Laaban JP, Chailleux E. Daytime hypercapnia in adult patients with obstructive sleep apnea syndrome in France, before initiating nocturnal nasal continuous positive airway pressure therapy. Chest 2005; 127:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/10\">",
"      Verin E, Tardif C, Pasquis P. Prevalence of daytime hypercapnia or hypoxia in patients with OSAS and normal lung function. Respir Med 2001; 95:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/11\">",
"      Fletcher EC, Shah A, Qian W, Miller CC 3rd. \"Near miss\" death in obstructive sleep apnea: a critical care syndrome. Crit Care Med 1991; 19:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/12\">",
"      Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/13\">",
"      Miller A, Granada M. In-hospital mortality in the Pickwickian syndrome. Am J Med 1974; 56:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/14\">",
"      Waldhorn RE. Nocturnal nasal intermittent positive pressure ventilation with bi-level positive airway pressure (BiPAP) in respiratory failure. Chest 1992; 101:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/15\">",
"      Priou P, Hamel JF, Person C, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/16\">",
"      Piper AJ, Wang D, Yee BJ, et al. Randomised trial of CPAP vs bilevel support in the treatment of obesity hypoventilation syndrome without severe nocturnal desaturation. Thorax 2008; 63:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/17\">",
"      Hida W, Okabe S, Tatsumi K, et al. Nasal continuous positive airway pressure improves quality of life in obesity hypoventilation syndrome. Sleep Breath 2003; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/18\">",
"      Tsolaki V, Pastaka C, Kostikas K, et al. Noninvasive ventilation in chronic respiratory failure: effects on quality of life. Respiration 2011; 81:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/19\">",
"      Heinemann F, Budweiser S, Dobroschke J, Pfeifer M. Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome. Respir Med 2007; 101:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/20\">",
"      Mokhlesi B, Tulaimat A, Evans AT, et al. Impact of adherence with positive airway pressure therapy on hypercapnia in obstructive sleep apnea. J Clin Sleep Med 2006; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/21\">",
"      Sugerman HJ, Fairman RP, Sood RK, et al. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992; 55:597S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/22\">",
"      Harman EM, Wynne JW, Block AJ. The effect of weight loss on sleep-disordered breathing and oxygen desaturation in morbidly obese men. Chest 1982; 82:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/23\">",
"      Nguyen NT, Hinojosa MW, Smith BR, et al. Improvement of restrictive and obstructive pulmonary mechanics following laparoscopic bariatric surgery. Surg Endosc 2009; 23:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/24\">",
"      Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/25\">",
"      Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/26\">",
"      Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/27\">",
"      Sugerman HJ. Surgery for morbid obesity. Surgery 1993; 114:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/28\">",
"      Johnson W, DeMaria E. Surgical treatment of obesity. Curr Treat Options Gastroenterol 2006; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/29\">",
"      DeMaria EJ, Murr M, Byrne TK, et al. Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. Ann Surg 2007; 246:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/30\">",
"      Lecube A, Sampol G, Lloberes P, et al. Asymptomatic sleep-disordered breathing in premenopausal women awaiting bariatric surgery. Obes Surg 2010; 20:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/31\">",
"      Sareli AE, Cantor CR, Williams NN, et al. Obstructive sleep apnea in patients undergoing bariatric surgery--a tertiary center experience. Obes Surg 2011; 21:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/32\">",
"      Haines KL, Nelson LG, Gonzalez R, et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery 2007; 141:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/33\">",
"      Hallowell PT, Stellato TA, Schuster M, et al. Potentially life-threatening sleep apnea is unrecognized without aggressive evaluation. Am J Surg 2007; 193:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/34\">",
"      Berry RB, Chediak A, Brown LK, et al. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 2010; 6:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/35\">",
"      Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/36\">",
"      Gallagher SF, Haines KL, Osterlund LG, et al. Postoperative hypoxemia: common, undetected, and unsuspected after bariatric surgery. J Surg Res 2010; 159:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/37\">",
"      Sugerman HJ, Fairman RP, Baron PL, Kwentus JA. Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/38\">",
"      Mart&iacute;-Valeri C, Sabat&eacute; A, Masdevall C, Dalmau A. Improvement of associated respiratory problems in morbidly obese patients after open Roux-en-Y gastric bypass. Obes Surg 2007; 17:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/39\">",
"      Korenkov M, Shah S, Sauerland S, et al. Impact of laparoscopic adjustable gastric banding on obesity co-morbidities in the medium- and long-term. Obes Surg 2007; 17:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/40\">",
"      Lettieri CJ, Eliasson AH, Greenburg DL. Persistence of obstructive sleep apnea after surgical weight loss. J Clin Sleep Med 2008; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/41\">",
"      Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis. Am J Med 2009; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/42\">",
"      Grunstein RR, Stenl&ouml;f K, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/43\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/44\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/45\">",
"      Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 1984; 310:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/46\">",
"      Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989; 96:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/47\">",
"      Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med 1988; 84:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/48\">",
"      MASSUMI RA, WINNACKER JL. SEVERE DEPRESSION OF THE RESPIRATORY CENTER IN MYXEDEMA. Am J Med 1964; 36:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/49\">",
"      Skatrud J, Iber C, Ewart R, et al. Disordered breathing during sleep in hypothyroidism. Am Rev Respir Dis 1981; 124:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/50\">",
"      Scrima L, Broudy M, Nay KN, Cohn MA. Increased severity of obstructive sleep apnea after bedtime alcohol ingestion: diagnostic potential and proposed mechanism of action. Sleep 1982; 5:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/51\">",
"      Krol RC, Knuth SL, Bartlett D Jr. Selective reduction of genioglossal muscle activity by alcohol in normal human subjects. Am Rev Respir Dis 1984; 129:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/52\">",
"      Sahn SA, Lakshminarayan S, Pierson DJ, Weil JV. Effect of ethanol on the ventilatory responses to oxygen and carbon dioxide in man. Clin Sci Mol Med 1975; 49:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/53\">",
"      Dolly FR, Block AJ. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med 1982; 73:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/54\">",
"      Geddes DM, Rudolf M, Saunders KB. Effect of nitrazepam and flurazepam on the ventilatory response to carbon dioxide. Thorax 1976; 31:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/55\">",
"      Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 1975; 292:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/56\">",
"      Simmons FB, Hill MW. Hypersomnia caused by upper airway obstructions: a new syndrome in otolaryngology. Ann Otol Rhinol Laryngol 1974; 83:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/57\">",
"      Wijesinghe M, Williams M, Perrin K, et al. The effect of supplemental oxygen on hypercapnia in subjects with obesity-associated hypoventilation: a randomized, crossover, clinical study. Chest 2011; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/58\">",
"      Sutton FD Jr, Zwillich CW, Creagh CE, et al. Progesterone for outpatient treatment of Pickwickian syndrome. Ann Intern Med 1975; 83:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/59\">",
"      Lyons HA, Huang CT. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 1968; 44:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/60\">",
"      Rapoport DM, Garay SM, Epstein H, Goldring RM. Hypercapnia in the obstructive sleep apnea syndrome. A reevaluation of the \"Pickwickian syndrome\". Chest 1986; 89:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/61\">",
"      Raurich JM, Rialp G, Ib&aacute;&ntilde;ez J, et al. Hypercapnic respiratory failure in obesity-hypoventilation syndrome: CO response and acetazolamide treatment effects. Respir Care 2010; 55:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/62\">",
"      Powers MA. Obesity hypoventilation syndrome: bicarbonate concentration and acetazolamide. Respir Care 2010; 55:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/63\">",
"      Jones JB, Wilhoit SC, Findley LJ, Suratt PM. Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome. Chest 1985; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/64\">",
"      Orr WC, Imes NK, Martin RJ. Progesterone therapy in obese patients with sleep apnea. Arch Intern Med 1979; 139:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/65\">",
"      Strohl KP, Hensley MJ, Saunders NA, et al. Progesterone administration and progressive sleep apneas. JAMA 1981; 245:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/66\">",
"      Cook WR, Benich JJ, Wooten SA. Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest 1989; 96:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/67\">",
"      SHARP JT, HENRY JP, SWEANY SK, et al. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest 1964; 43:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/68\">",
"      Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/69\">",
"      Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005; 3:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29192/abstract/70\">",
"      Conway WA, Victor LD, Magilligan DJ Jr, et al. Adverse effects of tracheostomy for sleep apnea. JAMA 1981; 246:347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7713 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29192=[""].join("\n");
var outline_f28_32_29192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H715527\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715328\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715504\">",
"      GENERAL APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2738498\">",
"      POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715738\">",
"      WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1606890\">",
"      TREATMENT OF COMORBID CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1606915\">",
"      PREVENTING COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5573090\">",
"      TRACHEOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715527\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37893?source=related_link\">",
"      Intraoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/9/34965?source=related_link\">",
"      Postoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29193="Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis";
var content_f28_32_29193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Alfred Buxton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/32/29193/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/32/29193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained monomorphic ventricular tachycardia (SMVT) is defined by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A regular wide QRS complex tachycardia at a rate of more than 100 beats per minute",
"     </li>",
"     <li>",
"      The consecutive beats have a uniform and stable QRS morphology",
"     </li>",
"     <li>",
"      The arrhythmia lasts &ge;30 seconds or causes hemodynamic collapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with significant coronary heart disease (CHD) or other structural heart disease, a wide QRS complex tachycardia should be considered to be ventricular tachycardia until proven otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will focus on the treatment of SMVT in patients who have had a prior myocardial infarction (MI). The diagnostic approach to SMVT and the treatment of SMVT during an acute MI, as well as the management of non-sustained VT, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"     \"Management of nonsustained ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the incidence and prognostic significance of SMVT in patients with a prior myocardial infarction (MI) varies according to the temporal relationship between the arrhythmia and the infarction.",
"   </p>",
"   <p>",
"    The role of VT in overall risk stratification in patients with a prior MI is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H12#H12\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Sustained monomorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287278073\">",
"    <span class=\"h1\">",
"     VT IN THE SETTING OF ACUTE MI (AMI)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early SMVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early SMVT is uncommon, occurring in up to 3 percent of patients as a primary arrhythmia and in association with ventricular fibrillation (VF) in up to an additional 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients with SMVT early after an MI (6 to 48 hours) have a greater risk of in-hospital mortality compared to those without this arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This increase in risk is due both to cardiac arrest and, if the arrhythmia enhances myocardial oxygen demand, possible exacerbation of ischemia and extension of the infarct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term prognostic significance of early SMVT is less clear. Ventricular arrhythmias early after MI (SMVT, nonsustained VT, polymorphic VT, and ventricular fibrillation) are often ascribed to transient arrhythmogenic mechanisms, which would not predict an increased long-term risk of malignant arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is evidence that, in contrast to VF or polymorphic VT, early SMVT reflects permanent arrhythmic substrate (ie, reentry), and therefore increased long-term risk. Some experts treat patients with early SMVT in the same manner as those with late SMVT. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prevention of recurrent arrhythmias and SCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients with early SMVT, additional clinical features that some experts consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical manifestation of VT &ndash; degree of hemodynamic stability",
"     </li>",
"     <li>",
"      Prior MI (suggesting arrhythmic substrate predating the current event)",
"     </li>",
"     <li>",
"      Left ventricular (LV) systolic dysfunction (as an aid to establishing overall prognosis of the patient)",
"     </li>",
"     <li>",
"      Late or incomplete revascularization (as an aid to establishing overall prognosis)",
"     </li>",
"     <li>",
"      Inducible monomorphic VT at EP study (to evaluate",
"      <span class=\"nowrap\">",
"       suitability/feasibility",
"      </span>",
"      for ablation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors provide clues to the clinical consequences of recurrent VT and the overall prognosis of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late SMVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late SMVT is a predictor of a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. This was illustrated in the GISSI-3 trial in which late VT occurred in 1 percent of patients between 48 hours and six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/4\">",
"     4",
"    </a>",
"    ]. Late VT was associated with a more complicated in-hospital and six week posthospital course, a higher incidence of pump failure, atrial arrhythmias, asystole, atrioventricular block, and VF, and a higher mortality at six weeks (35 versus 5 percent without VT, hazard ratio 6.13). An increase in late mortality was also noted in GUSTO-I [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it is important to note that although patients with SMVT generally have increased mortality, for those that do not initially present with cardiac arrest, risk of sudden death is low, though nonsudden death risk is high (resulting from progressive heart failure or recurrent myocardial infarction). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Relation between SMVT and VF'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-ST elevation ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the above data come from studies of patients with an ST elevation MI. In the pooled analysis noted above, which included patients with non-ST elevation MI (NSTEMI) and unstable angina, VT was a significant predictor of increased mortality at both 30 days and six months (adjusted hazard ratio 8 and 5, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef68599 \" href=\"UTD.htm?20/36/21070\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/6\">",
"     6",
"    </a>",
"    ]. The increase in risk was largely due to more deaths in the first 30 days.",
"   </p>",
"   <p>",
"    The relationship between the time of the arrhythmia and prognosis was not reported. The median time to arrhythmia was 78 hours, with the 25th and 75th percentiles being 16 hours and seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287278088\">",
"    <span class=\"h1\">",
"     VT IN PATIENTS WITH PRIOR MI (CHRONIC PHASE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of SMVT in patients with a prior MI occur during the chronic phase. The first episode may be seen within the first year post-MI, but the median time of occurrence is about three years and SMVT can occur as late as 20 years after an MI without apparent intervening ischemic events. Late SMVT often reflects significant left ventricular dysfunction and the presence of a ventricular aneurysm or scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Late arrhythmias may also result from recurrent cardiac events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=see_link\">",
"     \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In several studies that predate contemporary acute and post-MI care, the annual mortality rate for patients with SMVT that occurs more than three months after the infarction was approximately 5 to 15 percent (",
"    <a class=\"graphic graphic_figure graphicRef60905 \" href=\"UTD.htm?27/38/28269\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RELATION BETWEEN SMVT AND VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with SMVT following MI, there is concern for risk of SCD. The degree of risk is dependent on how the patient tolerates VT, and the primary determinant of the hemodynamic consequences of VT seems to be the VT rate. In general, faster VTs are less well tolerated. The risk of SCD for patients that present with SMVT that does not precipitate cardiac arrest is 2 to 3 percent yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 111 patients (58 percent with a prior MI) in whom an implantable cardioverter-defibrillator (ICD) had been implanted for malignant ventricular arrhythmias, 55 had a history of VF alone and 56 had a history that included SMVT as well [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/17\">",
"     17",
"    </a>",
"    ]. Over 14 months SMVT was detected in 18 percent of those with a history of VF alone compared to 54 percent of those with a history of SMVT. These observations suggest that deterioration of SMVT is not the only clinically important mechanism of VF induction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for SMVT involves acute termination and long-term treatment to prevent SCD. The initial therapy will be directed based on hemodynamic status and the presence or absence of symptoms. Additionally, treatment of any underlying precipitating factors (eg, myocardial ischemia, heart failure, electrolyte disturbances) is an important part of the therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute therapy of SMVT depends upon the degree of hemodynamic tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7842526\">",
"    <span class=\"h3\">",
"     Hemodynamically unstable, severely symptomatic, or pulseless VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with SMVT who are hemodynamically",
"    <strong>",
"     unstable",
"    </strong>",
"    , severely symptomatic, or pulseless, urgent synchronized electrical cardioversion should be performed (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 1",
"    </a>",
"    ). Patients should be treated with a synchronized 150 to 200 joule shock from a biphasic defibrillator or a 360 joule shock from a monophasic defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H8#H8\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Ventricular fibrillation and pulseless ventricular tachycardia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Wide complex tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiarrhythmic therapy (intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or oral agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    or amiodarone) is generally indicated if SMVT recurs. For repetitive episodes of SMVT, consideration should be given to catheter ablation. (See",
"    <a class=\"local\" href=\"#H7842533\">",
"     'Hemodynamically stable SMVT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7842533\">",
"    <span class=\"h3\">",
"     Hemodynamically stable SMVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are hemodynamically",
"    <strong>",
"     stable",
"    </strong>",
"    during SMVT, intravenous pharmacologic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (not available in all countries) may be attempted prior to electrical cardioversion (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. Lidocaine can be expected to terminate 10 to 20 percent of SMVT episodes, while procainamide terminates over 50 percent of episodes. Procainamide has the advantage of slowing VT even when it fails to terminate, usually resulting in greater hemodynamic stability, whereas lidocaine does not slow SMVT. Intravenous amiodarone is slower in action than procainamide or lidocaine, but it improves the reversion rate of refractory SMVT and decreases its recurrence after reversion, making it the treatment of choice for recurrent or refractory monomorphic SMVT that cannot be otherwise controlled or in patients with an ICD receiving multiple shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/19,22-24\">",
"     19,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an antiarrhythmic drug is prescribed, the following regimens can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      begins with a 150 mg bolus over 10 minutes, followed by a continuous intravenous infusion of 1",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      for six hours and 0.5",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      thereafter via programmable infusion pump. Repeated boluses can be given over 10 minutes every 10 to 15 minutes to a maximum total dose of 2.2 g in 24 hours. The blood pressure must be carefully monitored because the diluent can cause hypotension when the administration of amiodarone occurs too rapidly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"       \"Clinical uses of amiodarone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H2#H2\">",
"       \"Major side effects of amiodarone\", section on 'Intravenous amiodarone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      can be given in an initial dose of 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (typically 75 to 100 mg at a rate of 25 to 50",
"      <span class=\"nowrap\">",
"       mg/minute);",
"      </span>",
"      lower doses of 0.5 to 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      can be repeated every 5 to 10 minutes as needed. Immediately following the loading dose, a continuous intravenous infusion of 1 to 4",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      is begun. The maximum total dose is 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (300 mg) over one hour. It is rarely necessary to continue the infusion for more than 24 hours, and the incidence of neurotoxicity increases greatly after 24 hours of infusion.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      can be administered in a number of ways. The standard method is an infusion of 20 to 50",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      while monitoring the blood pressure closely every 5 to 10 minutes until the arrhythmia terminates, hypotension ensues, the QRS is prolonged by more than 50 percent, or a total of 17",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (1.2 g for a 70 kg patient) has been given. Once VT terminates, it is usually not necessary to continue a maintenance infusion.",
"     </li>",
"     <li>",
"      In countries in which intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      is available, the dose is 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (or 100 mg) at a rate of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/minute,",
"      </span>",
"      watching for bradycardia, hypotension, or the development of other arrhythmias that can be caused by the proarrhythmic effect of sotalol, such as torsades de pointes. This dose may be repeated after six hours if necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"       \"Therapeutic use and major side effects of sotalol\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If VT is not terminated with IV antiarrhythmic drug therapy, external cardioversion may be performed, as described above, or additional antiarrhythmic therapy may be administered (eg, second bolus of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to amiodarone, etc.) Conscious patients should nearly always be pretreated with a sedative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an analgesic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7842429\">",
"    <span class=\"h2\">",
"     Treatment of coexistent precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of underlying conditions which may precipitate VT, such as myocardial ischemia, electrolyte disturbances, and heart failure, as well as decreasing the sympathetic facilitation of SMVT, are important components of the acute management of VT. However, it should be recognized that most episodes of SMVT do not have identifiable precipitating factors, and SMVT is rarely precipitated by acute ischemia, although it most commonly occurs in patients with prior myocardial infarction (MI). Thus, appropriate treatment of heart failure and ischemia are important for improving the overall prognosis of patients with SMVT after MI, but they may not directly affect the occurrence of VT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjunctive use of beta blockers, in combination with antiarrhythmic agents other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , is an effective approach for reducing sympathetic facilitation of SMVT, especially in patients with frequent recurrences of VT within a short time period (eg, VT \"storm\") [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=see_link&amp;anchor=H5924401#H5924401\">",
"       \"Electrical storm and incessant ventricular tachycardia\", section on 'Drug therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the postoperative or intensive care unit setting, eliminating or decreasing the use of inotropic or adrenergic agents may permit easier pharmacological control of SMVT [",
"      <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/26\">",
"       26",
"      </a>",
"      ]. Similarly, the judicious use of sedative-hypnotic agents to lower anxiety, as the patient&rsquo;s hemodynamic status allows, may be beneficial.",
"     </li>",
"     <li>",
"      Electrolyte disturbances, particularly hypokalemia and hypomagnesemia, are not usually responsible for precipitating SMVT, but when present, they should be treated aggressively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In appropriate patients, insertion of an intraaortic balloon pump (IABP) may help stabilize patients with refractory recurrent VT until ablation or surgical treatment can be performed. Revascularization is usually not antiarrhythmic in patients with SMVT, although such patients should be investigated for myocardial ischemia which, if present, should be treated aggressively. The IABP can contribute to the management of medically refractory SMVT by reducing ischemia and maintaining blood pressure, and may provide time to implement definitive therapy in selected patients (eg, those with severely impaired left ventricular function, compromise of the hemodynamic status by the arrhythmia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevention of recurrent arrhythmias and SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion applies to the management of patients with late SMVT, although some experts approach selected patients with early SMVT in a similar manner.",
"   </p>",
"   <p>",
"    Chronic therapy of patients with SMVT usually requires utilization of multiple therapeutic modalities, including the implantable cardioverter defibrillator (ICD), antiarrhythmic drugs, radiofrequency catheter ablation, or arrhythmia surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three large, prospective trials (AVID, CASH, and CIDS) evaluated ICD therapy compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or other antiarrhythmic drugs in survivors of cardiac arrest or life-threatening ventricular tachyarrhythmias, including hemodynamically unstable SMVT. Although the AVID trial was the only one to demonstrate a statistically significant benefit, a meta-analysis of all three trials showed a significant improvement in overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/27\">",
"     27",
"    </a>",
"    ]. However, these trials did not address patients with hemodynamically stable SMVT. The latter patients are often those most challenging to manage because of frequent VT recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of an ICD in patients with SMVT and a prior MI was directly addressed in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and prevention of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar recommendations were included in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/28\">",
"     28",
"    </a>",
"    ]. The 2008 guidelines, however, included patients with a prior MI in the following more general recommendations addressing patients with SMVT and any form of structural heart disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement that ICD therapy may be beneficial in patients with structural heart disease and spontaneous sustained VT, whether hemodynamically stable or unstable. The principal benefit in patients with hemodynamically stable VT derives from the ability to reduce the need for antiarrhythmic drugs in patients with infrequent tachycardia episodes, as well as the ability to terminate SMVT with antitachycardia pacing rather than shocks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There remains some debate regarding the optimal management of sustained, hemodynamically stable VT in persons with a prior MI but normal or near normal left ventricular systolic function, in whom there is increasing consensus that VT ablation should be considered for primary or initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/29\">",
"     29",
"    </a>",
"    ]. Detailed discussions of the role of ICD therapy for primary and secondary prevention of SCD, including in patients with a prior MI, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have evaluated the efficacy of class IA, IB, IC, and III antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) in the long-term management of ventricular arrhythmias in patients with a prior MI. Despite some efficacy in initial arrhythmia suppression, antiarrhythmic drugs have limited efficacy for the long-term prevention of ventricular arrhythmias and SCD. No antiarrhythmic medication has been demonstrated to reduce the mortality of patients with SMVT, except beta-adrenergic blocking agents. In addition, antiarrhythmic drug therapy may cause early or late proarrhythmia, thereby increasing the incidence of arrhythmic deaths, ischemic death, and overall mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, the use of antiarrhythmic drugs in patients with SMVT is typically limited to two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an adjunct to an ICD in patients with frequent arrhythmia recurrences and ICD shocks.",
"     </li>",
"     <li>",
"      As primary therapy or as adjunctive therapy to catheter ablation, in patients who do not want or are not candidates for an ICD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When antiarrhythmic drugs are used for these purposes, the class III drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    are suggested by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for the management of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/1\">",
"     1",
"    </a>",
"    ]. This preference is based upon a greater efficacy and a lower risk of proarrhythmia compared to class I drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. The negative inotropic properties of sotalol limit its use among patients with severe left ventricular dysfunction; in these patients, amiodarone is the preferred agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term efficacy of other class III drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , has not been adequately evaluated, although a comparative study in 135 patients found that dofetilide was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    for preventing the induction of SMVT with electrophysiologic testing (36 versus 34 percent) and was better tolerated and more effective during long-term therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/37\">",
"     37",
"    </a>",
"    ]. Combination therapy using different classes of antiarrhythmic drugs is rarely used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapeutic use of dofetilide\", section on 'Ventricular tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The class IC drugs are contraindicated in patients with coronary artery disease or other significant structural heart disease, while the class IA drugs are used rarely because of concerns about similar proarrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link&amp;anchor=H5#H5\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\", section on 'Ventricular premature beats'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Radiofrequency catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;SMVT in patients with a prior MI is usually due to reentry in a circuit created by the heterogeneous electrical properties of residual myocardium in the region of the scar from the infarct. However, other mechanisms such as abnormal automaticity or triggered activity may occasionally occur. Radiofrequency ablation (RFA) can alter or eliminate such circuits or foci and prevent VT recurrence in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter ablation has been evaluated as a primary preventive therapy with good results in one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/39\">",
"     39",
"    </a>",
"    ]. In this controlled multicenter trial of 128 patients, there was a significant reduction in ICD therapies delivered for VT or VF, and a nonsignificant trend toward reduced mortality in patients randomized to ablation in addition to the ICD.",
"   </p>",
"   <p>",
"    Depending upon a number of factors, acute success rates for RFA of VT after MI vary from 70 to 90 percent, with procedure-related mortality of 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/29\">",
"     29",
"    </a>",
"    ]. In most large volume ablation centers, long-term follow-up reveals recurrent VT in 30 to 50 percent of patients. Catheter ablation of post-infarct VT has been applied most often in patients with frequent episodes. Two-thirds of these patients have experienced at least 75 percent reduction in frequency of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/29\">",
"     29",
"    </a>",
"    ]. Depending on the clinical presentation of VT (cardiac arrest versus relative hemodynamic stability), ICDs are usually considered as an adjunct to ablation, except in patients with fairly normal LV function who present with stable VT. However, it is important to remember that patients presenting with SMVT after MI may have other factors predisposing to sudden death, such as CHF or marked LVH. It is likely that the ICD may reduce overall mortality these patients by treating ventricular tachyarrhythmias other than SMVT.",
"   </p>",
"   <p>",
"    The role of RFA in the treatment of ventricular arrhythmias among patients with a prior MI was addressed in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines as well as in the more recent consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ablation is considered first-line therapy for patients with SMVT whose overall characteristics suggest them to be at low risk for sudden death. It is also considered first-line therapy for certain specific ventricular tachycardias, such as bundle branch reentry. The latter can be suspected based on ECG characteristics but requires diagnostic electrophysiologic study for confirmation.",
"     </li>",
"     <li>",
"      The guidelines suggest that the weight of evidence supports the use of RFA as primary adjunctive therapy in patients with an ICD who have frequent episodes of VT. In this setting the purpose of RFA is to reduce symptoms related to VT and to reduce ICD shocks.",
"     </li>",
"     <li>",
"      The guidelines suggest that evidence was less well-established for the use of RFA in the absence of an ICD, for the purpose of reducing symptoms related to recurrent, hemodynamically tolerated VT in patients with a left ventricular ejection fraction &gt;40 percent. Optimal treatment of patients with hemodynamically tolerated SMVT due to prior MI with relatively preserved LVEF remains uncertain, as ICD implantation has not been shown to improve survival in this patient group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with these suggestions, and in addition would consider RFA with or without antiarrhythmic drug therapy, for patients with VT who are not candidates for or who refuse ICD implantation.",
"   </p>",
"   <p>",
"    RFA efficacy previously was limited in patients with rapid, hemodynamically unstable SMVT, since most ablation techniques required that patients be in sustained SMVT for prolonged periods to map the tachycardia. However, newer \"substrate mapping\" techniques permit ablation of unmappable SMVT during sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/32/29193/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Surgical ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical ablation using endocardial resection was the mainstay of therapy for recurrent SMVT unresponsive to pharmacologic therapy until the early 1990s, when RF catheter ablation for VT became feasible. Although endocardial resection is rarely performed today, it remains a viable therapeutic option for selected patients with SMVT, especially those requiring CABG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular aneurysmectomy. Surgical resection has the highest chance for total cure of VT following myocardial infarction. In rare cases, cardiac transplantation has been necessitated because of refractory SMVT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=see_link\">",
"     \"Surgery for ventricular tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7841996\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained monomorphic ventricular tachycardia (SMVT) is defined as a regular, wide QRS complex tachycardia with uniform and stable QRS morphology at a rate of more than 100 beats per minute that lasts for 30 seconds or longer or causes hemodynamic collapse within 30 seconds. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SMVT early (6 to 48 hours) after a myocardial infarction (MI) have a greater risk of in-hospital mortality compared to those without this arrhythmia, although the long-term prognostic significance of early SMVT is less clear. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early SMVT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late SMVT, occurring more than 48 hours post-MI, is a predictor of a worse prognosis. In such patients, prognosis is affected by several variables, including primarily the clinical consequences of the initial presentation (cardiac arrest versus lack of hemodynamic collapse). Recognition of the latter is important because risk for sudden death is directly related to initial presentation: patients that present with cardiac arrest are at relatively high risk for recurrent arrest, while those presenting without cardiac arrest have low risk for sudden death (2 to 3 percent annually) but often high risk for nonsudden death due to heart failure.",
"     </li>",
"     <li>",
"      Most episodes of SMVT in patients with a prior MI occur during the chronic phase months to years post-MI. Late SMVT often reflects significant left ventricular dysfunction and the presence of a ventricular aneurysm or scarring. (See",
"      <a class=\"local\" href=\"#H287278088\">",
"       'VT in patients with prior MI (chronic phase)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute therapy of SMVT depends upon the degree of hemodynamic tolerance:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with SMVT who are hemodynamically",
"      <strong>",
"       unstable",
"      </strong>",
"      , severely symptomatic, or pulseless, urgent synchronized electrical cardioversion should be performed (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 1",
"      </a>",
"      ). Patients should be treated with a synchronized 150 to 200 joule shock from a biphasic defibrillator or a 360 joule shock from a monophasic defibrillator. (See",
"      <a class=\"local\" href=\"#H7842526\">",
"       'Hemodynamically unstable, severely symptomatic, or pulseless VT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .) If the defibrillator is unable to synchronize, a maximal unsynchronized shock should be delivered.",
"     </li>",
"     <li>",
"      For patients who are hemodynamically",
"      <strong>",
"       stable",
"      </strong>",
"      during SMVT, intravenous pharmacologic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      (not available in all countries) may be attempted prior to electrical cardioversion. In our practice, intravenous amiodarone is the treatment of choice for recurrent or refractory monomorphic SMVT that cannot be otherwise controlled or in patients with an ICD receiving multiple shocks. (See",
"      <a class=\"local\" href=\"#H7842533\">",
"       'Hemodynamically stable SMVT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If VT is not terminated with IV antiarrhythmic drug therapy, external cardioversion may be performed, as described above, or additional antiarrhythmic therapy may be administered (eg, second bolus of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      to amiodarone, etc.) Conscious patients should be pretreated with a sedative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an analgesic agent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of underlying conditions which may precipitate or accompany VT, such as myocardial ischemia, electrolyte disturbances, and heart failure, as well as decreasing the sympathetic facilitation of SMVT, are important components of the acute management of VT. (See",
"      <a class=\"local\" href=\"#H7842429\">",
"       'Treatment of coexistent precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic therapy to prevent recurrent SMVT and sudden cardiac death (SCD) involves the use of an implantable cardioverter defibrillator (ICD), antiarrhythmic drugs, radiofrequency catheter ablation, or arrhythmia surgery. In many patients, a combination of these approaches is necessary. With accumulating evidence of harmful effects of ICD shocks and antiarrhythmic drugs, early consideration should be given to catheter ablation in patients with recurrent SMVT. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention of recurrent arrhythmias and SCD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/1\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/2\">",
"      Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/3\">",
"      Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/4\">",
"      Volpi A, Cavalli A, Turato R, et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. Am Heart J 2001; 142:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/5\">",
"      Marchlinski FE, Waxman HL, Buxton AE, Josephson ME. Sustained ventricular tachyarrhythmias during the early postinfarction period: electrophysiologic findings and prognosis for survival. J Am Coll Cardiol 1983; 2:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/6\">",
"      Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/7\">",
"      Cohen M, Wiener I, Pichard A, et al. Determinants of ventricular tachycardia in patients with coronary artery disease and ventricular aneurysm. Clinical, hemodynamic, and angiographic factors. Am J Cardiol 1983; 51:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/8\">",
"      Stevenson WG, Brugada P, Waldecker B, et al. Clinical, angiographic, and electrophysiologic findings in patients with aborted sudden death as compared with patients with sustained ventricular tachycardia after myocardial infarction. Circulation 1985; 71:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/9\">",
"      Denniss AR, Ross DL, Richards DA, et al. Differences between patients with ventricular tachycardia and ventricular fibrillation as assessed by signal-averaged electrocardiogram, radionuclide ventriculography and cardiac mapping. J Am Coll Cardiol 1988; 11:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/10\">",
"      Bolick DR, Hackel DB, Reimer KA, Ideker RE. Quantitative analysis of myocardial infarct structure in patients with ventricular tachycardia. Circulation 1986; 74:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/11\">",
"      Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984; 54:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/12\">",
"      Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996; 28:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/13\">",
"      Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983; 308:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/14\">",
"      Lampert S, Lown B, Graboys TB, et al. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. Am J Cardiol 1988; 61:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/15\">",
"      Hohnloser SH, Franck P, Klingenheben T, et al. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. Circulation 1994; 90:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/16\">",
"      Brugada P, Talajic M, Smeets J, et al. The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Eur Heart J 1989; 10:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/17\">",
"      Raitt MH, Dolack GL, Kudenchuk PJ, et al. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation. Implications for use of implantable defibrillator. Circulation 1995; 91:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/18\">",
"      Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/19\">",
"      Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/20\">",
"      Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/21\">",
"      Waxman HL, Buxton AE, Sadowski LM, Josephson ME. The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications. Circulation 1983; 67:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/22\">",
"      Naccarelli GV, Jalal S. Intravenous amiodarone. Another option in the acute management of sustained ventricular tachyarrhythmias. Circulation 1995; 92:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/23\">",
"      Sch&uuml;tzenberger W, Leisch F, Kerschner K, et al. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J 1989; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/24\">",
"      Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/25\">",
"      Hirsowitz G, Podrid PJ, Lampert S, et al. The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J 1986; 111:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/26\">",
"      Jazayeri MR, Van Wyhe G, Avitall B, et al. Isoproterenol reversal of antiarrhythmic effects in patients with inducible sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1989; 14:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/27\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/28\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/29\">",
"      Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009; 6:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/30\">",
"      Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993; 72:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/31\">",
"      Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/32\">",
"      Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/33\">",
"      Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997; 30:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/34\">",
"      Kovoor P, Eipper V, Byth K, et al. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J 1999; 20:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/35\">",
"      Man KC, Williamson BD, Niebauer M, et al. Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1994; 74:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/36\">",
"      A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/37\">",
"      Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001; 22:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/38\">",
"      Greenspan AM, Spielman SR, Horowitz LN. Combination antiarrhythmic drug therapy for ventricular tachyarrhythmias. Pacing Clin Electrophysiol 1986; 9:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/39\">",
"      Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/40\">",
"      Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000; 101:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/32/29193/abstract/41\">",
"      Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol 2003; 41:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1040 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29193=[""].join("\n");
var outline_f28_32_29193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7841996\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287278073\">",
"      VT IN THE SETTING OF ACUTE MI (AMI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early SMVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late SMVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287278088\">",
"      VT IN PATIENTS WITH PRIOR MI (CHRONIC PHASE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RELATION BETWEEN SMVT AND VF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7842526\">",
"      - Hemodynamically unstable, severely symptomatic, or pulseless VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7842533\">",
"      - Hemodynamically stable SMVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7842429\">",
"      Treatment of coexistent precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevention of recurrent arrhythmias and SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Radiofrequency catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Surgical ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7841996\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1040|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 1\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/21/20819\" title=\"algorithm 2\">",
"      Adult tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1040|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/36/21070\" title=\"figure 1\">",
"      VT VF non ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/38/28269\" title=\"figure 2\">",
"      Mortality in VT after MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=related_link\">",
"      Surgery for ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43144?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29194="Chronic refractory immune thrombocytopenia (ITP) in adults";
var content_f28_32_29194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic refractory immune thrombocytopenia (ITP) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immune thrombocytopenia (ITP, previously called idiopathic thrombocytopenic purpura, immune thrombocytopenic purpura) is an acute, self-limited disease in the vast majority of children, it often relapses in adults following initial treatment with glucocorticoids, requiring additional treatment. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on a consensus from an international working group published in 2009, ITP is referred to as",
"    <strong>",
"     primary",
"    </strong>",
"    if it has no underlying cause, and",
"    <strong>",
"     secondary",
"    </strong>",
"    if it is immune mediated but associated with an underlying disorder [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <strong>",
"     Chronic ITP",
"    </strong>",
"    refers to ITP that has lasted for more than 12 months, and ITP is called",
"    <strong>",
"     refractory",
"    </strong>",
"    if it has failed to respond to (or relapsed after) splenectomy and is severe (ie, associated with bleeding or bleeding risk that requires therapy). In practice, chronic and refractory may go together.",
"   </p>",
"   <p>",
"    Chronic refractory ITP is not common. A review of six case series suggested that less than 10 percent of adult patients initially diagnosed with ITP may eventually be considered to be refractory and require further treatment following failure of splenectomy [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of patients with chronic refractory ITP, defined here as a failure to respond to both splenectomy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , will be discussed here. Accordingly, the use of splenectomy and rituximab in the treatment of ITP is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Splenectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of patients presenting with new-onset ITP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF CHRONIC REFRACTORY ITP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitions of chronic refractory ITP differ [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. We define refractory ITP by the presence of",
"    <strong>",
"     all",
"    </strong>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ITP persistent for &gt;3 months",
"     </li>",
"     <li>",
"      Failure to respond to splenectomy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons behind the choice of these criteria include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous remissions in adults are unlikely to occur after three months.",
"     </li>",
"     <li>",
"      Since splenectomy is the most effective treatment for ITP, this disorder cannot be considered to be \"refractory\" until splenectomy has failed (",
"      <a class=\"graphic graphic_figure graphicRef59587 \" href=\"UTD.htm?43/24/44429\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      can induce remission in some patients, failure of rituximab is an additional criterion for ITP to be considered \"refractory.\" (See",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Rituximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While a platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      documents significant thrombocytopenia,",
"      <strong>",
"       the indication for further treatment",
"      </strong>",
"      should be a platelet count less than this, typically less than 20,000 to",
"      <span class=\"nowrap\">",
"       30,000/microL,",
"      </span>",
"      <strong>",
"       or the potential risk of clinically important bleeding",
"      </strong>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This more stringent definition of chronic refractory ITP suggests the need&nbsp;for further treatment following failure of both splenectomy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , rather than the degree of thrombocytopenia, per se. A proposed definition from an international working group has agreed with this stipulation [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis of ITP",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is reasonable in all cases of chronic refractory ITP to make sure that the initial diagnosis of ITP was correct. As an example, some cases that had met criteria for chronic refractory ITP were later found to be instances of drug-induced thrombocytopenia, myelodysplasia, or hereditary or other non-immune causes of thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low platelet count alone is not sufficient reason for treatment. The presence of, or the potential risk for, clinically important bleeding must also be present. We believe a risk for clinically important bleeding is a reasonable indication for treatment, rather than requiring bleeding to have occurred [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Treatment decisions need to be based upon a careful discussion of risks and benefits with the patient and an understanding of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    values and preferences [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/8\">",
"     8",
"    </a>",
"    ]. A sequence of management of patients with chronic refractory ITP is proposed in the table (",
"    <a class=\"graphic graphic_table graphicRef69028 \" href=\"UTD.htm?6/6/6252\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THROMBOPOIESIS-STIMULATING AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview and limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of thrombopoiesis-stimulating agents (ie, thrombopoietin receptor agonists), including recombinant thrombopoietins (which are no longer being developed), thrombopoietin peptide mimetics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    (AMG 531, Nplate), and thrombopoietin nonpeptide mimetics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    , Promacta). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two agents described below (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    ), both of which were approved by the United States FDA during the latter part of 2008, may best be described as temporary maintenance therapy, to be used if a remission with other treatments is not achieved, or to defer a decision for potentially definitive treatment for a later time. Other limitations of these agents include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These two agents are not meant to be used to return the platelet count to normal and platelet count responses before day 8 have not been systematically measured. Accordingly, their efficacy when a platelet count increase is urgently needed has not been demonstrated.",
"     </li>",
"     <li>",
"      Sensitivity to these agents may increase or decrease over time, requiring frequent dose adjustments [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/9\">",
"       9",
"      </a>",
"      ]. Discontinuation of either agent may be associated with an abrupt fall in platelet count to levels below baseline.",
"     </li>",
"     <li>",
"      Increased bone marrow reticulin deposition has been noted with both agents, the long-term significance of which is not currently known. A theoretical concern is that stimulation of the TPO receptor could lead to the development of hematologic malignancies [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Romiplostim",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     Romiplostim",
"    </a>",
"    (AMG 531, Nplate) consists of an IgG1 Fc component linked to a peptide domain with four binding sites for Mpl, the thrombopoietin (TPO) receptor [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Romiplostim has no sequence homology to TPO and is not likely to result in the formation of antibodies that could also react with native endogenous TPO. This is a problem that did develop with the recombinant TPO polyethylene glycol-conjugated human megakaryocyte growth and development factor (PEG-MGDF), the use of which resulted in formation of antibodies to PEG-MGDF after multiple injections that cross-reacted with native TPO and caused thrombocytopenia that was profound and prolonged in some normal subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Peptide thrombopoietin receptor agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    multi-institutional dose-finding study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    was given to successive cohorts of patients with chronic ITP, in whom one or more prior treatments had failed [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/14\">",
"     14",
"    </a>",
"    ]. In the phase II portion of the study, 21 patients were randomly assigned to receive 6 weekly SQ injections of placebo or romiplostim at doses of 1, 3, or 6",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"    Their median baseline platelet count was",
"    <span class=\"nowrap\">",
"     16,000/microL;",
"    </span>",
"    14 had undergone splenectomy and 7 were receiving treatment with glucocorticoids. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the one patient who received the 6",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      dose, the platelet count increased to",
"      <span class=\"nowrap\">",
"       520,000/microL",
"      </span>",
"      on day 21. Because of a concern for symptomatic thrombocytosis, the review committee closed this highest-dose cohort to further accrual.",
"     </li>",
"     <li>",
"      The targeted endpoint (a platelet count of 50,000 to",
"      <span class=\"nowrap\">",
"       450,000/microL",
"      </span>",
"      that was at least twice the baseline count) was reached in seven of eight patients receiving the 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      dose and in three of eight patients receiving the 3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      dose. The endpoint was exceeded in an additional two patients receiving the 3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      dose. In the majority of responding patients, the response had occurred by the time of the first assessment on day 8.",
"     </li>",
"     <li>",
"      Mild to moderate headache was seen in 39 percent of those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      . The only adverse hematologic events were bleeding due to transient worsening of thrombocytopenia during the post-treatment period or in patients who did not have a response to the study drug. No patient developed antibodies against romiplostim or TPO in this or the subsequent phase III trials of this agent.",
"     </li>",
"     <li>",
"      One patient in the placebo arm attained a spontaneous remission. This patient had undergone a splenectomy 3.5 months before entering the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a similar dose-finding study in 16 patients, platelet responses (as defined above) were seen at a dose equivalent of &ge;1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    in 8 of 11 patients [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17121939\">",
"    <span class=\"h4\">",
"     Romiplostim versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results are available from two parallel placebo-controlled phase III trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    in 63 previously splenectomized and 62 non-splenectomized patients with chronic ITP and a mean of three baseline platelet counts of",
"    <span class=\"nowrap\">",
"     &le;30,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/15\">",
"     15",
"    </a>",
"    ]. Eligible patients were randomly assigned in a 2:1 ratio to receive either romiplostim (starting dose 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    SQ per week, adjusted to achieve a platelet count between 50,000 and",
"    <span class=\"nowrap\">",
"     200,000/microL)",
"    </span>",
"    or placebo every week for 24 weeks. The primary objective was a durable platelet response (ie,",
"    <span class=\"nowrap\">",
"     &ge;50,000/microL)",
"    </span>",
"    during six or more of the last eight weeks of treatment. Results included [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A durable platelet response was seen in 16 of the 42 previously splenectomized patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      (38 percent) and in none of the 21 patients receiving placebo. An overall platelet response (ie, either durable or transient) was seen in 88 versus zero percent of those receiving romiplostim or placebo, respectively.",
"     </li>",
"     <li>",
"      A durable platelet response was seen in 25 of the 41 non-splenectomized patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      (56 percent) and in one of the 21 patients receiving placebo. An overall platelet response (ie, either durable or transient) was seen in 79 versus 14 percent of those receiving romiplostim or placebo, respectively.",
"     </li>",
"     <li>",
"      Eighty-seven percent of patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      reduced or discontinued concurrent therapy for ITP (eg, glucocorticoids) compared with 38 percent of those given placebo.",
"     </li>",
"     <li>",
"      Adverse events were generally similar in the two treatment arms, although one non-responding subject developed reversible increasing bone marrow reticulin and two elderly subjects with previous histories of vascular disease developed arterial thromboembolic events. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Increased bone marrow reticulin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional analysis of this study documented that response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    was accompanied by an improvement of health-related quality of life as measured by the ITP-Patient Assessment Questionnaire, an instrument developed specifically for adults with ITP [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17121946\">",
"    <span class=\"h4\">",
"     Romiplostim versus standard of care in non-splectomized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open-label, 52-week study, 234 adult patients with ITP who had not undergone splenectomy were randomly assigned in a 2:1 ratio to receive treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    or &ldquo;standard of care&rdquo; (SOC). The latter group was treated according to standard institutional practices or therapeutic guidelines, although the prior use of splenectomy, other thrombopoietic mimetics, or investigational products was not allowed. Eligibility requirements for the study included a history of one or more types of therapy for ITP and a pretreatment platelet count of less than",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    Primary endpoints were the incidence of treatment failure (ie, a platelet count",
"    <span class=\"nowrap\">",
"     &le;20,000/microL",
"    </span>",
"    for four consecutive weeks, a major bleeding event, or requirement for a change in therapy) and the incidence of splenectomy. Results included the following [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, 97, 59, 24, and zero percent of the study patients had previously received glucocorticoids, IVIG,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or splenectomy, respectively. Seventy-three percent had received two or more previous treatments.",
"     </li>",
"     <li>",
"      Those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      had a rate of platelet response 2.3 times that of the SOC group (95% CI 2.0-2.6). Treatment failure (11 versus 30 percent) and subsequent performance of splenectomy (9 versus 36 percent) were significantly less in the romiplostim-treated group. The romiplostim-treated group also had a lower rate of bleeding events, fewer blood transfusions, and greater improvement in quality of life than the SOC-treated group.",
"     </li>",
"     <li>",
"      Serious adverse events occurred in 23 and 37 percent of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      and SOC groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study confirms the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    to achieve durable increased platelet counts, as previously demonstrated in randomized studies [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The important clinical decision highlighted by this study is the choice between indefinite maintenance treatment to support the platelet count as provided by the thrombopoiesis-stimulating agents, versus management with splenectomy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in an attempt to achieve a durable remission without need for continuing treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Long-term safety and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results are available from an ongoing, open-label study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    in patients with chronic ITP who had completed a prior romiplostim study and had platelet counts",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL.",
"    </span>",
"    One hundred forty-two patients were followed for a mean of 69 weeks and a maximum of 156 weeks. Results included [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet responses (ie, platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"      and double baseline counts) were observed in 87 percent of all patients and occurred on average 67 percent of the time in responding patients.",
"     </li>",
"     <li>",
"      Nineteen treatment-related serious events were reported in 13 patients (9 percent). Those leading to discontinuation of this agent included two cases of increased bone marrow reticulin and one case each of vaginal hemorrhage, deep vein thrombosis, and monoclonal gammopathy of undetermined significance.",
"     </li>",
"     <li>",
"      Serious adverse events not leading to drug discontinuation included congestive failure in three. Headache was the most commonly reported adverse event, followed by nasopharyngitis, contusion (purpura), and fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least two years of follow-up are available for the first 72 subjects enrolled in a French compassionate use program for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    in patients with ITP who had failed to respond to successive treatment with glucocorticoids, IVIG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and splenectomy, or when splenectomy was not indicated. The following observations were made of this cohort [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary platelet response (ie, platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"      to at least twice baseline) was observed at least once in 74 percent.",
"     </li>",
"     <li>",
"      At two years, 47 subjects (65 percent) were classified as long-term responders. Thirty-seven of the 47 had sustained platelet responses with a median platelet count of",
"      <span class=\"nowrap\">",
"       106,000/microL",
"      </span>",
"      and 35 were still receiving treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Of the 27 subjects who stopped",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      , 15 did so because of treatment failure, two because of achievement of partial remission, and two because of intolerance to romiplostim (headache, arthralgia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Increased bone marrow reticulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    to rats has produced a dose-dependent increase in bone marrow fibrosis that resolved after treatment withdrawal [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, of 271 patients with chronic ITP treated with this agent, 10 were reported to have increased reticulin deposition, which often decreased soon after the medication was discontinued [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/10,18\">",
"     10,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of reticulin was associated with prior splenectomy, exposure to multiple prior ITP therapies, relatively high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    , minimal platelet response, and possibly the presence of nucleated red blood cells on the peripheral smear. A subsequent clinical trial of romiplostim for treatment of ITP will require bone marrow biopsies on all patients and will systematically evaluate marrow reticulin in order to determine the incidence of this complication.",
"   </p>",
"   <p>",
"    A retrospective study assessed the grade of bone marrow fibrosis in 25 patients treated with thrombopoietin receptor agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    : 9 subjects;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    : 15 subjects; AKR: 1 subject) who had at least one bone marrow biopsy. Reticulin in biopsies performed after a median of 1.4 years of treatment was graded zero, 1, 2, or 3 in 12, 76, 8, and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no clear evidence for continued progression of fibrosis with sustained exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Administrative issues and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States FDA has approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/21\">",
"     21",
"    </a>",
"    ]. The recommended initial dose of romiplostim is 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    once weekly as a subcutaneous injection. The romiplostim dose is subsequently adjusted to achieve platelet counts",
"    <span class=\"nowrap\">",
"     &ge;50,000/microL",
"    </span>",
"    as necessary to reduce the risk for bleeding and should not be used in an attempt to normalize platelet counts [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA-mandated restricted distribution program for this agent, activated in 2008, was discontinued in late 2011.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Eltrombopag",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8703499\">",
"    <span class=\"h3\">",
"     Eltrombopag versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TPO non-peptide mimetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    (Promacta) has also shown significant activity in chronic ITP. In a phase II dose-ranging trial, 118 subjects with chronic ITP and platelet counts",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL,",
"    </span>",
"    who had prior relapses or were refractory to at least one standard treatment, were randomly assigned to receive placebo or oral eltrombopag (30 to 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO) for 6 weeks. The following results were reported [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median platelet counts on day 43 were 16,000, 26,000, 128,000, and",
"      <span class=\"nowrap\">",
"       183,000/microL",
"      </span>",
"      for the placebo, 30, 50, and 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      cohorts, respectively.",
"     </li>",
"     <li>",
"      The primary endpoint, a platelet count",
"      <span class=\"nowrap\">",
"       &gt;50,000/microL",
"      </span>",
"      at 43 days, was reached by 11, 28, 70, and 81 percent of the placebo, 30, 50, and 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      cohorts, respectively. A platelet count",
"      <span class=\"nowrap\">",
"       &gt;200,000/microL",
"      </span>",
"      was reached by 4, 15, 37, and 50 percent of the placebo, 30, 50, and 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      cohorts, respectively.",
"     </li>",
"     <li>",
"      There was a trend toward fewer bleeding events on therapy in those receiving the 50 and 75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      doses. Toxicities noted for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      were similar to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized (2:1 drug to placebo), double-blind, placebo-controlled phase III trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    was performed in 110 evaluable patients with chronic ITP, a platelet count",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL,",
"    </span>",
"    and one or more prior ITP treatments. Patients received standard care plus once-daily placebo or eltrombopag (50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    increased to 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at three weeks if the platelet count was",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL).",
"    </span>",
"    Results at day 43 included the following [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoint, a platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"      at 6 weeks, was reached in 59 and 16 percent of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      and placebo groups, respectively (OR 9.61; 95% CI 3.3-28). Response was independent of baseline platelet count, concomitant ITP drugs, number of previous ITP treatments, or splenectomy status.",
"     </li>",
"     <li>",
"      Of the 34 patients who increased their dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      at three weeks, 10 responded (29 percent). Platelet counts generally returned to baseline within two weeks after the end of treatment.",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      had significantly less bleeding than those receiving placebo (OR 0.49; 95% CI 0.26-0.89). The frequency of adverse events during treatment (3 percent) and adverse events leading to study discontinuation (4 and 5 percent) were similar in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8703506\">",
"    <span class=\"h3\">",
"     Eltrombopag versus standard of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase III, double-blind, placebo-controlled study, 197 adult patients with ITP were randomly assigned in a 2:1 ratio to receive treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    (initial dose 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or &ldquo;standard of care&rdquo; (SOC) [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/25\">",
"     25",
"    </a>",
"    ]. Eligibility requirements for the study included a history of ITP of more than six months&rsquo; duration, a response to one or more previous treatments for ITP, and a baseline platelet count",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL.",
"    </span>",
"    Prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenectomy was allowed, provided these had been completed at least one month before study enrollment. Concomitant treatments other than IVIG were allowed, provided that the dose had been stable prior to enrollment. The primary endpoint was the odds of response to eltrombopag versus placebo, as defined by a platelet count of 50,000 to",
"    <span class=\"nowrap\">",
"     400,000/microL",
"    </span>",
"    weekly during the first six weeks of treatment and every four weeks thereafter. Results of an intention-to-treat analysis included the following [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Response to treatment at least once during the study was seen significantly more often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      -treated group (79 versus 28 percent, OR 8.2; 99% CI 3.6-19 for response during the six-month period).",
"     </li>",
"     <li>",
"      There was no evidence of differences in the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      compared with placebo in any of the prespecified subgroup analyses. Similar responses were reported irrespective of splenectomy status, baseline platelet count, or prior treatment utilized.",
"     </li>",
"     <li>",
"      Concomitant treatment was reduced or discontinued significantly more often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      group (59 versus 32 percent), while rescue treatment for ITP, defined as an increased dose of a concomitant medication or use of a new agent, was needed significantly less often (18 versus 40 percent).",
"     </li>",
"     <li>",
"      Thrombotic events (2 versus zero percent), mild elevations of alanine aminotransferase (7 versus 3 percent), and increases in total bilirubin (4 versus zero percent) were more common in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      -treated group, while serious bleeding events (&lt;1 versus 7 percent) were less common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6313107\">",
"    <span class=\"h3\">",
"     Long-term safety and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The open label, long term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    extended dosing (EXTEND) study assessed outcomes with ongoing eltrombopag treatment in 299 patients who had completed a prior eltrombopag trial for ITP; 38 percent had had a prior splenectomy [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/26\">",
"     26",
"    </a>",
"    ]. Eltrombopag was initiated at 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and titrated to keep the platelet count",
"    <span class=\"nowrap\">",
"     &ge;50,000/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     &lt;200,000/microL;",
"    </span>",
"    the median duration of treatment was 100 weeks. At an interim analysis of treatment up to three years, the following outcomes were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common adverse events were headache, nasopharyngitis, upper respiratory infection, and fatigue (occurring in 26, 23, 21, and 15 percent of patients, respectively). Most adverse events were mild; events of &ge;Grade 3 severity occurred in 28 percent of study participants.",
"     </li>",
"     <li>",
"      There were 38 adverse events leading to study withdrawal, including 11 thromboembolic events and five liver enzyme elevations that met the threshold for discontinuation. Six patients withdrew because of liver function test abnormalities, and 11 of 18 patients who had liver function abnormalities during a prior",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      study tolerated eltrombopag without recurrence. One hundred thirty-five patients had 147 bone marrow biopsies after receiving eltrombopag for a median of 12 months; 60 percent had myelofibrosis grade of 0",
"      <span class=\"nowrap\">",
"       reticulin/collagen,",
"      </span>",
"      33 percent grade 1, and 7 percent grade 2; no patients had grade 3 myelofibrosis. Four patients developed cataracts; 11 reported progression of cataracts; and one patient had a trauma-induced cataract. There were two cases of lymphoma.",
"     </li>",
"     <li>",
"      Enrollment platelet count was",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      in 87 percent of patients, and 85 percent achieved platelet count",
"      <span class=\"nowrap\">",
"       &gt;50,000/microL",
"      </span>",
"      during the study. Most of these were sustained elevations. Concomitant medications could be stopped or reduced in 45 of 69 patients who attempted to do so.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    maintains efficacy over time and that toxicities with long term use are acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8703492\">",
"    <span class=\"h3\">",
"     Guidelines for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA has granted accelerated approval for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    for the treatment of patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/27\">",
"     27",
"    </a>",
"    ]. Attempts to use eltrombopag in patients with thrombocytopenia secondary to chronic liver disease (the ELEVATE study), an unapproved indication for this agent, have led to an unacceptable increase in the incidence of portal vein thrombosis [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recommended starting dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      is 50 mg once daily for most patients. The eltrombopag dose is adjusted to achieve a platelet count of approximately",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      as necessary to reduce the risk for bleeding and",
"      <strong>",
"       should not be used to normalize platelet counts",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      For patients of East Asian ancestry or patients with moderate or severe hepatic insufficiency, the recommended starting dose is 25 mg once daily [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since hepatotoxicity is a black box warning for this agent, patients should have liver function tests measured before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    and every two weeks during the dose adjustment phase. Prescribing information also describes drug interactions, including decreased absorption if taken with food, especially foods or supplements containing polyvalent cations (eg, iron, calcium, magnesium), as well as with statins.",
"   </p>",
"   <p>",
"    The FDA-mandated restricted distribution program for this agent, activated in 2008, was discontinued in late 2011.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of the thrombopoiesis-stimulating agents has substantially changed the management of chronic refractory ITP [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/9\">",
"     9",
"    </a>",
"    ]. Most patients with severe and symptomatic thrombocytopenia following failure of treatment with glucocorticoids, splenectomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    respond to these agents with significantly increased platelet counts [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/6\">",
"     6",
"    </a>",
"    ]. Although remissions are not induced and indefinite treatment is anticipated, these agents can be used to provide effective supportive care.",
"   </p>",
"   <p>",
"    Although experience with long-term treatment remains limited, most patients tolerate these agents without adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The potential effect of increased marrow reticulin on hematopoiesis is not yet clearly defined.",
"     </li>",
"     <li>",
"      The risk for thrombosis is similarly not clearly defined. Worsening of renal function has been described in two patients with the antiphospholipid syndrome who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      for thrombocytopenia [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. One of these patients had evidence for post-treatment thrombotic microangiopathy on renal biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT WITH OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuing question for the management of patients with chronic refractory ITP is the role of other agents. In patients who have responded effectively to thrombopoiesis-stimulating agents, which patients should receive additional treatment in an attempt to induce a durable remission? More experience with the thrombopoiesis-stimulating agents is required in order to resolve this question.",
"   </p>",
"   <p>",
"    Before the introduction of thrombopoiesis-stimulating agents, it was imperative to avoid treatment with immunosuppressive agents unless thrombocytopenia was severe and bleeding was a clinically important problem in patients with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. However, many patients with ITP and platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    may have no or negligible bleeding symptoms (",
"    <a class=\"graphic graphic_figure graphicRef72370 \" href=\"UTD.htm?19/27/19901\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ITP are often young and in otherwise good health and may have a completely normal survival in spite of persistent thrombocytopenia. Therefore, the relative benefits and risks of further immunosuppressive treatment of patients with chronic refractory ITP have been uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Incidence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If further treatment is considered in an attempt to induce a remission in patients with chronic refractory ITP, there is no guidance by a proven algorithm [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/5,35-39\">",
"     5,35-39",
"    </a>",
"    ] and no treatments have been demonstrated to be effective in randomized clinical trials assessing outcomes of bleeding and death [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3,40\">",
"     3,40",
"    </a>",
"    ]. The only measure of success has been the short-term elevation of platelet counts [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/41\">",
"     41",
"    </a>",
"    ]. Accordingly, the use of these agents must involve consideration of their risks, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment most commonly associated with poor health-related quality of life in patients with chronic refractory ITP is the use of glucocorticoids [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exposure to immunosuppressive and cytotoxic agents should be minimized, because death from treatment-related complications may be more common than death from bleeding. A cohort study of 152 chronic refractory ITP patients with a median follow-up of 10.5 years reported two deaths from intracerebral hemorrhage. However, there were three deaths related to steroid and other immunosuppressive treatment and one death from pneumococcal sepsis following splenectomy [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    English language publications from 1966 through 2003 reporting results in &ge;5 patients, including at least one patient with chronic refractory ITP, illustrate the poor results obtained in patients with chronic refractory ITP [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    had the greatest number of complete responses (17, 27, and 24 percent, respectively), although 36 to 42 percent of patients had no response to these agents.",
"   </p>",
"   <p>",
"    The issue of differing values and preferences regarding treatment with glucocorticoids between hematologists and patients was illustrated in a survey of 80 patients in the Oklahoma ITP registry and all 83 hematologists in Oklahoma. Responses in patients and hematologists were significantly different from each other, regarding both the frequency of severe side effects and the risk of serious bleeding following such treatment [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 13 of the 18 glucocorticoid-associated side effects explored in this survey, patients reported a significantly higher occurrence of severe symptoms than did hematologists.",
"     </li>",
"     <li>",
"      When responding to two case scenarios describing patients with platelet counts of 10,000",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      microL and 5000",
"      <span class=\"nowrap\">",
"       /microL,",
"      </span>",
"      69 and 93 percent of hematologists, respectively, reported being very worried about serious bleeding. This degree of concern about bleeding was significantly greater than that of the 51 ITP patients whose lowest platelet count had been less than 10,000",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      microL (31 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As shown in this survey, an awareness of the different opinions about treatment side effects and risk for bleeding between ITP patients and hematologists may improve management decisions.",
"   </p>",
"   <p>",
"    The following sections are a summary of treatments, other than thrombopoiesis-stimulating agents, that have been used in patients with chronic refractory ITP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to treatment of chronic refractory ITP is to determine if a safe platelet count can be maintained on a low dose of glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    may serve this goal even when the dose is comparable to physiologic glucocorticoid secretion (ie, approximately 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone). Indeed, some patients maintain a safe platelet count on oral doses as low as 5 or 10 mg every other day. However, even these low doses can accelerate the development of osteoporosis [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/45\">",
"     45",
"    </a>",
"    ] and other troublesome side effects [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/44,46\">",
"     44,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For more severe and symptomatic thrombocytopenia, an alternative is to give a brief course of high-dose steroids on a repeated schedule. One such regimen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    40 mg by mouth daily for 4 to 8 days and repeated every 4 weeks, has become popular since the publication of an uncontrolled series of 10 patients (6 of whom had failed splenectomy) in 1994 [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/47\">",
"     47",
"    </a>",
"    ]. Although all patients in this initial report responded, subsequent experience by others has been disappointing, with failure to achieve complete remissions, short response times,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased toxicity [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3,48-50\">",
"     3,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different immunosuppressive agents have been used in chronic refractory ITP, with reports of success in small, uncontrolled case series [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/40\">",
"     40",
"    </a>",
"    ]. However, these case series often included patients with mild short-term thrombocytopenia or had only a minority of patients fulfilling formal criteria for chronic refractory ITP (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition of chronic refractory ITP'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The most commonly used immunosuppressive agents in this setting have been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and the vinca alkaloids (",
"    <a class=\"graphic graphic_table graphicRef69028 \" href=\"UTD.htm?6/6/6252\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of ITP is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cyclophosphamide and azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    can be given as a daily oral dose (50 to 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day) or an intermittent intravenous pulse dose. The intermittent (usually monthly) intravenous regimen had reported success in an uncontrolled case series of 20 patients: 65 percent achieved a complete response and 20 percent achieved a partial response [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/51\">",
"     51",
"    </a>",
"    ]. Five of the 13 responders relapsed at four months to three years. This regimen is supported by its common use in patients with other severe autoimmune disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Cyclophosphamide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the initial report described intravenous pulse treatment with either 1.0 or 1.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    this dose may be associated with neutropenia; a lower dose, 750",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    is more commonly used initially in patients with lupus nephritis.",
"   </p>",
"   <p>",
"    Larger case series have also reported success with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    at an initial oral dose of 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/52\">",
"     52",
"    </a>",
"    ]. With either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or azathioprine, four months of treatment may be required before a response is seen [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to the vinca alkaloids appears to be independent of the agent used (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ) and the mode of delivery (intravenous bolus, prolonged infusion, infusion of vincristine-loaded platelets) [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As a result, the simplest regimen of an intermittent bolus is most commonly used. Responses have been reported in uncontrolled case series in approximately 70 percent of patients, but are usually transient [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3,54\">",
"     3,54",
"    </a>",
"    ]. A common regimen for vincristine is 2 mg IV weekly for several weeks. Side effects include peripheral neuropathy, which may be persistent, and constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the management of lymphomas, combinations of agents have also been used [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/36,56-59\">",
"     36,56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (750 to 1000",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      IV bolus, day 1),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      (2 mg IV bolus, day 1), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg IV bolus, days 1 through 3), or one its many equivalents, as used in the treatment of indolent lymphoma, has the appeal of extensive experience by hematologists and a minimal risk of short-term side effects (",
"      <a class=\"graphic graphic_table graphicRef69028 \" href=\"UTD.htm?6/6/6252\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      was given to 19 patients with refractory chronic ITP who had failed a median of six prior treatments, including splenectomy [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/59\">",
"       59",
"      </a>",
"      ]. Responses (ie, a platelet count &gt;30,000 microL and doubling of the baseline count) were seen in 14 of the 19 patients (74 percent), lasting a median of 24 months, after which time eight relapsed. Of the eight relapsing patients, six responded to additional treatments. Only two of the original 14 responders remained in remission after stopping all medications. Responses required continuous use of these agents in the other patients. Severe adverse events did not occur.",
"     </li>",
"     <li>",
"      In a series of 12 patients who received up to six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus one or more other agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ), seven had a complete response which was sustained in four for 60 to 150 months, and two had a partial response [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    , an attenuated androgen, can be utilized in male patients and nonpregnant female patients with ITP. In uncontrolled case series, responses to initial oral doses of 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have been reported in up to 40 percent of patients [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Its efficacy in patients with chronic refractory ITP is unknown and may be limited [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/38,40\">",
"     38,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ACCESSORY SPLENECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major regrowth of functioning splenic tissue (eg, growth of accessory spleens or residual splenic tissue) is suspected when the patient with ITP has disease relapse and the circulating red cells no longer contain Howell-Jolly bodies (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"UTD.htm?38/45/39638\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Howell Jolly bodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Hyposplenism and asplenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, surgical removal of accessory spleens has been commonly mentioned as a treatment option for patients with chronic refractory or relapsed ITP. Recurrent or unresected accessory spleens may be detected via computed tomographic scanning, preoperative or intraoperative radionuclide imaging using Cr",
"    <sup>",
"     51",
"    </sup>",
"    -labelled or Tc",
"    <sup>",
"     99m",
"    </sup>",
"    -labelled, heat-treated or anti-D opsonized red cells,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by exploratory laparoscopy [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/62-66\">",
"     62-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the literature on the success of this approach is anecdotal. There are numerous reports of incomplete and transient platelet count responses to accessory splenectomy in both children and adults [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. As an example, in a single institution study of a cohort of 14 patients undergoing accessory splenectomy for refractory ITP, the complete and partial response rate at one month was only 50 percent [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/70\">",
"     70",
"    </a>",
"    ]. There are few studies of accessory splenectomy that document efficacy as defined by long-term complete remission rates and only very rare adults with severe chronic refractory ITP due to the presence of accessory spleens have been reported and improved via this approach [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3\">",
"     3",
"    </a>",
"    ]. Because of the absence of evidence for durable responses to accessory splenectomy and with the availability of thrombopoiesis-stimulating agents that have a high frequency of responses, it is anticipated that consideration of surgery to resect an accessory spleen will become less commonly considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     AMINOCAPROIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe bleeding in spite of other treatments and supportive measures, the use of the antifibrinolytic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    may be an appropriate adjunctive measure. Three reports describe successful management of critical, sustained bleeding in patients with ITP and other causes for thrombocytopenia, typically using doses in the range of 4 to 12",
"    <span class=\"nowrap\">",
"     grams/day,",
"    </span>",
"    administered orally or intravenously for several days up to several months [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Miscellaneous agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments have been described with anecdotes of success, including vitamin C,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/74-76\">",
"     74-76",
"    </a>",
"    ], interferon, ex vivo perfusion of plasma using a protein A immunoadsorption column [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/77\">",
"     77",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/78,79\">",
"     78,79",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/80\">",
"     80",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/81\">",
"     81",
"    </a>",
"    ], infusion of ex vivo anti-D opsonized autologous red cells [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/82\">",
"     82",
"    </a>",
"    ], humanized anti-CD40 ligand monoclonal antibodies [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/83\">",
"     83",
"    </a>",
"    ], an inhibitor of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    phagocytosis [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/84\">",
"     84",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment of a concurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of acute and chronic bacterial and viral infections have been associated with thrombocytopenia, which may often be hard to distinguish from immune thrombocytopenia. The most common of these include infection with the following agents [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis C virus &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H11#H11\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Autoimmune thrombocytopenic purpura and hemolytic anemia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      HIV &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H3#H3\">",
"       \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Primary HIV-associated thrombocytopenia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cytomegalovirus and Epstein-Barr virus &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Other manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H15#H15\">",
"       \"Infectious mononucleosis in adults and adolescents\", section on 'Hematologic abnormalities'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Parvovirus B19 &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Hematologic manifestations'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Helicobacter pylori &mdash; (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Helicobacter pylori infection'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with chronic refractory ITP it may therefore be worthwhile to test for an otherwise unsuspected, persistent infection with one of these agents for two important reasons [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of the ITP (eg, steroids, immunosuppressive agents) may have worsened the infection, thereby increasing the degree of thrombocytopenia.",
"     </li>",
"     <li>",
"      Treatment of a concomitant viral infection, if found, may improve the thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Helicobacter pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some regions of the world, up to 60 percent of patients with chronic ITP are infected with Helicobacter pylori; platelet counts have improved in some patients in whom this infection was eradicated. In one systematic literature review, a platelet count response following eradication therapy was seen in 51 versus 8.8 percent of those who were or were not infected with H. pylori, respectively (odds ratio 14.5; 95% CI 4.2-83) [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short-term response rates have varied widely among series from different countries, being highest in Japanese and Italian reports and lowest in those from the United States, Canada, and Spain [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/90-99\">",
"     90-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental observations, including the induction of platelet aggregation by certain strains of H. pylori [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/100\">",
"     100",
"    </a>",
"    ], and cross-reactivity between platelet-associated IgG and H. pylori cytotoxin-associated gene A (CagA) protein suggest that geographic differences among various H. pylori virulence genes may explain these differences in response rates [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/94,98,101\">",
"     94,98,101",
"    </a>",
"    ]. The final common pathway leading to thrombocytopenia in H. pylori infection is unclear, but may involve alterations in",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    Fc gamma receptor balance [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues concerning response rates to H. pylori eradication in patients from different countries, in those with relatively recent disease onset, as well as in those with severe degrees of thrombocytopenia were evaluated in a meta-analysis of 25 studies, which included 696 patients with ITP evaluable for response to H. pylori eradication. Results included the following [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The weighted mean complete (platelet count &gt;100,000 microL) and overall (platelet count &ge;30,000",
"      <span class=\"nowrap\">",
"       micro/L",
"      </span>",
"      and at least a doubling of the basal platelet count) response rates were 43 and 50 percent, respectively.",
"     </li>",
"     <li>",
"      In the patients with a baseline platelet count",
"      <span class=\"nowrap\">",
"       &lt;30,000/microL,",
"      </span>",
"      complete and overall response rates, as defined above, were 20 and 35 percent, respectively.",
"     </li>",
"     <li>",
"      Regression analysis indicated a significant positive correlation between the prevalence of H. pylori infection in the patients in each of the studies and the reported response to H. pylori eradication.",
"     </li>",
"     <li>",
"      The most consistently reported characteristic associated with a better chance of response to H. pylori eradication was a shorter duration of ITP [",
"      <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/92,97,103\">",
"       92,97,103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sum of experience is that, while eradication of Helicobacter pylori infection is an option to consider in patients with ITP, results are not consistent from country to country, and have been especially low in studies reported from the United States.",
"   </p>",
"   <p>",
"    In any event, patients with lesser degrees of thrombocytopenia and shorter duration of disease are more likely to respond. The clinical value of H. pylori eradication in patients with unstable disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe thrombocytopenia (ie, platelet count",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL)",
"    </span>",
"    is uncertain [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Autologous hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose chemotherapy followed by autologous lymphocyte-depleted peripheral blood hematopoietic cell transplantation has been reported in two series of adults with chronic ITP who did not obtain durable responses to glucocorticoids, IVIG, and splenectomy; a number had Evans syndrome (autoimmune hemolytic anemia plus autoimmune thrombocytopenia), a disorder known to be difficult to treat [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 14 patients, at a median follow-up of 42 months, durable complete remissions were obtained in six, durable partial responses in two, and no response in six; there were no deaths [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/105\">",
"     105",
"    </a>",
"    ]. In a second series of 14 patients, durable complete remissions were noted in five, with transient responses in three; there were two treatment-related deaths [",
"    <a class=\"abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/106\">",
"     106",
"    </a>",
"    ]. Additional experience with this approach is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Evans syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following three criteria are used to define chronic refractory immune thrombocytopenia (ITP), although this definition is not, by itself, an indication for treatment (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of chronic refractory ITP'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The ITP has been persistent for &gt;3 months",
"     </li>",
"     <li>",
"      The platelet count is",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      The patient has failed to respond to",
"      <strong>",
"       both",
"      </strong>",
"      splenectomy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low platelet count alone is not sufficient reason for treatment. The presence of, or the potential risk for clinically important bleeding must also be present. Treatment decisions need to be based upon a careful discussion of risks and benefits with the patient and an understanding of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      values and preferences. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment goals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment with other agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with chronic refractory ITP in whom additional treatment is indicated, options include thrombopoiesis-stimulating agents, glucocorticoids, chemotherapy, or supportive care (",
"      <a class=\"graphic graphic_table graphicRef69028 \" href=\"UTD.htm?6/6/6252\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The most successful treatment is with thrombopoiesis-stimulating agents. The limitation of these agents is that continuous administration is required in order to maintain a platelet count response; remissions are not induced. Additional limitations include their great expense and the potential significance of their stimulation of bone marrow reticulin. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thrombopoiesis-stimulating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the other regimens will be unsuccessful; there are no randomized studies indicating that one of these options is better than another, or that treatment with any of these regimens is better than no treatment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment with other agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the patient with acute, severe bleeding, in preparation for surgery, or settings in which a rapid increase in platelet count is required, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Life-threatening bleeding and surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/1\">",
"      Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/2\">",
"      George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006; 4:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/3\">",
"      Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004; 140:112.",
"     </a>",
"    </li>",
"    <li>",
"     European Scientific Working Group on Thrombocytopenias www.tcpeha.org (Accessed on July 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/5\">",
"      Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/6\">",
"      Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; :CD008235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/7\">",
"      Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. Am J Hematol 2012; 87:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/8\">",
"      Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011; 152:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/9\">",
"      George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/10\">",
"      Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/11\">",
"      Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/12\">",
"      Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/13\">",
"      Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010; 150:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/14\">",
"      Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/15\">",
"      Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/16\">",
"      George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/17\">",
"      Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/18\">",
"      Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/19\">",
"      Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118:4338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/20\">",
"      Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011; 155:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/21\">",
"      Jamali F, Lemery S, Ayalew K, et al. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 2009; 23:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/22\">",
"      Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/23\">",
"      Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/24\">",
"      Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/25\">",
"      Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/26\">",
"      Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/27\">",
"      Dmytrijuk A, Robie-Suh K, Rieves D, Pazdur R. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 2009; 23:1171.",
"     </a>",
"    </li>",
"    <li>",
"     FDA safety summary available at file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm211796.htm (Accessed on July 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/29\">",
"      Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/30\">",
"      Sperati CJ, Streiff MB. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. Am J Hematol 2010; 85:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/31\">",
"      Jansen AJ, Swart RM, te Boekhorst PA. Thrombopoietin-receptor agonists for immune thrombocytopenia. N Engl J Med 2011; 365:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/32\">",
"      Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/33\">",
"      Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/34\">",
"      Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/35\">",
"      Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/36\">",
"      George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000; 37:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/37\">",
"      Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br J Haematol 2002; 118:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/38\">",
"      Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/39\">",
"      Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/40\">",
"      George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/41\">",
"      McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008; 83:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/42\">",
"      Mathias SD, Gao SK, Miller KL, et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008; 6:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/43\">",
"      Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/44\">",
"      Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 2009; 83:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/45\">",
"      van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     Zukerman E, Ingelfinger JR. Coping with Prednisone, St Martin's Press, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/47\">",
"      Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/48\">",
"      Demirolu H, D&uuml;ndar S. High-dose pulsed dexamethasone for immune thrombocytopenia. N Engl J Med 1997; 337:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/49\">",
"      Borst F, Keuning JJ, van Hulsteijn H, et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004; 83:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/50\">",
"      Stasi R, Brunetti M, Pagano A, et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/51\">",
"      Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/52\">",
"      Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/53\">",
"      Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1976; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/54\">",
"      Facon T, Caulier MT, Wattel E, et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994; 86:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/55\">",
"      Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol 2006; 81:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/56\">",
"      George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/57\">",
"      Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/58\">",
"      McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001; 344:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/59\">",
"      Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 2010; 115:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/60\">",
"      Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/61\">",
"      Maloisel F, Andr&egrave;s E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/62\">",
"      Altaf AM, Sawatzky M, Ellsmere J, et al. Laparoscopic accessory splenectomy: the value of perioperative localization studies. Surg Endosc 2009; 23:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/63\">",
"      Quah C, Ayiomamitis GD, Shah A, Ammori BJ. Computed tomography to detect accessory spleens before laparoscopic splenectomy: is it necessary? Surg Endosc 2011; 25:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/64\">",
"      Bergeron E, Ratte S, Jeannotte S, Recoskie MJ. The use of a handheld gamma probe for identifying two accessory spleens in difficult locations in the same patient. Ann Nucl Med 2008; 22:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/65\">",
"      Kirshtein B, Lantsberg S, Hatskelzon L, Lantsberg L. Laparoscopic accessory splenectomy using intraoperative gamma probe guidance. J Laparoendosc Adv Surg Tech A 2007; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/66\">",
"      Phom H, Kumar A, Tripathi M, et al. Comparative evaluation of Tc-99m-heat-denatured RBC and Tc-99m-anti-D IgG opsonized RBC spleen planar and SPECT scintigraphy in the detection of accessory spleen in postsplenectomy patients with chronic idiopathic thrombocytopenic purpura. Clin Nucl Med 2004; 29:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/67\">",
"      Facon T, Caulier MT, Fenaux P, et al. Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol 1992; 41:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/68\">",
"      Choi YU, Dominguez EP, Sherman V, Sweeney JF. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. JSLS 2008; 12:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/69\">",
"      Woo JH, Park SH, Park YK, et al. Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. Korean J Intern Med 2004; 19:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/70\">",
"      Thanarajasingam G, Vaidya R, Erie A, Wolanskyj AP. Accessory splenectomy for refractory immune thrombocytopenic purpura. Am J Hematol 2011; 86:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/71\">",
"      Gardner FH, Helmer RE 3rd. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980; 243:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/72\">",
"      Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 1989; 149:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/73\">",
"      Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/74\">",
"      Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/75\">",
"      Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/76\">",
"      Perrotta S, Amendola G, Locatelli F, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003; 121:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/77\">",
"      Snyder HW Jr, Cochran SK, Balint JP Jr, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/78\">",
"      Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/79\">",
"      G&oacute;mez-Almaguer D, Solano-Genesta M, Tar&iacute;n-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood 2010; 116:4783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/80\">",
"      McMinn JR Jr, Cohen S, Moore J, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 2003; 73:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/81\">",
"      Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/82\">",
"      Estrada-G&oacute;mez R, Vargas-Castro O, Oropeza-Borges M, et al. A single-institution, 20-year prospective experience with an affordable Fc-receptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura. Rev Invest Clin 2007; 59:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/83\">",
"      Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008; 141:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/84\">",
"      Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/85\">",
"      Zaja F, Marin L, Chiozzotto M, et al. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol 2012; 87:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/86\">",
"      Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009; 46:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/87\">",
"      Stasi R. Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias. Semin Hematol 2009; 46:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/88\">",
"      DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol 2009; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/89\">",
"      Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/90\">",
"      Jackson S, Beck PL, Pineo GF, Poon MC. Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005; 78:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/91\">",
"      Rostami N, Keshtkar-Jahromi M, Rahnavardi M, et al. Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. Am J Hematol 2008; 83:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/92\">",
"      Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/93\">",
"      Michel M, Cooper N, Jean C, et al. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2004; 103:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/94\">",
"      Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004; 124:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/95\">",
"      Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004; 164:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/96\">",
"      Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002; 118:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/97\">",
"      Stasi R, Rossi Z, Stipa E, et al. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 2005; 118:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/98\">",
"      Emilia G, Luppi M, Zucchini P, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110:3833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/99\">",
"      Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/100\">",
"      Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/101\">",
"      Franceschi F, Christodoulides N, Kroll MH, Genta RM. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med 2004; 140:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/102\">",
"      Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008; 118:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/103\">",
"      Kodama M, Kitadai Y, Ito M, et al. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter 2007; 12:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/104\">",
"      George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009; 94:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/105\">",
"      Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults/abstract/106\">",
"      Passweg JR, Rabusin M, Musso M, et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol 2004; 125:749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6678 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-EF0408A01F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29194=[""].join("\n");
var outline_f28_32_29194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF CHRONIC REFRACTORY ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Confirming the diagnosis of ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THROMBOPOIESIS-STIMULATING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview and limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Romiplostim",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17121939\">",
"      Romiplostim versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17121946\">",
"      Romiplostim versus standard of care in non-splectomized patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Long-term safety and efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Increased bone marrow reticulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Administrative issues and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Eltrombopag",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8703499\">",
"      - Eltrombopag versus placebo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8703506\">",
"      - Eltrombopag versus standard of care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6313107\">",
"      - Long-term safety and efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8703492\">",
"      - Guidelines for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT WITH OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNOSUPPRESSIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cyclophosphamide and azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Danazol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACCESSORY SPLENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      AMINOCAPROIC ACID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Miscellaneous agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment of a concurrent infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6678|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/24/44429\" title=\"figure 1\">",
"      Remission from splenectomy in ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/27/19901\" title=\"figure 2\">",
"      Platelet count and bleeding in ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6678|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 1\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/6/6252\" title=\"table 1\">",
"      Treatment chronic refractory ITP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_32_29195="Diff dx child vasculitis";
var content_f28_32_29195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for systemic vasculitis in children based upon pathologic process",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lesions outside the vessel wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurofibromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy (tumors, lymph nodes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lesions inside the vessel wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vessel thrombosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated intravascular coagulopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombotic thrombocytopenic purpura",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antiphospholipid antibody syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombosis secondary to malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Embolic disease (endocarditis, atrial myxoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombocytopenia of any cause",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bleeding diatheses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Vessel spasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Raynaud's phenomenon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug induced vasospasm (eg, ergot, cocaine, phenylpropanolamine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Abnormal vessels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coarctation of the aorta",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibromuscular dysplasia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29195=[""].join("\n");
var outline_f28_32_29195=null;
var title_f28_32_29196="Diff dx mesenteric masses";
var content_f28_32_29196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of mesenteric masses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        CT appearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathologic conditions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Round, well-defined mass(es)",
"       </td>",
"       <td>",
"        Non-Hodgkin lymphoma",
"       </td>",
"       <td>",
"        Retroperitoneal adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastic deposits",
"       </td>",
"       <td>",
"        Small bowel nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium avium complex infection",
"       </td>",
"       <td>",
"        Hepatic and splenic lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple's disease",
"       </td>",
"       <td>",
"        Thickened small bowel folds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric cysts",
"       </td>",
"       <td>",
"        Fat attenuation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Castelman disease",
"       </td>",
"       <td>",
"        Hypervascular mass",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Ill-defined, irregular mass(es)",
"       </td>",
"       <td>",
"        Small bowel carcinoid",
"       </td>",
"       <td>",
"        Calcifications; small bowel mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric fibromatosis (desmoid)",
"       </td>",
"       <td>",
"        Gardner's syndrome; abdominal wall infiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor infiltration (pancreas, gastric, colon)",
"       </td>",
"       <td>",
"        Primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"       <td>",
"        Retroperitoneal adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric panniculitis/sclerosing mesenteritis",
"       </td>",
"       <td>",
"        Calcifications",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Stellate mesentery",
"       </td>",
"       <td>",
"        Carcinomatosis",
"       </td>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal lymphomatosis",
"       </td>",
"       <td>",
"        Adenopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal mesothelioma",
"       </td>",
"       <td>",
"        Ascites; pleuroperitoneal plaques",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneal tuberculosis",
"       </td>",
"       <td>",
"        Ileocolonic thickening; ascites; peritoneal enhancement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic amyloidosis",
"       </td>",
"       <td>",
"        Thrombosis; focal mesenteric thickening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular thrombosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheth S, Horton KM, Garland MR, Fishman EK. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003; 23:457. Copyright &copy; 2003 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29196=[""].join("\n");
var outline_f28_32_29196=null;
var title_f28_32_29197="Strict glycemic control slows progression of retinopathy";
var content_f28_32_29197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strict glycemic control slows progression of retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of progressive retinopathy in patients with type 1 diabetes and very mild to moderate nonproliferative retinopathy who were treated with either conventional (dashed line) or intensive (solid line) insulin therapy for nine years. There was an increasing benefit of intensive therapy over time, although intensive therapy was associated with transient worsening in the first year (p&lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29197=[""].join("\n");
var outline_f28_32_29197=null;
var title_f28_32_29198="Prevalence rate of asthma";
var content_f28_32_29198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Asthma period prevalence, asthma attack prevalence, and current asthma prevalence for all ages: United States, 1980-2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 384px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asthma period prevalence: A family member in the household has had asthma in the past 12 months.",
"    <br>",
"     Current asthma prevalence: A doctor or other professional has previously diagnosed a family member in the household with asthma AND that person still has asthma.",
"     <br>",
"      Asthma attack prevalence: A doctor or other professional has previously diagnosed a family member in the household with asthma AND that person has had an asthma attack or episode within the last 12 months.",
"      <div class=\"footnotes\">",
"       * Statistically significant trend.",
"       <br>",
"        <span class=\"bullet\">",
"         &bull;",
"        </span>",
"        Trend not statistically significant.",
"       </br>",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. National health statistics reports; no 32. Hyattsville, MD: National Center for Health Statistics, 2011.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29198=[""].join("\n");
var outline_f28_32_29198=null;
var title_f28_32_29199="Pertussis epidemiology US";
var content_f28_32_29199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pertussis cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 713px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington DC 2011. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf\">",
"      www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf",
"     </a>",
"     (Accessed on September 12, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_32_29199=[""].join("\n");
var outline_f28_32_29199=null;
